var title_f26_39_27248="Emerson iron lung";
var content_f26_39_27248=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F61051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F61051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Emerson iron lung",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 242px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADyAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pwKCKKazACgBCKQqM1zg8RXJ8Sajo0toIpII0uYJt25ZoW4zjsQwII+nrTb6ee5gmhmlbZIhRgDjgjB6UAdJt9qaQK5nwDfM1hNo97cvcanpbeVLJI2WljbJjkz3BXj6qa6gigCI01sU5qjfp9aAGtxmoiRkU457modxyOaAHMQD3pN1MZs5J/nURbnGe1AEhI59TTN2MjPemZ+9369KjZwM5oAkd+3r+lRlhuHemFwe/wCtNZjjrxigCbcBnrTt/wAvXFVt3B5zjvSoxwc4oAn3c8UpbOOtVw+CcHk0pkAHXJNAE4ccVG78d6iDjsfamu4A5z1oAXze9Jv4qrJL8xOOR+VRmVlAKtxjmgC/v6DPFO34HNUElZRliO3PWnJP79KAL5k4PpTS59fxFVRcZ6nnqeaUSAcfpQBY34GRwKY0mM54qJpOxxiq7y9SDznpQBb8z5ufypyuM8cc1T83JBA56c08SZYcZegCyW55pQ3OetVmkB2/Nyacrj1+gFAFjcRilD8Zqq0nHUeo9KA+RknI7dqALayDIqVX49qoJJ65H1qeNuCDQBdV+TU0TVRjftngnr6VYVuQBmgC4Caep9arB8YJ5qVXyeM0AWF6Dmnj3qFDyKkVuaAJB1opAeaKAJnbGaryOe1Olz+NVnOeM0Acp8RIbiGxtfEWnRvJfaMxkkiQZM9s2BNH78fMPdRVie4iMKzbl8kpvVmOAVIyOvTg1vLKQ/Q/jXlHj7V7NfiG9n4w0wLpQgSS0v1kJiVWOMzJ/d3cFuQpIzwaAIdX8Z2Gi67ba7prtfyWiNBfxWylg9seeX+6CjAMMnoT616xoGv2euQzfZxJDdW7Bbi1nAWWEkZG4DIKkchgSpHQ1x97YW8djLaRwRLbNHjy1ACkEe3UEVR8KaW11AdNivDZa9oigaZf/eMtk3KRyr/y0QEFCvbaCCCc0AeoOeOahkYYrF0PXTfzTafqVuLHXLZQ09oTlXTtLC38cZ9eoPBANabkHHIx35oAezAqarMx4JNSueOeCKrsQTzzigBHfB689aiL/IOefSiQ4PT9elQOeCc/X3oAkVyOc/Smu+W44479qhDcdttMdsL973zQBK7kLx/Om78nBqEuCTzx19eKRmxnJODz6UASmXCEhjnJoEobOMdD0qqz4Y4yf5YqN3wFyfy7UAXWlwfm4Gc801pse471RaU5JJqNpyB6fzoAvifJ68dT71FJNn72Pz6e1UxNwO/bFVpL6PeEaeNWYkAMw+Y+goAvGUMMAgnp1pFlI46VQaYlgAw3eneovPdT9wEYzjOKANTzBg8UB8tkHBz1rM8/KknrgfWnJdFQQSB6elAGosgA7804Sgjd1JrLS5AbOcd+KeZtwJ6j0NAGgZjknt0571GzAHoaqLKAeRnPU0quGOAevY0AXRJ82S3PQ0vmktznGeuaqq/Jx+dKhy+OCBzQBbZ8lTjPvS7/AJ8+lQNJtPpSFiTjHbgUAWCwOOuO/GaC+48cd/pUGcc9D2pyngk5HqaAJ/M55zzViFyflwc9xVOPPPXBqzG+SPvZ9+9AFtWz1B6d6ljck8Y/OqqHPJHf1qRDnByeKALqkseOO/FTrnPoD3qmjcg96shh1NAFiMn8jUqHPQVWiOTjHFTryOKALCnnpRTE60UASS8dRVeQHBPUVblXrUBTce/+FAFGQcg7jz1rmvHelyajpcF/aQrPqOls08cLKGFxCRiWBgeodc8eoFdiIOTmnpEEbI5PagDxfTZE8P6Yl9pkk174KnXfGhVnm00H07vAPTqnuOncaL4djudQ0nXJWXzLVXe2eNgwkSRcHpxtIIP4CujsbCx0qIxWFrDbx5Y7UHAycn9Sa4PXbX/hBrafWvDE8kGmQSLLfaO5327RM4DvCDzE4yWwvynHSgDrfE2ix63aRqsrWuo2zGWxvUHz20vYj1U9GXoRkVzeifEHSb2/0/RtSuYbPxHcebE9pnKiaJyjqG7FiMqDyRXS3FxPIskdkDJLt+U57HvXC+LfB9nZ2N54pudMtV1WyheSO4I/eGTBCHI6ncw5oA6vSfEVhrEc8li0rQxTPAJChCyFDhivquQRn2q+kySBXjbKHoc1gaToqaB4Ct7SPIlEUduCT3A+Y/nuNRaD4i8LGzLSa9pxKNtYF9uw9gaAOgmbr0qFn4BwcfyqODxB4XnLCLX9JZwdpxOvX8asNqnh8/L/AG5pYwcY+0oP60AVjuGSO/pTHJ2gNg45xV0XuhEZGsaYc/8ATzHg/rSLPoz8LqumkeguI/8AGgCoANuQeCQOOKgdwCcdTWkZNJ2gDVLAD2uI/wDGomGlFif7SsMH1uI/8aAMqRwByajaZT1P4VqSLpZJP9pWGB6XEf8AjVWT+yFHOq6aBnqbiP8A+KoAzZLkZGWGPaqrXIycYAHatZU02eYxQahp0szciJJVLkfQHNcd8Ypb3w14DvdX06SOK4hnhXcEByrNgjn60Aal/O4sLgw/fEZxt4P4e+M1NZWWnyaUmbWN9Pa2LmcgEA5HO76Z5r5of4seI0QvHqEq3A5CNDG6f+g8j61V/wCFn64yySHVo43eLcYks41i8wdtgGPxoA+k7KU/YYGdizlep6kdj9cYqYzAEcnjjnvXzlB8XddVkL35nyAW3WsY57ivavhZqs/i/wAIx6ndJG1ytxJA5QbAdp4OO3BFAHQmXjGcnpWda+INMvNTudPtb6Ga/ti3nwKTuTBwc8dia3ZNPjbKO8aORjiYAjjrjtWFa+BbK3v4byK8ulkjbOEuFxJ7PxlhQBoLNnnp+PepUmyOM9c8VbTR1IxGS3X+LPNTxaN38tse1AFVJVPPWlEy89QM9a0RojZJ8tx6cGj+xJMtmOT070AUBKTgZ5J5zUkcwyTnketXf7Fk2/dkHODxSnRZiSPLkA+lAFNpssMAZpwkIIODj9asnRZc8xuO/Sj+yJl67sDuRxQBXWQhfl9etSxs2fQUp06UE8g5/WnpZTgcYxQA5GPfrU4bpjt05qOO1uMnhSc1m3uu6TYXb2t/q1lbXMeN8cjHK+n9KAN6Jj2HHqDUsZyADk/TvXOQ+JtFw2da09QOcl8f0qebWJWsJb7QvsetQW/M1vby/vio67D0Lf7JxnpmgDo43yQBxUytkHA+tZOi6vZ6zpttqGmTCWzuV3xtjB9CGHYg8EdqvI+Oc0AXo2AxyODVgSY6nms3z9qjnBPcmpY5gSBuBFAGkrdu9FV4ZORyOaKANllBHNRsmOgFS0hHHFAELjBzjioZ3AX09asPwP61m3z4yR3oApXtwefSuc1+D+2NH1CwYc3VvJB+LKQDV+8lGSDxjr71RMmJRz0INAB8Ftei8QeF4r7y7pJo0S1k86LaGkQYcof4hkfhitn4k7pdAtrPgC9v7aAj1XzQzfoprL+DOmjTdI1iIDag1OYIMYAXg8fUkmtnxmvnaj4Zt8ZzqPmH6LDJ/UigCr8QZPsvh3d3ihlm49QmP5tXxZ4xn1C01WKKCbIjhTLQnCsf6/iK+zfikjzaJdxRI8jtbFAiAknc6jjHsDXzdq/gjUbu5N2LS5jWQkCJoJGZAOAG4oA5rQvHWnWmk21tqvhpr29hBElypVTJycH1z0/KrLeP/DDE+Z4QlPc5dT+dSt4Fv2lKtbzxnn5ntpAB1PXFUj4LvcYe2l3H1hfj9KAJj458KugDeFLjauSFDrxn8aWLxv4UTJHhe8QngFZADz15zVSXwRfRJuVC+RnARsj2PHWmweF7w+cpRo8r8wZGG7kHA460AXx408KdvDN5nocuP8aH8ZeFXYbvDV4SBgEuMD9apN4UuUX5oH9f9W3+FDeF7gOVEZY7QflRmHI9cdfWgCwfG3hSPcP+EZuxuxn5hg49eajPjzwkOnhucH1wh/rWbc+EL6VJWQICoGQysGOfQY5rGn8GalEAWEfP+zJ/8TQB6t8H3i1Txnpt9DCIbaea4MavgyBf7rHrgdq9b/aJRV+Duvs0YkCtD8pJGP3gAPHp1ryf4G6dLp3jHSrKcO0tqJhK6DMWCMrtOOev0r2D9ouPPwb8RjH/ADx6/wDXVaAPh+4ypaqnzYBPpWldW0iSELgtk8EHgetVhHJ0IQYPctQBApYdTjPSvq79k90uPAWrRbTmDUeSTncWQHPt9PavlgRSA8eX/wB9GvqP9kLLeGfE6P1F7CeDkcxmgCl8ZjY6P49mur9R9mltonfbnccqV4A6j5a4MeJ/B5biCXg4yInGP1r0T9o3R2u/FulPHHLI72KxhUjLA/vG6kdO1eOtoQRyHimUqcHMD8fpQB0X/CTeEGYEvdK2OMLIMAfQ1PF4o8Irx9uv4+emZea5ptCRYkcqQr5CnYecdf8AJpI9Bjlzs2lgpYjaQQByTQB2A8WeFIkDJrOoo/XIllAFMk8W+G2zs8RaovP3vtE3NcedItFYq8sK49aJdDt4jtmkiRiA4DcZB6H6UAdl/wAJZ4fOzHinVwAMDbcTfrVTxD44tbTTi2g67qV5ellXy5LiXATux6VzUOkQrHI6vE8Sn5/Rc9M1VudOnclNOhW4cnAVME0AWk+IviIkhLmb8J5Tj/x6vUPgz4r1HUvEGny313cSG5eS2lV5WZFJ5XAJOOQK6n4E3PhC28DSWni220my1VZnjm+1qoeaPqpyeuMkfhXm+lWseg+M7s6YzLpkWrCexdskTRhx93Hse9AH1iLZSoIXjtg0pth6cjvV2IBkBqTZ8vIoAzVgGfmHTvXjvx50ZbW40/WII1H2jNvPx1ZRlD+WR+Fe5FBzxXBfGyyW4+Hd3KxA+yTRT5PGBu2n9GNAHzwboM3QbSOldd8LtbOi+L7M7wltdN9nlA4UZ+634HH51yf2Ns/MAozgE96e9tJA+2Iqzoch0OQCOQQaAPZJ/wDij/ibeaap26T4ghbUbWHGFiulIEyqe24YbFXbzxL5e4RY3e1c/wDGe5+2fDrwt4vjz5um3cE7nuI5F2SA/iKwBdLIA9uwaF/mRgeGB5BoA6OfXLuZjulI5zxUltrN1G4bzScetcuJ+cn7wNSRTNv4JPvQB6doviQMyR3AGW6HPFFcNYSHcD6HrRQB9DUUUUAIwyKyNTQiPj171sVQ1NN0fHagDjLokO+W+maou55z/wDX+taGoJtA7846c1DFo15csGaMwRno0h6/hQB1vhEf8SOFsg7mY5A/2jVPXhv8YeGlOcKLmTr3CqP/AGatzTYUt7GGKJQqIuABWHqzZ8c6Ep6C2uT+sf8AhQBqTf8AIbhGT/q/8a0ayC3/ABUoXPSP+hpPFfiCy8M6NNqOoNiNOFUdXbsooA2KqS6lYwvtmvbWNumGlUH+dfPHjHxxq+r3nlyX6C0dd0dvZOwVlwDzwGPXnPGelc1G73VrI0EKTAN5bwkLv39uSRtwATmgD60jkSVN0bq6HoVOQaXA9q+WNJ1e+0fUUFtc3GmO/wA2HfYG/wDZSK9t8I+Oor4ix1N0a+VSySQ8LOoOCwXqD7flQB3ZGetJtHPA/KhGDorL0IyKWgBhRc9F/Kmso/ur+Qp561m69qsGj6dLdXALBQSqDq3+AHUnsKALbRKT8saZ9lFcr8RvDcfi/wAG6p4f+2xWrXiqvmsQdhDBgcZ9qoS3U+rW9ze6jeeVpscmwAOYIWGM5/vP/XsK5O+t7NdX22hM0LRq4jW0bzHIJJMIbG7I4JOfbmgDhT+zDfjBbxPA4I/54sKbF+zTqiZWTXdJkTnB+zyBh6c5P8q9Q0rUIYVkl0nUpLZo2VZIH3DYW4AeJ+x6ZH4Gu00jXYr6BTKjxTYzjYQGGcbgDz+H0oA+dG/Zk1cksPEOng9gI3wP0r1T4KfDi9+HematbX19b3kl9Mku+EEKu0Fcc16cCGUEcjFBGTQBTlsreZg09vDKwG0M6Bjj05qvNBpdt/r4rCLI6OFUkewPWtJgK4j4g6XNfXunS2rCOaHLB9m8Ag9GHcHkEcUAdEiaLIuVGmkH1Kg/kaU2OhuwZoNMYjjOVz/OuFbwhqOoySXMkC3EoZot6lUQ7TjgMxbHueazj4QupNUeyjWFbxIlaS1DRO+wnO7lvl6YzQB6U2j6DJ9+y0xs+u3/ABqH+w/DE8jRrYaS7x8Mo25X681xkHgm7QsJNNnGRwUaI4/8eqvp/hLV7SMw39m0sCZEZiCbjnqxBfCk9wOM80Ad+PDPhwjH9k6WR/uL/jSjwr4b3ZXRtLz6iNa8613Qng0q6nktZrJIyoeeYxBEBI5OHzz04HesmLTpXthJJZ3LSFd6lI12OD0KnfnGMdaAPWX8I+GN6htH0ssfugouT+tSnwh4dZAp0Wy2joBHXjtrHqEUV9a/2eBDMfmeZtrxqw6bQCG5XhgwI6GvXvBSyJ4c0yMs/wAluqHccnjigDdRFjUKqgKBgAelPxSd6Xt15oAQrUF5Z297ZzWt5BHPbToUlikXcrqeoI7irGaXtQB474w8G+CvB32O7s/C2myPMzoBc3joowAcKCSCcf8A1qx/CWieCvGer/Z73wvaWcxiJj+zanJuYL1ygIx169691nt4LldtzBFMoOQJEDD9ahi0+xgkEsFlaxTAYDpEqsB6ZAoA4j4raHbN8IPEGmWVuscFvpx8mMH7gjwwA+mK8S0O5FzoGm3GMB7ZD7cDB/lX034htRe6Dqlr1E9pNEQf9pCK+H/hzqsttqK6ZM7G2ukOxWP3JFGePTIz+QoA9PWT5qljlIPHBqhuHBOP60lzdJZ2s1y5GyJS5BPBwKAOmspM47/5/nRXC/DHWtT1hL6fUZd8CuEiG0DaTkn8AMCigD7MoooJxQAVVu13fKByeKtE461XlkCMXOOBmgCrb6ZFFJ50uHkHTPRf/r1FfXNukio0g3FsY61XvdVhAYyShAvauI1rxdYw3USWc013eQXCtPb28DSyJGBuOcAhMjnJ7A0AenafIZbONykiE54kGD19KwNTY/8ACfaQvb7JMf8Ax5KS98WaTYeG7XV73URaWsz/ALtpV2mQ7jlQp5PAPSuU0zxppXiHx1Zy2d/bGGJHjXLbGIJBGQenQ0Adpv2+LmX1iz+leM/G7Vr/AFD4gWWj2LI4tETEWejOMliO5xivWmmX/hNwNynKbeGB/hr5I+J+t3Gn/FbxI0rlbkXjqrZ6DA2/pigCv4x1GKDWBbaFdwoLXMUiJGASwPzMT3BOeKp2utz2AMa+XGySMxiUEDcerD68VwX21y4lV41YE9ep5/WmvqkjSE7twJ70Ad5q/ia4uLba/wC8TrsYfp9fevRvBVs2nDRtThEFrZzmJlZE+Zg5ABz0HX9K8BmvROn7smPB5GcgV0dv4hvktNNt2u5WitYVWJOwAJIGKAPv/S7k3FlE7riQZRxjGGXg1b3+1cj8Pr2a68MWs90xNxIFaQn+8VBP610gkyegzQBYLYJqDyUEtzc3QXZs2DcMhYxyfzPX6CqthqNvfKJLaTegfacggg+mDXzD8QPijqyajqOlyXMqXNrNcW6FSeRuIwfwxQBua94ilTxMlrotxDp9tassVjHbsEitkPJwOgY55ODknHQVv6Lbf2h4itNc1C7F7qVlbu1uTGcQg9yANrH5jXzfb+L7iTU2ln2AyTbmkC8lfQk+levWPi9F06N7EKJBysgbhTjB+maAPVZLeTWrVZNZmW4EDYwIl3Jn2IGR6g8HpXcW+mf6DbLDDbwRwplY0BJ3Y7MecfXsa+Pda8caq7MJpZQYmO1lf5SuRx+lejeF/jDrEPh+3srdVub7KiMTYyVYcDJPbHHtQB9HJH8g+Rl46Y6U7Zz91vyrD0fU57iySSV23tyQT0yAcfhmr/22TPD0AWyAP4WP4VXu54bUI81tcSh2Cfuoi+3646D3qI38oGA4/EV5z8VvifeeCb/S4beK1lW8iZ285SSNrY4wR16UAeqwGONHwjKC7Egr6ms37JpFnrVzrS2ajU54lhluViYuyDov04H5V5jpXxQ1vXNES806zgEhyzKCPlXJ656cD3rivEPxp8QorxQ3kNvKj4JjiU49Ac0Ae/3Piixt5fLeC+ZuwW2bn86yP+E+tJC3l6NrLpj732cY/nXzU3xo8VT3LLNqLNG5J+VtoQ/4e1aVn8YfEkUhZLtYwekaIHB4680AezeL/FOi61pb6VrPh3WJbechmjC+WSRyOQayLnx3o9tHDbLpd7aRQoFjDQAqEA4A5Fef3Xxp8QyIGxBKehLxAZH4Gud1f4oapfXTPc6fajAHyqW5PsKAPe/BniXQ9VXUry7uIrWGIQx5nAi6hzxk812Hhe7t7rTUmtGV7dy5jZTkMu84INfOfhfx9ZQWMyaz4dS6MzrKpUqGiG1hjkd691+H97DdeGrC4toBb28sRkSFRjYpY4FAHXBxx2FKGGM1WMmFz70iSZ4OM96ALW8Z9KUNxUAcGl3ccUAS7wc8U1nHoaiDY6/jTS49RQBLkMSrDKkEE/hX54RTfYvEVrMgOIrsEfTdiv0I8zGTwcKx6+1fnTqEubmSQfeEhYf99ZoA9vchZCp4AJrlviJqAt9CMCEhrhguP9nqf5VL4T1yfXbW5uLuFI5IpQg2AgNkZ71zfijdrXi+y0xCcb1jYemTlvyAoA9E+H1l/Z/hvT4nXbJIpnf2L8/yxRWxblRIoUDYMBR6CigD6pPFR5yaWQ9u9eO/FL4pLYST6J4ZnVtR5jnvFIIgPdU9X9T0H16AHsJPAFZ+osfs02OgFZPhLxJZ654ds7qO5jM/lKtwjuFdJAMMCPr+dRatqcKqQt3bq57mRTj680AZ66bJfyAcxp1ZyeD+FcL8TNKiv9f0/StJvJtLheFluryxnEbysTjY6j7+V4GegyK3ta8VXptTbxXOlwqQQ0kMuXP59K4WKeCx1FtQea1lkRdyq8gY+p79/egDhp9Yj0+3VNSuJ9Qs9LtWt7JbpyUjYuVEhVe2MEr3IAzgVT0nR7/WjZT3d/ptqlys0sTXdq0aExsoABB3AHd156cUSacW8K6frNrukj1OW4gmJGQlwj7hj2KnOP8AZr01tU07WL7w1qNtbwi0m0+Rbm1B4jmR0EigduTkexoA8m03xn4k8G+I4UhZ77XLeSSORJXW4gnVtu0IQNx4Gd2R296g+OOl6jqmv2XiS4wv9oRwxXhVeIZgoHOPUD8xXuWsaVpUWsxyaVBHGkqLtkwNy568+lbV14UsL7TmtNQt43SRdj7ejj3FAHx/f6Fa2999nMwecDcyZUs4IBBUg7SeeRnI564qudHYg5t/LK/3mWvdfF/wA3u1x4Z1FZFIyLe9Ygj2D+n1FecXfwo8WWMjRz+HpZADxJEUZPwINAHHDR0huo0vEaPkM6bgGI9AQe/r2613PhTw+3ibxoqeSI7ONhPdvEwaJEU4CIffGB+Jq/4a+Dus3kwbUo1s4c8oi7pD7f3R9ea998I+CtL0PShaJH5MedwSN8sTjlmbuaAO+8PJHbaPAsbKxI3sVPGTV55ywIUgEjGc9PesG0eGzgSGJjsUZG41IL5c5z/+ugDSgDQwRxmYylBt81z8zY7n1NfMP7R3g4ad4sHiKPzE0zVXBlmQZWCYDDAr/tAZHqcivod71c8MMn1/lUeoxWGsaZdadqttHd2NwuyWGQZVh2+hHXPagD4Y1HS5YNYNvbwsZGCsI96u+GUMMbSQeDnA5HfpV2DTvEEKsIdKvFQDHmeWcfzr1bxh8Br6z1CS98HX8d7AM7ba6k2TRZ4wr9G69Tg1wT/Dvxpbt5U+g6lweofKn3yDigDAt9JvzqKWepiW1aQAiNvlLZ6DB9fyru/h34Zl1jxrJC5mfTtOmEt28gUgMpwI8r8pJIHTsKt+HfhFq+pXEb69iwhXGRG5luG9gei17r4a8M2Gi6PHYWUC21vHyqofmJP8THux9aAOw05BDaIvmK5b5iV5Az2qzvxjn61iWrx2ibFcnHQ1Obxc9/XFAGiWGTk8HoK+bP2sZ2HiLw7EhPy2TsQPeSvoE3eBzjP868U+NvhrxHr3jGw1bRdLkvbS1tFiJR03htxLFVb+LB4ODQBy3geHxHL4OtrnSbKW5tWiMMjQOM8Ek7hnIIzXM6voPifFw8mi3qw5J8xlHPuecmp7r4a+N5JZmstIvoLd3ZkV7xN4TPAcqQCcdTioB8MviA+AljdHH96+Bx/49QBxky3e9o5YZRIuFK7SCPrWvpUtwRlYWCRsBwMgDtn0rpIvhn8QIh8ulOY85Yfak5/Wreo+AfG+qQhoNAure45SdfOjSMkH5dgByRt7nJJyc0Ac4tzJdTmK1RpJ+T5aAux+nFW4oNRWT95p12uejGNhn9KdH8LPH0UgK6ZOrDulyoI9+GzUknw2+I462GpMO3+l/wD2VAFHUL6WzvCJY5kJQZBHIxnqDg96+tPhXKU8E+HwGwGsUccevP8AWvmCTwT4sk0+Sxfw/qTajGV2FwrJsIO4+aWzu3Ywo4xmvpPwq8mlaHpNrcIUltrOOKQHqGCgH9aAO8MwPXmkWfv6eveslL1HXcvHqSakW5UDJzQBqrKeoJ9s04O+M55J/KsqO6GR8351KL4DjJz9KANAswU84/Go92eCwPJ6VQF4G3A9femvdjqDk+xoAs6jdC2029nJ4it5X6+iE/0r8+44jcXVrCh3PNIgyPUkV9rfEXVRY+AvEVwTjZYSgHPdl2j9TXxXo13FYavZXVxG0kUDh2VepwOMUAetzuLOzbcRsjBy3A6etcf8PYW1DxNearJ9yENtP+2/A/Jc1U1HxDPr10lnaWTG1ZvmjL4aT2LDoM9hXa+G9PTR9LitEw75Lyvj7znqf6UAdRaHofSiorVyWHHI70UAepfH7xdqujWNjpGiMYZ9SWRpbhTh1jUgbVPYnPJrwrTtNFnAZLghmJzu719OfELwLH4tFrcw3At9RtAUjdwWRkJBKkduRwRXDJ8HtW80yT6jppA+4o34H14oA53SBH9gUqgHt3/Gobza+4hF2jvx1712o8A6jZqEF7Y8DHy7sVxHxMjm8F6ANVvyl9D9oWAxwHawLA4OT24/WgDn7wHzNi7VAwW4PTtjtVa001tU1KOzhZhGSDcSAcoh7D/aboK4u5+JsE6t5OkXA67S0gYA+pwOar+H/itqWkaVe2MNrDbz3IONRjjLTxsTy4ycBscAj7ucjmgD0WJ59G8Lx+A9DRda8US6k97Z/Ynz/Z671ZTKSMeYNpyvQA8nnFSeJdK1Xwrf21xd21lp11eFs24l3WtzJgbxC/8AyzY8HaRx0BIra/Y/1WxvE8T2sdhFFeRiKU3JO6SVCzAhifcA8dc12H7R2l2d94Z0PzwFA1ErhTgnMTc/mBQBwul+Iob2NoSlxb30J3tbXC4ZR6qejDPcV2mm+LN8aLM21xxXnWh6Np1rapNJemJrfiFriUkJvHzBFJwM4Ga27KxsbrprtigGclpFGP1oA9CTV0YEo2VPb3px1fAwrH/PWuKjFlYPtfxFYNCeMrIp/TNdFaRaFLEGuPFFnB2+cqv9aAND+1QVPzNkdKhbVOh3Y+nemfZvDQPPjTTR/wBtE/xqM23hjJ/4rXTcHH8af40ATNqZVPvZ5701dSIOdxzjGPWmfZ/DBUY8babn/fX/ABpPsfhrcB/wmmm5x3kT/GgCVNQOSS30JqWPUSMkMMnpVU2vhxW58Zaaev8Ay0T/ABp4g8OLHuHjHTCF/wBtf8aALv8AabFiMjPTmpF1I7Blj71REXh7Bx4u0w/9tF4/Wl+z6GSQPFmmHP8A00X/ABoAttflhjdnPtUct8UU4bjpVdbbRjgjxZph9vMX/Go5LXSAhZvFWmKg9ZVH9aALDaiD9fWk/tIKQBjAzUB02wbgeIrM55454qubbQgTv8V6aMcEeYM/zoAvnUdwyByOtPj1XbjB4FZMkfh8A58WaZgD++OP1pFbw6PveLdOUH1YUAbf9qjn5upo/tJf7wBPXArJ8nw8GyfFdmoPPqKeh8OP8qeLbEn3oA2F1TAAyad/afOM5HTJrNs7LSLuQxWviWznkA3FEGTj1x6VZ/sS2JP/ABOo+vaM0AWZNVy3LZI9aadTy33z703+wLUk41dPqYjSNoVvzt1mLH/XI0AB1Pbj5mNVn1BXBLDIz3qX+wLVgca5F+EZ4pw8NWzLzrSE9P8AVmgCub8KpEeT/sjvSpqwAORKp7ZBGKsp4btxk/2zDj3jIpB4diYYGtQcDqFoAgGsIp2lzycdCf6ULrcRLYZ/XGwj+lS/8I4gPy6zbk+u001/DyLnfrNoPrx/WgBqavuJwkn1OBn6VIuogrzxnrUJ8Pqgyda0/HByzAD8yabbaKtw8iwaxp0pjbBCvnH055oA4r47ayLb4aXcKvhr2eK3HPUA7j+gr5knQRXbRj5yF4GOrEcfrXtHx6uYxr+k6ObuGeOwikvLoR8qjHhVPvgdPevK/CVo2p+J4pHH7uMm4k9MDoPzwKAO60TSYdKtYYwAZwgDuf73etmM5xjr/OqzNl8/zqeHGc0Aatk2cDPQ0VHZ8kdDRQB9bKeBUUz8EA8ika8s/KV/tMZQjIZTkEeoxVC71WwRcmSRh6qhoAq3rZyfT8K8Y/aLjE/wvvm7x3VvJ06fNj+tela74u0bTLKa5vGeOCNSzs7AYA9s5P4V87/Fb4waP4o8N6jomkaPdkXW0LdzuEC7WByF69u+KANj4EXZHw5VAqEpezAkqD12n+tdxNMWwNkTdseWv+FfOXgL4j33hHR5tOtdOtb2J7hp2aRiGGVC4B6Y4zXf6T8UZ9Yt3ktdOvhKh2yR21sJQv8AwKgD3f4aMG1fUNsSIDbDlUAz849Kzv2ipEtvh5HdSL8lvqVq7ELnau4g4/Osr4Ha7qWp+JtRjvrK+t4BYl1a4CqCRIvAA5zXS/HW1W8+GmqQyMFjJVmYjOwDPzfhwfwoA+f5LhI4mWSUSR5B6bgPqKgS6t2IIMTj/cArnpda06fSxuvrOO92fPCUKkv3+boR3+lM8P8Ak6/JPHaXEKSQHLRsrBiucbhjgjNAHqnw7hsdR8Qv/o8UsWnwG4kOwEGRjtiX88t/wGqnxXvYLO/srGDydyp9olBUZyThQf1Ndf8ADHw02g+CIpC8b3OqXTXU0mCD5KDYgH5E88V5L4tsbjW/Euoai725jmfEQ8x1IQfKoOBjoKAKsepRdCIeOM4qxHfwEc+SPwrFPhyYZxKi8f8APUn/ANlpj+HroA7LpQf9rn+lAHSfbLTqTB78daiF1aFjl4Mf7tcs+j3qdbuFQO5B4qH+zr7tdW5A9dwFAHcR3NoB96Ad+FqQXVqq/eiwfb/61eXXerSW1w0QmSYLxvjJKk+2etXtOk1G/j3RCOKMfxSkjNAHpMVzaknDREnj7tSiazC5IiPOPuV599m1QKSZ7QDP95v8K9B8EfDDWtSaO88R3H9n6Y2HWGL/AI+Jx7A/cU+p59BQBf0ayl1m6+z6TbCV15kcoFSMert2+nWu3i0Pw/4PtBqety29xcLjE00YIB/uxR9z78n6VkeJvHGjeDNO/srw5b289zEMLBG37qNvWR+rN+ZrwfxBr2u67fteardJPN0UZIWMf3VHYUAeteJvHlxqzyQWYFlpxz+7XHmS/wC8R0H+yK5o6pCMfJGOP7orzN7u/Tq6f99VF9vvM8lD2xuoA9UXVYQTgIcDqBVmyv4LiVY3aMJhi2QBwBnFePNqN4By6cck7q6n4aWV54s1u7sUuEhjit2ndmyc4YKMY/3qAPSU1qNlOXXafX1p39qxo2TsK9jjrXHfEfQrjwlHpTCaK4+1M64BYfdxyfzrgD4gvJHb5lTb/tY70AfW/wAFb9dSuNemWNFNukMIZVwfmJYjP4CvTIjucDceTjPpXh37KU0lx4U8T3Mzbma/iTcPaP8A+vXtQYFc9O1AHkeqfHSXT9S1C1k8K3Mi2srxLIJ2HmbWKg8x8Zxnqa9fjuDJbxSN8u9FcjOSMgHH4dKle4cLgs3HGM1Ud/mA28Z7GgC2hZsFATmuan8eaHa3M1vN/aYkicxvjT5WXcDjggc/UV82fGnxZrNv44v4rbU7yKBJnSKOKUqqqDjH6Vy9t4s8R+UhOvaqrsdkY+0HAOMnP4UAfXtx488P21x5E9zdiUHlRZStj8lxXQLcLLEskYIRl3LldpwfaviP/hMPE8doHXxFqgkZWk2+ecbRxn65zX1v4KMi+DtD+0ySSztZRs7u25mJGckn60AM8Q+JbjTr2aGK1hZFC7ZJDwSR0wKTQNfm1S/NvcRWuRGz5Qcgj6/WptV8P2+pTGWaaWJ26lPYcDninaXottpcxkiYu+3bvYDJoAwvizcwW/hjLxRlZLhF5QYPWvF7rVrOGJ5poYFjjBZjgDgV6D+0E0reFbFYZEjAvPMd3YqqqFPJIBwMmvmjxBdxPJbxW9wZ0WJTOwYlGlySdvAyAMD8DQAl5e3Gs6nOUXE19LuIz91ey/QDn8K7DwJbJb219eRj5JJPIib1ROp/E1ymkmKz0m7v/Nja8kBiiQN8y546V6Dp9qNP0u1s14MMYVvdup/U0AW8jPQVNEQpHHHSqsbDOMZzVuMcr0oA1LMgH9cGimWeF4PXNFAHu7+BHitooZvFeutDGioscTpEFUDAAwM9KxL34c6C6hrq71u7PpPqEmD+AIrv9RdigII5GKw75m2jOVAHTrQBx1x8OfBbwSRS6NHIrqVLPK5Ye4OeDXnurfBjw15jC31LWIYyeU81HH0yRmvXpHdUJ4P061z2oSN5pz0J7d6APN4PhL4Rs2zKuoXm3tNPtX8QoH866CGzs9OtUtdMtYbS1TkRxLtGfU9yfc1ryrvBwcZ4NZ80Em5sHK9BQB1fwkcjxNdLjk2bfowrqvij4gXw34G1TVHUN5ShFJAOxn+UNg8HaTnHtXmPwm1e8PxdutHkhEFmmmyyK7od05+XkN0AHpXVftGw+f8ABvXlLqgVoG3N0GJVoA+V5fAqReIYLZtTkuLeYxOLiOLaXVwGyATx1r0mLwxpvhie8tNJikDl9jTTNukf0yemMntXl+majrLatZHTtTk1mQGMMhifykA/hLMBjA4yK9r8SMJNcJTB82438f3VAJ/XFAHd+KtQTS/DTxW7ACC3Syhx6425/ma8fc7VCjPTH1rsPEF019BbRZyFzI2O56D+v51gtZcnjj6UAY7d+OnFQyM2w/Tj2rWe0IU4HPaqzWTyEhVOfWgDJLGUhNocngbRVTVNIaaDE8hihPGxPvSH+7710ZRLPCIm+4bnb6e5PYVn3VvcuxeYgtggkcYHoPQUAceugWlu5kePeQeFzkD6nua2dG0zUdd1FbHSLRp58ZwuAka+rHoq/Wu88K/D+61lYrnUWey04gENt/ez/wC4p7f7R49M10+r+J9E8F2LaXoFrHJOp5hjORu/vSv1Y/54oATw/wCFtE8D2H9q6/dQXF7Hz58o/dRH0iU/eb/aPPoBXB+OPihea0ZbXSPNs7BiQ0mf30v1P8I9hzXN+Ir3U/EN99p1S4eZv4EA2pGPRV7fWsaawKLlgR26UAVnnBGAOKqyvkHuOtWJbZ1B4qjLG68nr6UAVpmJHtUORjoPep3ViAOtRiEnHX34oAzJmBkfaw8tiCxx0Nd38KddtNG1TWhNfxaZeXunNb2d3KmYo5dwIL4BwOOuDXnjjDsPQn+dPmxiPaQfl59qAPRvid4ifUdJ8PWB1i31jUdPSU3d7bKfLZnI2qpIG4gDlsV5tnNS28jKyhSuc9802BYmkxPI8aYJ3Km45xxxkdTxQB9JfALW08K/BbXNWlhWZTrIj2MxAb92o610tj8Y1ubyGD+yYI/OZUybkk7jjAwBzWf+zDHb6j8Kr+2vrSG4gi1dsJIMhiYkOT+deb+OfiVq2i+Ndb0/S7bRktbO9khg3WCMyhWwOTzmgD60ZwrbTzg0zcDOg45Iz718f/8AC+PHZYn7dZA9c/Yk/wAKb/wvbx3nP9oWef8Arzj/AMKAM/4m3Tz+MNQkiuIlbz5d/wA4BBLsP5VzsvkSmNmu0zGAAMjDevfj/PSupf4z+LnOWbRnJ5JbSbcnPfkrULfF3xOxy8Wgt9dHtv8A4igDl2MRYstwhJ+XbkcDtg19z6TC1npdpCSu1YI1AU8cKK+Q4/ix4hBBa08OsPfRbf8AotaqfHXxxIpJu7AlBuK/YkxgUAe8eK/GOpaTrklpaw2jW6hSDKhLcjnoa2vCWtXGs6fPc3KxKFYKvlAgEYycgmvntPjL4wZtxm005HeyQ5rpPAfxL8Uaz4s0vTrx7A2txKVlWK0VDt2kk5HfigDR/aK1Ke3ttGtopXjE5mMiqcB1wowfUc188anFBGIBCpVnJB5zXuX7QBW51zSE5+S3djn3Yf4V4texh9X0+DjDOoP/AH1QBq2ukWK+JtNjtPNZFBmmWUhsben5ntXcSygEsTyeciua8NqJdQ1O9X7pkFvEfRV5P64rcdsZDDr1+tAE8b88fpV2D7wOetZ8WCeT+HpV2AYPy5oA1LPhh6iiizHzKOv4UUAfSzgkbSRiqd9ny8HaD0zjpVjeGXI7VTvm2kYPQUAY1+4RTtwB0rltUf8Ae5ycmuh1Biw4x7iuc1AszADJ5yOelAFNHwT2qVCrdvyqqQyk4A6YxTo1l2H5G46cUAdR8Ozt8VxKf4oJQM/Qf4V0/wAR0VvBWpCRVZcISrAMp+cdQa43wJuPiyzj84QyOsgXkFvuknAPXpXoHiywOp6Bd2QIUT7VJz23An9KAPE7jw7NeS2t416lvatAh+zJAB0z8xPTGPasKzupNXWPVTH5ccyv5IHdfMYBvxCivQPivO+m+GHtdPTF7qDJptmq9dznb+i5rk/iBJbeC7Agxs9npKR2aIjYMhGF4+pyaAJEt8qu7JYDJqN0VUY7j715nN8XppZFjstCQszYTfMWZiegwB1r3n4XeCNd1GKPVfHNpa2YcBrfSY0O/wBmmJJx7J+fpQBm+F/Bd1r2LqYtbaf0D4+eX2UenvWl4w0yw0SzW1iiUXZXEUackD+8f/r0fGT4z6Z4Eim0jQTDqHiQLtKjmGz44346sP7g/HFeEeCvD3jv4l6hLql3rF9a6Y8h8/UZnYBz3WJRjefYYA7kUAd9Y6RLJMsNvBJLcyEsVxkn1JPp712NnoeleH7M6pr09ufJG8tKcQRenX75z+Fc5reueF/hLYGzs5Z7vUJI8vG82+4uX7NK38C+gGB7HrXz7428aax4xvfO1WfECn91ax8RRj2Hc+5oA9y8X/FGxvfNhs9Yt7a2P3nV900g9PlHyj2HNedyeJ/DseR9rlkxn/Vwtz+deWUtAHpMvjnSEyIbS9k9yFUfzrPufHcTZEOlkj1km/wFcNRQB0tx4vuJARFZWkY99zH+dZkut3sjE7o0z/djFZtFAE73ly/3pn/A4qJpHb7zufqxptFABRRRQA6NisisOoOaaTkk1NZxiW7ijYgBmxzUTqUdlPUHFAH1/wDsx2Yh+EltJCCJLrUppGJ5GRtUfoK+XfH0pm8d+I5G6tqVwf8AyI1fWn7OsflfB/w5jq9xPJ/5ENfIPilvO8TazMDw99MeTzy5NAGX9KKKu6Vp0uoNcmNoljtYTcTGSVUPlggHbk/MfmHyjmgClRWk1rbjOHyPWjyLX7rFue47UAUoSwycHaRj860IbApkylgrAYYcEZzSWKQEzQT53L8yEd/UVs6pcWNvJDb3EszPsiYtEoOAUDcg/wC929KAM3TJtuInGGXKqT/Fj+tepfBZFl8caeWB8yMSOP7oAQ8+uc4rzCSFXupoYnDLJl4nU9HXg/nXq3wAb7T4rE4XlbKUnjo2VH+NAFv43zbvFsaAkCO0UY9MkmvGrq48rWopm/5YJuA98Ej9a9T+Mc3meN75c5CRRp9Pl/8Ar15dDa/b/E8dvglN67+P4VGTQB3GgWTWuk2UDA7inmPn+83Jq8QfMwR0rRskWZwwA59O1PkswtwCTjJ6UAUIRjJ7nitGBc/j6VUI2SlAQB1NW7U5AAoA07UEOOM0VYsbdm5I7UUAek6j8W/AumQmOTxBDNIM/LbRvIf0GK4/Wf2gfCUeRa2urXZI6iFYwff5jXzHfE+a/Hc9KovuPXPFAHuurfH6OVz9h8OnHYz3X9FX+tcrqHxm1+5/497PTbYc9I2c/qa8x74pQCegNAHYXXxK8WXBP/E2aEHtDEifqBmsS78R63eMTdavqEueoa4bH5ZrLCNnG05p3lsDg4H40Aemfs3Tufjb4aMjs5Mkq5Yk9YXr7au8mHHXkdfrXxF+zrFt+MvhdyQf9Icf+Qnr7Y1zUYNI0i81K8DfZ7KMzy4H8K8mgDzS/jj1r412EQw9j4Zt5bude32g42j6/Mn5V5R+0hLc6jqui+H9Mie4vbotdyRR8k5JVc+33jk16X4T8U6I7XpgVFk1IRzXWoKOJZWJkYHvwWAz6AV26W3h7SfD9/4i8RJZ2sc6YnvJFAdol+4gPU+wHXNAHjvwO8HaL4K1OHUPEKQXWtsf3U7EGK0452Z4Lernp2x1LPjR8e5J3l8PfDqR3eQ+VNqkYy0hPGyAdf8AgX5eteb67qGtfEXWLux8M280ekK53SynaFjzx5jdhj+Ecn3rodI0vQPhzaC+u5lmvyuPtDL87H+7En8I9/zNAD/ht8IIIca38QWBVf332BpMD13Tv+u0fie1WPiX8b0jiOk+B1jVI08r7asYVIlHG2FOmPevMvHPj7VvFshgLNbaYG+W1Rvv+7nuf0rkPIZQC/HtQA25mmuriS4uZZJp5CWeSRizMfUk9ajAGec1KwVSMGoz16UAIR7UlOAz9KXyzjmgBlFPC8/dzijaR1oAZRTygC9Tuz0x2pCMDoaAG0UUUAFFFFAFrSQp1O2MmBGr72z6Dk/yqK6dXupXQhlZsg1o+E72307xHY3d4AbeNiWBXcDlSOR6ZNdP8T7HTIJw9hIvmFvMVFAwI2AOOPQ/zNAH058A1kT4Q+FfMUJxO/1XzWwa+LtSbfqN2396Zz/48a+3fhcn2X4R+FMj7ultL+e5q+G3be7NnqSf1oASkpe1FACliaXeabSgZBI7dqAF3NkEHBHSrmptaubd7UShmiAl8xs/MABx7VRPTivQZtFg8UeFv7U0qKOK8tI9rwI3UKOVx9ORQBwMbNG4aNirKcgr2Ne4fszXPn61qsZTb5Fl9/OclpBk14aORxXvf7Klrun8TXJXICW8Q9ssx/pQBgfE25juPG+t7ZEZo5QjKDyMKO1cj4FjE95qF7JkuFCD/gR5/lVT4iz/AGjx74glB/5fpR+TY/pWfomtXOkNKLdYnjlxvR1649D1FAHrOnM8TiReR3Fa0ssM+CrAHuK4fRfFWnXTr50n2CccBZDlD9G/xro450eRZI8HP8SnII9RQA51/esuO9XbCFjKoAzzVRCGbPrXUaDYh5YmKnFAHQ6bYhbR2ZMnbxRW1HH5dhJjgmigD5TudOjaeQEsQCeM4qq2nRKUPl8nHJBrtpdIMkhyxCZJ+71NVptHkGVYMc8Ajt70AcfJF5bArGNv8J6c1XkhLcEMM+ldjJpIC7j9zvnnNQSaeUZQoDHsAc/pQByXkgfw5YfwnuKX7IzYAXJPpXQfZE3Yxx3wKlFqrMVKtx/F3/KgDe+ANu8Xxa8LM2T/AKWR7f6t6+z/ABLYR6poOoadcM6w3kLW7lDhgrcHB7V8ifB+NLf4n+Fsuy5vQhB4wcMMV9kak6xWkrk4288euaAPnL4geHofh7oF79juWOnwgxQTOS7ozcAN6kZ/SuRurnXPiffafdeJZriHw5ZokdtboSjTBVALgdmY9XP4V7p4gu/Dd3Zz32stp11p2n3JkaWZw8cU65BBGeXXPQ5+lfN3xK+IkniC9mh8KwvY6c2Va4b5ZJvp/dX6c0Adh4z+IWgeGtPi0jwxbWyTwrt8mP8A1UDdyx6u3r39a8Q1bWZdTu5bu+ne4uW6s3ceg7AVUOlyhcmaAcZOWxVZrZwpIaJsdQHHFAE8cjOx8uNRk9alNs5w0hJ49CKziCp9D7GnB5iMB5SAOmSRQBZkiVcgfrUM0arIVQlsD5vQHvj2qIs3cn8aNxoAl2ZHbnsTUnyAYJz+NRKdx5aNfrkVoW1nJKV8oWL7uADeRof/AB5hQBRLAN8ueuRRuPp19q3V0jUI1D/2XLKOxgkWQf8AjpNVLiyvIf8AW6XexZ5BaBsUAZWGYDP5U1lIHSrMjhCDIjr6blIqBnUk4PU0ARnrRSk5pKACilAzu5AwM89/akoAK7nwxZ6VrOgXE2v6q1vLbTCNIUXLyIy5LZweAR+tcNXf/BO7t4PF01rdY231o9sCexJB/pn8KAPq7RoItO+FmmxxuWW30NlWTGMqImwa+EV6CvvTXv8AQ/hjfbj80OhyDI/65GvgsfdFAC0UUUALnqMA+9S27TRiWSB2TCFXKtg7W4I9wc1DRQAo47Vs+FdbfQ9UWYhmtZPknjH8S+o9xWOVK43KRkZGRjI9aMfjQB2Pj7w9DaNHrGkFZNLusE7OkbkZH0U/ocj0r2D9lWHb4c8Q3GM7ryJPT7qMf615l8Mtdgkjl8Ma3tksLsFYCx4Vj1TPbPUHsfrXt/wP0R/Dvg7Xoi5dF1CZ0c9SqxLgn0PXNAHzr4q06zuJtY1XTtUF2Uuy08TW7RlfMdsYY5Dc/SuVqxLLKTOodxHK+51B4YgnGR3xk1ABQBctL8wxGGaGG5tz/wAs5R933VhyprvPDut6XcRQWsX+iMi7FhlbI/Bu9eb4wcGnAjHSgD26FSpGSR7V6J4Si3lCFJ+XAXFfN2heKL7TCsbEXNsP+Wch5A/2W6ivoD4ZeKdG1vyoLS7WK9I/49Zztkz/ALPZvwoA7rUoxHYoD3P1/OirGuoFSNBkc4OeoooA8Wkgw7MUwB2qG4gwcAcAD8a2JIkEnybsueuOBVWWNULhlLMcgYPBFAGPJEu5Q+0KeuRx7celZVxG0KuPLAkdgSQMbT7V0Fx+8I3JvZ8A9+nr6VTnhDR7sMTkkA/xc0Ac7NbHkqQVfDbV6k+9VyPN3O+VUcEKeQa6G8tVVyyoC/C5BJ47Y/8Ar1lXUJidgwAOep4PvxQBs/C6Lzfid4VaNiQmowtk9cc5/nX2ZqDw2lncTSrmGBWkcBc/KvJ47181fs2eELbX/Ft5rV+JDa6G8a2ke4qJLogsXOOuxccdPmr6ivYGa1mCDMhRtvGeccUAfIfx+1vwY/huGDw5bXNnfz3LS/ZmspLaORCfmlKtwzZyN1eBx3MmNkY+gAzivcf2iYIJfG1m19P9tv5LFZZm8zKxqWIjQKOEPBOB6+9eWrCtv/sD2AFAGE9rdyndLG/P9/j9KrvH5blXIyK2rrUogrRqDIfU1jzMGdmGeT6UAOthGGBkYACtD7XAsTAHDdsDpVG3UZwI95xz6VLL8wOy325HGaAGTz+YMbyfQmoIj8/OPrTjC/XYRSCFj0HSgByhP4lX1qVRAesIOPciolgY9BkDkmpPsrnnGO2aAIZFi/hjK/jSxzzRf6qaaMDoFcirH2CXd8/y1MumnaSSeKAIYtX1KJdseoXar/d81sfzoOrXzD95P5n/AF0RX/mKs/2XhyCHypAJPApj6YwYDJz3NAGeZmbqsX4RqP5Co/wrR/s05wZMHOM4pJdMaNwpkBJ6EDIIoAzxzwASTQeDg1beykQgq2ccjtVVgQx3de9AElpLHDPvmt0uE2spjdmUZIIByCDkHkfTvUmmXb6fqNrdxk74JFfjvg8iq1IaAP0J13SRqnhC60uSVoEvdNFqZVXc0YdAM474zXkcP7MnhozG3bxZqL3CoHKLboCFPAOMnjIrwVfij44WzS1XxRqgt0RUVfN6KvQZ69qUfFLx0OnirVh9JyKAPoP/AIZb8OjGfEWs5/64x/4VLb/sw+FI2f7TrWuTqVwoVUUqfXOK+dT8UPHJ6+LNY/8AAlqY3xJ8bNknxVrJ/wC3pv8AGgD3XxR8IPhhouqeT4h8Ta7bXksYm2sF5XoD8sZ9KzR8OPgugRj4r15t43LiMnI6doa8Wf4geLpDmTxNq7e5umJ/nULeN/FTHJ8Saxn/AK+3/wAaAPeH8D/B27Mfna94ruRDFtjxBJhUHYfua3vCXwV+GGvvLc6RceJLqK1dRJHcAxqxPQfNGpI+lfM3/CZeKMY/4STWsf8AX7J/jSL4s8RuQH8Qaw2Omb2X/wCKoA+x5/gr4DW4jgOjzxvLuZAkeBle+7t19a25vDEOi+FtRs9MMgDRSkSXD5JkZcbmOOO3SvEP2YZfFmoa/qeoyajqlzYW9sp+z3cztFdFmxgMxIBHJyK94l1TxdDFNbr4etJwqMRPJfqkbL1+b5flx3oA+FPEeg3mgarLp2pxKlzHg5RtyOD0ZT3B9ayim0g85Br1D4v/ABDi8dR6XCuiWmnTacZEaWGTzN4JxgNgZXIzXnAGVzQBTf5myaTFW2h+Unn2qMx4Gc5HvQBCDzxU8LMGU5KlTkEHBB9RSBMnIp6xkdqAPTPCvxW1yw8i21mRtWsI8KPNb98g9n7/AEOaK86iBDDNFAH0LMhLbVAYBvXGBVWWPBcKMN71rSxCMt1JB5O3j2pgiBwixktzknowPpnoaAMWeASBcBXGccDDD3qusT/cZCYwST2GPf8AHFbJt2MkbnCkDAJ4JGfbvUdxayFhnoepIz9RQBzNxA0hKkkdgOxOevuPasvVhHaQSzySbUjUF3YZ4PX8f8a7G5hLEtMAzqdwGAD9c/SuJ8aQeVpsMhH7lLyJ5sDgxg9cfXFAHpHwK8GDxNpviGPULq8052EE9v8AY7+SOe3Zs5Lop2rvULwcnA7cVseMfA1v8PdBudd1Hx14jgjhOIEivn8yaXqsaA9SSO/QZNY/wY8X2vgS21l9Usb65m1CeADyQCTgOS2SeRznjNeefHTxjfeNtYae6xDZW8nk2VsrgiJSeSfVyBlj24FAHm9/qOq6lqFze3M91Pd3L+ZLIzF2b0yT1oTSdRuCvmxuvOMytjH4V0Ul/a26CNSZXQ4DL0I/qPeoJtYnlQCOJULAqS3agChFoDsVWSQhj/Cq89eak/sSBDl5GcA+2cVGTdF8rJIee1PtbW4nk2bnGBz16UAWY3srVdgXcP8APX3qnPd+YCqJ19q27fw8hYF3DMQfl68AdatW+lQRK+wFgeFO3r70AckYppRkIx3etTx6ZJuU9XPQCuwW3JG0DClgwAxwcUqWWWycLjq3UfjjvQBy76c0fOzqARzxz71YSxGwsDlhxtxkAEetbrWpEYyoAC49zzUJhLyDKbs8HjAH0oAyliCAbkLexpvlN8pkU7On0rY8mYMAN3A69cGljtfMPzBAQcndxQBjhZHBwpPHzbT94DvVdlkb5SBzjpW01ucggEhF5UnG4+1Ri1Z/MOQrEYAIP6UAY4hKlSGHHp2pklswZdpBB685Pr0ra+w7Su7DjJDBeuKY9gxJABx1HfH40Ac/Pu2fXoPSsq5iZWJPOTxXXC0cMCF+YHPTr7iqFzp7SAgIOPmI7/WgDmT16AUVqyaW+RgbQaQ6VJsO0FiOc9KAMw8nJ6mkxWgNLus/6vp707+y5wCGUAg+tAGcMUqgnpV/+zJARnIHXp2qddPMeQVJPUHPagDJIwfagCtpbLIJwCRzg077DuGQnJ9KAMYDjNWtPije9to5h+6eRQ/+7kZrQNoeMR4HsKeLOSaFYjnYCSo9M9aAPpr4J61pfhcXsuv3iQy6k0NvA5Q/JtDEhj0VR9BjFcp8ffivda9ZyaR4Ylkt9A8zybicZWS8PPy+qx8dOp78cVw+g+LruxtbZNV0GLVWthtjuPNMbMn91xgq3T72AfXNYHiXULzxFfNKLGGwtUZmS1hJIUnqxY8s3QZ/AYoA5kDBx2qUIM4q3Hps+QSBjpxV5NMOBuO4Z5wOlAGUqNwduRSG3ydpAA9a6SPTYzhcllBwMd6f/ZapnKgj1BoA5cWrK2FAY9sd6mS0ZgCTgk9O4rqU04MPlQED396uJpKyfeXaemQM/wCRQBycdlxyCCD1HeiunXSZFZh6dPr70UAe03HzIVPK7TwelNuFHlwnAyY48+/FFFADdOAe8AcBgHAwee9IUUzL8q/6xh07ZPFFFAFExoYZsopwOMjpyKx/EUaPa3aOishUgqRkH5aKKANn9mJ2u9GgS7Yzrb3hWESncIh6LnoPpXlnxsjRPjF4hiRFWJJjsQDAXIBOB2oooA4xVBkbIHUV2Xh+1t3t5C0ETHI6oD2NFFAG9HbwiyhYQxhs4ztGab5UYSIhF++46UUUAUo1C3NvtAHPb8aWIDdLwPl3Y9uRRRQAy9VRc8KByD09qnlG0TbeOnT60UUALNy0xPJBwD6UhRPs6naucelFFAEd0i+ZMNowI+Bj6UqEme2YnJKDJ/GiigCSRFM2SoJJBPFVNqi44UDBbtRRQBGfl88LwORx9asxqPLBwM7Cf1FFFAFO6UByAABUEiqEBAGQeuKKKAIgqmHBUY57e5qmgAxgD7hoooAQKolIAGM+lG1csdoznriiigAdVyflHUDp7U3avm42jGPT2oooAa6qC2AOnp708qA5wB09KKKAJti+UPlHft9KnsY082P5V+96e9FFAHU6wAl/AFAUeWBgccVz9woF22AB1oooAYUUHhV6elWgAJFwAMoM0UUATxquwfKOV9Pep1Rd+Nox9PaiigCaJVx0HHTj3rRtlGV4HDYoooAsXSKZnJUflRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Emerson iron lung exemplifying design dating back to the 1930s. Patient's head protrudes through neck collar on left, and electric motor beneath the tank generates negative pressure via the leather bellows on the right. The device weighs 300 kg.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27248=[""].join("\n");
var outline_f26_39_27248=null;
var title_f26_39_27249="PA catheter leveling";
var content_f26_39_27249=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F69197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F69197&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 511px\">",
"   <div class=\"ttl\">",
"    Position of pulmonary artery catheter pressure system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 491px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two methods for referencing the pressure system to the phlebostatic axis are shown. The system can be referenced by placing the air-fluid interface of either the in-line stopcock or the stopcock on top of the transducer at the phlebostatic level.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Bridges, EJ, Woods, SL, Heart Lung 1993; 22:99.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27249=[""].join("\n");
var outline_f26_39_27249=null;
var title_f26_39_27250="Fibroid embolization 4d";
var content_f26_39_27250=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F56265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F56265&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Right uterine angiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 399px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGPAYUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDou9HSijrQAUGig0AJRS0lABRS4rU0bSpNRn2jKoPvH0oAo28Ek7qkakkntXXaRo8NqwM/zyjHB6Vs22m2mn2pjtkDy95CeaiZtrjJViMZagC/daVBeWjNGFjkK8L2z9a4kNNFJg7kdTtxg9utdeLmRF+QjHp2rH1uHzU+0Q7BOOq9m9sUAJpOqTQ3Kljg45rv9HvkvInKnkHP515dpLG5ufniKOOuDXbeG7i3tZXWQmMlcc4wcUAdRLJtHGM1z99fKl1hwCe/tT9Rv1kIa3mTAOMk1Rvk8+zZgQW7YOeaALY1DTZ7fzC/75fcr+nSuU1RbW81QGGJERScHGSwwOCTk/8A6647Wry7TVkiKskLHazdCOK0r/UZA0LWcbSKSo4Hrkevt60ATTWM8G4QyB1IwFQDJB5qGG7nt1OWki8sdBwPXP5fWrOlX8syItwnzg5DKBnv1x/StbUCJ4A0+n7pcZDBevp+NAG94V1L7X4e/fkEmNmyRyfm6k9O/SsRLtLO/eK3Z8A7lTt/ntVSwlv4bWOK3hbbKkgyTjblifXtgVHFpl1LGHVh5+MkhixOPYH2oA17OWV5HluCXlQ5HPBIHr09q6jT9ShuoUiZNgxtK8cVzOnKXhWOZow4AVxtP/16i1iOaznie0njUkFSSDkcnFAEPiSwj0qfDpuDcoRjOK82F9cXesT2sYHk7tse7+8K9hjRtU02RdTRQ8YLpKp5PHcGuA8P+HmbxEyoyNufecHjr1oAjs/At/dWpuYMAM3IJxtxmtGK6vdLUwSo6kffHrj+hr1OHSESIIZZCuOVBwP5VXfw9YmR9yuySD5lLdMdx6UAeVxagv2rIDRrIOUPRuR/jW3pVsYbZ44iTHu3Ln+6QSMGuutvBemW9x5yiZz/AHZGBA/SsvxmiWKwT2yqirlCo6Y7fSgDldYU6haSW05GVyVY9iK4F4fsr7WJCFu/Uf5Nd+HNxIW6jP5e9Vb/AEiOdtysT64FAGZosplUIm4AjPcV0kNyYoFXq4YYBPb3rCFtPaE7UDAcVBPeTGVIueMHPegDqWvCYhuIVsYx7VNaSRiYKScNxn1rA06Qyptdvm6ZIrbtkG5HBUsDg47CgC89vG9wGIHXFZuqWCNIxUY49K07iQkkp0H68VkXE7mQrkDPU96AMKe2aM1VIIzXSC3WTGSxX1Jqnc2CktsJz6GgDG7UVPNbtGeRxUBGDQAlGKWigBKO9LRQAmaKKWgBBRSgUUAJ3oIo7migAo70lFAC0CgfSpYoy7BQMk0AS2Ns1xcpGAfmNdvDHHY2/kw4yPvMOprK0u1SzG5gDKRn6VYlkzhtwyDk0Aa2f9GZvNAYnGKochzuGQ3OR0qH7R5i4z9OKsbk8v5Tkr3zjIoAcz4HXjHArNuZWI5609rhUnKzcjt2rM1m4jSMlWJJHAB5oAbNq32Bt0ONw+99KrQatcz3SyRsfKZtw59e1c9czMwbzG7cDNU7C6lspGkyWj3fdPb6UAemNc3CA7gvlEbu3WqWq61HbWpzJsZeSVbFRQa9b3NizHbuKVwfiTUVuGaOFi/PJFAHS6bei5mkmeRZMZznk8ngfl/KtK6VZYsw9gCVHBUHJwB+P4VxGiNt06RlOJC+GJ9McfXmtS8vpIZ2ji+6u3JHuD/KgDdRxlWYgkkde5wePpW+Z2KoCqtBtDE85XGM+/WsjRJI9QgBuYkJ3EZAwOvT9K2gVaCOMDy27kdz/wDqJoA1dHtUmtkmyxw2QSMEjJ6fnXW2dnHGxYKpUqO3Ws7RoV+yooG0bRg4xyOv8q1o4SmG80lR1GKAOZ1iyW3u5BBhWk5Ud85z61BNExtVlmczO4yox3xge9a2rajYIzAhZJCP84/I1wepa4N6GLKsME7vXj/CgDW1G8I0W7lTcu5mVR0xtxn/AAz7GszwTn7RbzPtDyNk8+/Ss27uBLYJCCzPI2cck8tyeKueHZBbeWCwLRP2P4/hQB6Y2s2qSvGSSyLuwOeKwE8Wf8TR1kgxDtHKgnvXJ2Wqs+qzSSEOJR6U9wiaiSmfmxkH86APUbXULW6j3wToy9euP51yXjO8trrZDbGOUrkyEcj2x61jyErgjgDjAPJpRHGMDYXfvg9PrQBjQW8kFxuA3Jxx2FbZVFw0aAK68g/Wo41Mfyv0J5Apb3CKsiM5XOSuc4zQBFcBcgooKjtisHU9i3inaE46Hpitae4L72hPAGSvrWDqxSZ4XiBIUEHnOKALkW6NhsVQSM/hWjatIqlzwWGMHoax7FyUOdpUcc9auidVAVWJYDlSeKANk3KID5gPI6Y6Vk3yZmZkYEemKdGx85S2Dnr7D0p13EHUFQMjvQAW5MQ5J6dCKerAjc4zjpioIpCCVzkY61PHsY4J+XqeaAHSJD5Q8xcM3Ssm+sDHH5inI74q9JKXm5GEXj60l1cAW7rxyD1oA58iingeY3y9KaRhsUAIKT8aU0UAIaUUUUAFFFFACUlLSUAFLigU4DNACoucVu6bbJbKs0/VugI6Cs2xAjlSV0LKrAgV0M2J4XaM4cDJVx0J6YNABfSCNTJE24YIyB0rN+0K7NvUgE84PvUyvcfYZLaaMFiuQRVNbKd1YgKnc55zQBcSQIWRmXaVBVj1NS2k4VipOR7moIrBJfmuEDqvQL1FVWtZYC8hIIznB5AFAFm9kHmZUgjoT+NUNUtDJZ5iYlk/Wp7cqyyMAEJHI609FLZwyn2xQBxt2jKGDA7selQ26Eo5K7lPO01115ZI53KNpHVSKamlxLAZN4IOcgDpQBz80KfYUMYHpXJyoRI23jJ5PpzXfXFhIluAIyYwflIGQRWPa6LJJJI5HyKx5xQBm6XcLbafN5z4KruAPQ8f/Wrcv5I0mYsQzHnAOO1ZmsWJlt5EVyC3y8DpnvWnBEj3m58AEDgDjAHFAG54f3xOoYdV5GeM9a6aKRXBdgc8MB79KwLdeQxyOcY7/wCea3rYMkZbna4HXnvQB2OntiKMgY4HoO1O1a8ZYlRWCbuSAee1Zun3KOkRzww24z6cVQ1W6JlxnBGCM9PSgCnfTQktsJVlUc5znisSa3SZzEhAlALLnB5xgc0+4kcTDeQBIMHrwc8VAgCjG5s4wTyCTj+lAEM+k3llaNMsMjhW2fKeDx2/Cs3T7meMslyPIfdgjP8AU9a9I0OV77S5LV8F1TKFh35/wrhvEelOvM6sVBDfMO2fWgDL0uRReS+WC2MYdmI/yK6wIpe2mnwAeCcYzXDWSm11QwyhlHONpHHpXo9pJbtolu5bMjMSc+2KAHyvGWAiQqvdietIdoIcEe3NUnmzJyQ3JxzVG4uCkuMfhQBrm6QxlSqg+pPWq0tyrKU389sevpWRLMWGFzkjkZqGOR0LFiSvegC7MGgO9cnP3l71Vu445YxNADhjhgOoNPsJTMzwv1Byhzz9KtCIwSebHtz0YYxkUAZf2eRfuNlScjmplEmQWwcDnNaXlxhfOiQmM/eXrg1XuImzlRgH0oAdE4eRCcZz0q053Erx6DtVBCyYbJB7DFSlWZ1bJBHHNADpIyrcfjSO67Ai8H1ovLtFjCov4+pqkHwpOAWPP0oAnkfZ8rc9qguAdh2ngqc5+lMLs68nNRyZ2H6HB9qAIbf5ZV46Cp5kDBm449DVJHywHcDrViVg0Qx0PegCHjNFJwDiloAKSiloATFFFFAAetJS0CgBQKnt4hJIAxwo6moFxuHvW9p0kUafZ5IhIWIZj1yPSgCxYT2ySKGjU4PymtSSaNm80D5iMnjg1mzW1sWxG3lkgkAVJB5k37tOGUc7ulAErYwQVyD2Bras9Ca4RfmKgqM8ZwKwjE9q6M+D8/Jz2713enysqiRRnIBz2oAwYdFezkdUD+W7ck96z76JbeH95bcHIDN0FegrcRSDDlRketZV/CZ4Z4iitEw79vxoA82eEMpEaFVyfxqVImVCeBj0rUaxkt5GaRP3Y+UEHtUbwqoPXBzzQBREfynew246YoEY24XK/pxVqNB0yMnjmmyQ5POR6HNAD7ONxbuNqOpP3CKZdWu6KT7P0IYbVHIPpirNipLnPAx1pLpgJ9yAK+eSO/1oA4TUrZ1fB3ZXLEZPWqMMjR3CKykkcbvX6j15NehNDBej99Gqygdzgn8qyrrw9C0jMkjg5HAXOD9SRQBWsi1xJhcE5HU+pxXRkbYogDkAY54HT/GqVhYwwIcPukUbcnK4+uMfnVtmVBh4gVA+9sBOPxzQBY0++jinRRKv3gygHkc8iqt1JulYK27BK9D2PWiM7Sm3Ckc5H161Sa9Z5HRiBIHxjB44oAlkhkkXcu8yDplT+laVpaWFrtmvT/tbW4ye/wDOo7W5S3VXZQ8x7ZxgVSvtQk8/5njVW5DBASOOgJFAGnqPiIQ7YbFkgjUYBVhk/jmud1nxFc2kEpabKEEjcM5GKbcXrlSZ5ZOOcE5zWBfWD6xciaRy6IuzH0PT8iKALGneIhrUKXN1pschBALoNrcV1k9xbPpULWaERZbKk9DxxXKeFYVs757J1IRiXXPHX/JrtbqG1tpYofMVTccMP7rDp/OgDADB/u4zyODT1jMgOxtx6YzzirVzE9tcFJIcr2x2FRo8LZIGD0+tAFZrUhSwyfUdMVBIpDYYEqRWrjcPkwU9DyajeFhgnnPOKAMNmMFxG6EgqeorfsWEuQ+GPUNWbd2+7+HHcEVowxlbdBj5gOtAD2UwsShO08HFNbPAA2jrg9j9aiZyD84yO+OKasjSOqoeAPlY/wAqAJAg5xyQeabeMI4gqnJ7mrBdFgO0qD/EO+f8Kz7kqzFnzx070AQw4ZjvyW7D0qCVgnOOTU6ZEuVYGoLlP3uefxoAajnGfemXDfumXvikZ+CPeoLhwseSc5OCKAIo2xKR0GBippGyevPWq0eDk9sAU8tyRzxxQApkHmgHvzUqncSR9KqlgQMkADvU1qwyMcgnmgCcjFJTpXBO7GAelNHPPagAFFFFACDqaDS96dDG0rhRjH8qAI3k8lC+0t7DrTDcNLtWAvDMOQzdBUd3fCK4EUseBnAYelKs9vPsQsN+cZ9aANjSmmSHffXAljAy3QcDuOKg/wCEhS2dntwxjU8qSOn51IYSbKTaP3akAnPUVy0tityj+Weeh55Pv+tAHSSeMIZMCVWHtx/jW/p/iqF4UAdllYHAzxmvMLPw3dSTqkcxA6fPXT3OkzWVpaLtMk6H7w7jNAHpWm3khtWS8nj3yjK4FOguLoXDLucqTgDriuLihluLVXjZmnA5UtnA9q6/RrxHkjVi5AUEEjr14oA0WYpcFLhHIbkFl+X86yJAYZCsi/I3T0rqUmjkIZkQgjGO9Z2uWQhQywgeXwCrdqAOeuIwG3AL7U2HTJ7nDR/KvuTVnMcsqqR3xkGtoSCFQqDp0z2oAZoekKjnzHLP71JrGjLLtcEKehxU1jexi7RRyemQa3LhFktgc5A55oA811O1aBimzOOSR1qlt6CQMSACNx7f5xXeXdoJMsqbx054ritSSSK/lVwUAx2yccUACsEdWHBHHTqMe1StKso3qr8nJDYB44NVFUYyTIWPGc8/yGKVUCKWZDtzklmJ2n8T0oAkAkDHaBtxkgkc1jaxbMkr3ML5zge44xg/lW2koQcIpAHPB/H+VVWuJctgAxEnK7QSKAMKLWREGWRXDKeqgt/KmT6nFdLkCT5R2jPPbrjir97Yh13xnbz09sds1ztzZyqMFHXsWzjHegCZr97iQQtbyquPvEqcdeeGrrvD2nf2hG0KHvn8e+frXH6NGsMkm4ng5JbOT1r0bRFksrNWt1QSFuvYDjnr/OgDM17RH0+P7QGAePn5etcxrGuLe2sDxhhIr4YEdD6/jXZeKdXgeIPPKGYn5gOx9fauE09rW11Vbq4DNFNhGzwBz1AoA6mw1aLVLNYbjdHdRjKswIDDvzU9pYyXDkKgGOpbgVeiOns6RQRRtu43DPGe4rCvdQmh1Ga0aTEaH5RnBI/z/OgDoI9Pt7d8zyKzEdFNWjeWCQ7Qrk9OVH+NckbtclGmGe3PSn+ajnBkcEdgaANO8ngkbbHkAjB/KqskjMqAA5AGfSqFzcrHESN5I5qOG6murc7TjBPUDkUAWpJQT8xHHpUyAPHhFwKoR/unB2Zz61ZSR8DCpn1JzQBZQBc9Q5GN3qKrzZKkdOMYphdw5DlWJHAxSzSL5Z9RmgCEKS4Cjc3tUlxaTeVloTgdTWno0QJLlcnjJx1rYcKIyrcg+tAHCHCqw6NVC9fG0ZzznFa+vRiG9IXnPNYN2wMyjNAEkB+Y7cA0M55Iz97ioIWAz6A0EgqTycNQBI5UFsDqARn1p1uSqEc56D61FMMoAD8wGP8ACo1f5/TZyR+tAGjcNmNQTwBTLe4BIVsZNRFx9mZj1U1AnCByBxQBrCioLaUSRA8UUAT1aKGCEKTtkcZqC3GZckfKvJpZ5GaXcM9e9AFLUIDMn7sLvPc9qz7axc3DvKh3Kd2VPBNac+JMZOGHvVfzkguAXYYk7CgBLJb6V3XdmInAx1ArQtLaO1eQyDfJ06dKdbMpBaIDa3II7VOH/ffIxLZ5UjINACMGUROw4BB/Krl9fswgRDtiUZOAc0skDPa+cu1WXLbcdT7VGGkaNzcs0ZKnaCuM+9AFIXEsc7LBImxl5OMZ4rY8O6xDLdxRb2gYHacklciuSWMrcMS4VBxuBwTTYIZfNLxNwWznGdxx/wDroA9jN3sIwRheCB1NaOuTxnRWweScAHr16msHRSt7p8M4QAjaGOO9HiaWaOBUPKnk+vXNAHK6lq8lrKVicgg5LYoi1qeY7pX4PocVk6jLvlbKY54qDcqgY78jigDs9J1AC9iLnAyK9ItXW5symc8Yrw2yuy1ygEmdpGQTz1r0/TNZhs4N8jE5AG0Dkn0FAFnWpxZWrb3w7D5QOuenFcc7CSBjNlmHK5HzY9adqU8+qXElxcSMu3IRR0FZgaUTFJ2DA5wRQBaRXlcLEpxuwTTrt0ghCs43H5eRnPtxUU135CN5PQ8bsc9aqCV55d0rE9wpGMcUAOgndowr89s569ev50/gj7wVuSRx/ntTZB2HK98d8f8A6qa21QcnbjPRsZ6/4UAEo3xEbihHQnjP+eKhd1YqkqZcfxgZOMe30NTHIJJyVIz1zmqwJEjh2yoPVuAPQUARyW1sJklLGPaOcDI+lGra5LYRpCELOVAXaOM/lmplClc5IB4ztHNZfiCx3QpM0gj2YLN3xyScY+tAFLRrSee9e81KQu0mdsZ6D0zWwlgt1JPBKvOP4eoqtaBDFuWVCTyFAKgfpV1ppFh32xJlHynjp6HP50AM0a5S0vlsp2JmQ8DPOKz/ABFBJc6lK9vJsZSTwcE5+lQJ5sesQ3UxTMedxXgnOOc/nW5dxf6S08bEpMA4OCO1AHLJ5hdfNDKQR/FxW3Arptzgjt/jSrp8Ujtv4LjIPoatWiNEPKmBAAwp9RigClqMrmBgp+boMGm+HXYW7pIDuHI5/SrOoQqqlk5GMYNRaF/x7NuGOQRQBdDbyQThh2NSL94ADPGaayhmGBhuD9ajlY8EdehGMUASFsvtBDH1HpT1wxcFcrjv+tRQYbJPHbAqQtiPPGO9AGno86KuxiQo+6c/zpNW1yKBTyBisC6ldLdvLJU+lcdqd1PcMd7HK/y9KAOgudcS8mZyvGcZNUrx922RASh7+9YVqpJU54PTnOK6SeELbInfbzx1oArWzkucHPPIpytlWIJ6nNQpuWQn06j+tEbgybc/e5oAmLcAE4JXg1Ej4KkjBJIP8qJDubHqBx6GmMx346BgePcUAXQwMbLntuP1qDJAkTPpiiF/3wcDIY80xWDeYR1OKAEE4t2ZC2T147UVEWIPC/pRQB027aqonU/e9+aY7fNxVeKQu5Oeewp8rkAZ4+lAELtifGcDjPFW4LKO4fe5GMdKy53zKDjvjNbFq6pEcj5scHNAEMMIgkYRkgEEfStbT5EMUkk0SsytgN7YrFW5CzkE/vCe3enXOpBJY7cJtcyZAHQ/5zQBv25a4SH7Q7ISSVXAGfSnTXEMkhDhgwGAyr2/yaqSXZWSNmTAbAQKeea0w4FmwOPOk4QHn9aAMHUIbeH5LeQKWyWOOT6Dmp9PtjvRYm3Afez0WsXWknUMk6KWfGe2KqrdzWV+2SVSUDjPcUAe4+EliXQxbugbDE8Dr71n+LBCmnuucP8AeFc94S1eC2t5ZJZG3Lnndyc9Kk1rVZ9UhJ8p0jX+9yTj3xQBx92/PzHpnoKrRzbsIxAHp1zVy4USbmRCfXB5rPltywJC4+oNAFe9vBEG2Dd2ArrvDdteX3k3Eu9k2Ar6A1y0On/aDtYfL3NeraWfK0y3hjGyGKJBngZ+Uc0AYOtSMl+6L0ABOOBms0BTIdwHTOOfxqbV5lkv2KnJIGDnIqsxxknjPcigBJIAzHPCt90DjGf8iplRIwFyd3rnNQxzB8EZ5yaeGBY/TgmgCV1Upx5ZBz15/SlGAB6+3btURmUAjcuPukbhQpY4IGVznIXOaAEXdj5t20Y7c1FOwQje6oWYDBON3+FPlWYgDHB78Y/X2quRcSufkRtoIJ30AWsZPPU8Z/pUcyI0LoV6rggdT7fzqlGlz5u2QH6gg8EetXFZwRvXtzkHkCgDE0l9geLOTG2Bx2rb08xuWjbHzjI4xyKzZbIxXEk0XzpJjGB0I6/0qazmMcqvjlSDtNACasqR2zqVBBPOfpWwxS40uzdQBtTB4z2x/SsK8uVmuUjxgDknFbVgrNpEqjJwcjtxk0AQrv6HBA9O1E0hdgEG6RR2OQKqzb0PDAA/57YrOvLsWsgc7QRj6/nQBe1CfFqXBOckDHr/AJxT9JQQwKsn3yASelR6WjX+6a7iAhAygJzk9j7VfUHnAGCOcfSgBH28HGcVFJGWT5eSBx9KUgBcknPTaDSAtuIGT/SgBsEjK2GHUU+ZiI9pp3l713dDUFwzFgORgUAMcEgkkYNUJdPtpctsIbrweKvhd8gBHHvUjwqkbPwMDPAoAxWs4YFzCuW6nnPHrVslXiDE/NxiklHyGRf9Z/CDUMT/ACMy9M/MPQ0AV9oMh9xWdIxjlBzyDitRmbPHr6VQvowQGA5z2oAkuGG0OODxkj/PrUMjEJvI5U5PtSI+5GUnrx/jTX4jCnliMH2FAFi2J3YVs5GQTTITtzKT8mSCP0qKEkDntkZp0R3PJEfugkr+dADJ5HEp5xRTpeSDgYI60UAa8ZIJI6g1IZGO04HQ9+lVkbKg96R5QAeeOlAEWN1yihurZ/WtmfhEHcVjWSB7zeWJwc/StS4XzcCN19yT0NAFO8wqIUyWOSMdiOa2PDWjCe4hupFTy4suzPySaoRWXlxtIZFODk/N0HqK0NMuJWtjHvxtHJU53f5xQBY1CS1W7cbSzZBUDjaOMVWF1JtDjKgH5frVW6jYB8CTzG7kc1CsrLtt2jck9zQA+9u7u4XZtw4PBbBJpkHh+4u5YmvZSqpnCdSatsIrWESswLDuTmi41C4cI6OUDjdjvQBt2Uen2e2IhFiUchjyxrvbTS7d7dtjKY3XkDnrXjTSPLJ82WcckgZr1PQ9QNh4cMt7KjS46KR7YoA5DXNHk029kMbFoyeP8KdHF5sEYdBlh2FPu/EdldSeVMTGxPXdkVWuL9thhhIwOCw70AMdU8xYV4BOG28V0M1+YbNRFBI42gZUYAOB3JFc9o9sLi8JnDAL6n3NbeszounZUDIGBQByM0s0t0zhRuHBGRx9TUkchkdsAkAkcH3xVS8YxxdduWG4rwcdMCh2aNCsC564DZwM/XrQBeVsE7jtB9MHFTK6jOVDH1Yk1mxq+P3jZOPXOal8p2yAzADnAAoA0A7ZGAo5xnHb8acX4wZBlRjlsfyz6VT8ttjEuufp0qKWASOpb5gjZHGQT6/TFAF2aSIrteUENxxuGP0pqukDuVZiMbsgHr+OKoTRSKuF3MD/AAtyPfgms2eSVUeOWABtwATB2tnvnt+dAHRWE8KGebksMADB4HvgZp090oTLDH4c4/H6Vy8d3eZkidAIUGVaEjLfp2xipbea6lYNKTv3bjuHb09O3b9KAOh+0KSA4yPfnP5/So7i2jnJKN5RA7AfyrM8933B42jcHPIyD1/z+NSwXZRyJCzY+8QOPbHHNACSaXcQurI0cgPTkA/ka37WK5tbcAxPyuOBVBbiORhluh5wSR+VN1LW9P0qIzajewW0WcEyOFFAEd2Z5GZIopGf34Aqtb6O5nE91NvcDhR0/H1rkNS+LGnvM1t4bsb3WbjoPKjKoD2ySM498VVjt/iN4lPzz2nh20bsnzyntz1/QigD0PU9WsNKtjJqd7BZpkZMrgfT/wDVXFz/ABY0pr9LbQ7S/wBWcuFkeCFtqDPJwBk/gDnFJpXwo0aGcXWtT3WsXQ6tcyEr+XcexzXcadZWWn2yw2FrDbouAqRIFGP8KAJiUkUyFCrMMjPf/wCtTreIRIWfoeM9acWVxlurHmq+4ooQMxTrQBcTaeh4zioLsANweBx7ULMqqCW+X6Uy5YyAGMcY6k/060AJCv7wnqB0z3qpfyuQAnc85IIqG9+0Mg2bcfjVa3FyMs+Pb5m/rQBNISCGXA2+4pJEBYzRHOeJF9R60wlsEsu73BGf1pizhCW2S8jDDYSP0oAbMFTAySCeDmoHwRgY45qWeSLBAV9jEEHY3FVVk3OQyttOQD0/rQBVf+I9+KUncAcjtn6U5yAevcDFMZNqSMRgEDFADm+4xOcYBP1psZxLz0ZRT3y0BCkbiORimIBn5STkkA+lACyS+WcFS6dsdj3opQ+fvk+v496KANCNgsTEkg4/GqmS5zjPFPZsQk9C3AJ+tNiUbRlsgHJoAvWQIGP4jzzUO97RnZjgAggdc1LbOMOyj5gCRz3rN1GG4Ll0LMSckL3HpQBZZJ792eK68tFX5kzgYrZs1e2GF+63zZ554rIsFUQkSDh1HHcH/OavrLMWxMy7QNoOeOKANSZvMYNkEHjHvSECOPeF3OSSOnAqvHOgdRvAJ5xmr6eX5TDI3YPXkUAYWoySPcCIKQvGRj1qyY9vX7oHepdThaO5TDBlPfFZ108rSiNcjHb0oA0rSMSQkL3I3Gn+K9XNnax2qOQWGSBxjj2pltiC3JY/L1HGK525s3vNSaa4kUruJPOeAOlAEen2817OrNnAOe/NdcuFwMZJ/WqVt5cVtm3QcD7o649atE8Zzz60AXLGUpI+G257k1FrNz8gAJxkjGev+c1BanbIeg6g5NZ2pXyQOsO15biQfJBEu5z74H8zxQAk37zZwck4C54/Wp0Y7gMYb2+tZl019BKJbzS7qCBQdzsyt5eT1ZVJI47mtK1BPzE4BA98fT86ALCJkHcccYOKfggDn5e/t0qJ3VcfNkHGOfrStKBgNx36nvQBIOW25yPUg4z6VOrDyvmAK9CMGoARtz+YxnFHzKdqjqB259eKAJ1IUclfXJ5z+tQTBOn3wO/XA/CmK+MgsPQgY/T8qilYLg5bc3GBQBN5Su5AUfL2x/Ko9mHKOdrA+ntQhxuKHdtBzjkD/CmTTKSokVkY8Lnp+dACahd2NjZS3V48cMUXLuxwPx7eleTTfFe6vPE8NroWli6s2zGIXYLJMegIPTjqBj/GvQ9V8P6ZrEqnVraO8CfcDsQAOeeMDvis2L4c+FUuEubfS9k0bb0ZbiXgjoQA2OooAwmj+IXiFyXktfD9oT91MNIB9ec/mKs6N8MdMiuhca3LPq1xnhriQkfQjuPrmvQwqR4BYgkYGec1KmFLMUOSenIx69qADSLGzsLdLewtobeIDaFjjC4FXOFGSSPXOeOtMj6Da2F7MaWTd827b8y8fmKAEDBemMZ9fr/jTXALEjp7UdfQHrj/ACail3AfKSMe1ACupZCBkccHpiqt3MQojjBO08N61L5pfID8cfhUV8u6IMeSP4aAG24DkGUE+5ycfgauPEyR7k/eRjuv+FZkBJ3I5PqpzV22leJwwYkjr83WgBjOSdy464GQKiaTPUYwO3art1HvQzRjbn7wA6GswYfOG5xnpigBrDLL1IqOVzkgDOOD0p7jaGOenqapF+fmwB7Hj60ASkqEKsuN2OB9ajuIswgrzJjOT0xTYfmdgehGetSpnBjGBjO09PzoAz9pccMMjrgjijf5sboeNo3AH8f8asTr/wAtYvQhlqHaroSpAYrjcO3FACIQ0kfOFJ+amqNuP9k/5FOibbhGGWAHJHWnJHgHJy2SCfXnrQBVl8tZGEhOO1FSyxq5AP8AD60UAWZckxqPTn2pZSqY+YAdOopCRkknbzilQfxDjJ696AJYJEBHcHjIpSTsPVGzgGmbyGUE5xzzVolTtyc+vFAGekV3tG+Qsu7jGOa1xCZWRnjXH8Pp9ahVYl3eSpYEZC5/pUkV6YECyAE/pQBdVVQpvQOQO2MgVeSONI1lVWBznAPasrz2g2G5PlxvkrjrjPXNMV5ru6lSNGaAYwRwH/OgC3qF3ndJlXUL37Vj6XZz3V79tvlZIx8sMRPJPcn/AD3qW+t/OeCAHylLdAP0xV4zjT3jLglT8p3E4U0AHinUbfS9JYRjMyqXOM8H0z+VYuhXk15YRSTKqlm2qO5xgc/j/KqHxBmT7PDGhDNO24kH07Dj1xW1pqm1jtIERHjRNpYnuMcj8TntQBsr8iOoIJI5/Oq7MVOWIKY6Ac04SADbxz6dagu5kihkkkJEaDp6+1AEV1cSxFfsyl55G2ogONzYHfsB1oylrAyQMgnfmeZCMyt3IPZc9B6fnRbxyQSb5lJu5kClf+eS/wBwe/TJrKvZS6MCM2pcjcGB3j6DkA0AWLZsXJcrgsm0K3Ur3B+tSWwCRBFdi6blHocHH+FZ2YWRxuiABOBx+Hv61Jp8oKZJGWZjuAxn/OaANXc2Q2zIHqcn8x0pwkJ6rgnjp061GsyjIBJAPA6np9KzLy4kjmbbux3A4Az7dv8A69AG3DIoO0jByMbv8/1pWkVs5PfHXnP6VjJfgorPgHGMBu5qxHdO0Q3EsoB5z/n1xQBotI2QFIxggY9aqtIBPlsEAYPP5VXe5dnATv78n8P89aasTnJboO3WgDSeX92XH4Anv2qRlSaNlkjB7lTwfccjP61nwlkwrgNjjJPTtiplufLdGIw5HINAE4VkiQq8zRjPP3gQMYz+BNVrYXTNHJG3TOV5wOaeCWUwq+U9DU9s6ohIAweM57D/AOvQBZihZ2DyMoCEE7se9Wg0YKtINxPGOuOlUY5flIbGWwcYx/Spg/yqQRz6jP8AnpQBcGWxsx6YHTHtUbZJyvHBxnp1H+FIkm3CK3HUAHjBH/1qaQGJ3HoO/wBKAGsRg89OM9KRdw29PYk/n+lOP3+CQSAORx0pjEkkY5HHNAESgKo6hccD8aX1BxjbwM012ywPG7OMUjNg8AkkfyoAruPKuI5GwYicA+hq2GGME+mCPWjAlQocncMEEVCY3iXjc6/qo/rQBdjf5TkZBIyKy7+F7WfKtw3IA9D0qzyV3CTC46kdxUeoTPOiEr0UKCec47/zoAqsxZCSOfTNQSj+8Tn1qfaSjEdMUzhUK85HPt+dAFSLHmuwGTx+WKkZgGBDYwcHNMjLEPu756c/SpCPm6nP6daAFPUsn+sAIwCOeP5/41WaLymLxf6tidw7qanJcMHBG7OetOVBuZx6HcD370AQzIHVyv19c4pifMxHqaVU8of3lP071Jt3N8hyODx2oAgkC8Fjx0GPairTQCQZwG578YooAi2KWJz704ZJ4FK+PcnPXHFCEZPagCNciViVBOOpq5BCzyKEA2ngjtUO0bS3Xb7VYs59kig5wcbuO1AF+x0rzbiUJK4O3jPSi+0WJ2QMz7wckMe1bFo8USthiBs3DuajuZZAURU3knGSKAMXVrVJIfswZi5xgZ6CshmvdHjdACY2X5ST0NbWvvLDcxEBVkK7MEYzVzTLBrqdBMTK7HIBXIHpQBj2bSWlmJbvLNnAI6YqHUS0kOU+Ynklu1bmu23kSLbrI2VbnHr6VlXsUZtnAYF8Ht7UAcg27VtQSMsDHBhenvya61JCYUcEkqARj8M1m+GLTyxdkqBISQCRn9Ks2wMT+WMnJyAaANOKVGBKEE57dRUEb/aL1d2Gjt8OynoZOdo/Dr+VQwTq8jnp8qg8Y9aWCREiGxuXJlb3J5H5DAoAlmkKiWSTBwpYljkHjJrEnkieEbSQBmRCP4Rjp/P86s6yUksZon3bWXnYexPrWPqU0aERQ7QATwvTb9KAI9RkZIpRGxYt8oIA/wAetWfmtYmUkll+Q8DqorGtp3j1CBZ4227jI4zkFV/H6flWp9rhaEGVcsxJyf8AP40AKt7IyArkckHjPQ+9MdppWblQid2z+dItzHDDuKBlB/hHTjj/AApizee6rGG8lz1bHzfr04z60ASwmKOVNpLsBk4HAPtW/ZOUjX94FJ6jrj8ay44kjUYC5zu4H4en61dtpcYXiTrkD/ODQBohoAGBAz1zyf8APWnPKiKRCiHcOAAPX0qkxlXLIpAHVSKkjJKAgEEHOMnA9+KAJTckbshCM5A29/THT0prRkAOucMR9f8ADuaakQfdvLD5sZNPPlxkZbPTt/n+VAEisY+uTI/Cj196mjTy0VS23b3ySO/Q8f59aoaa7zTyTuyqPuRsMg9eeTWiih9/QluT1IPWgBXYAdwMevBHFEMhYMFOB0yemM8frRKigbjgsew5/wDrVOoMfAOBjoO1AE0ZLIqkr8vzAdR345FPhkww54HHBxURyRlMEkZOOef0pyncxbpyMj3/AM/WgB5QqpYjk4yce1RtgAZ4p54Xvnqev86YwCrg7vXtQAw53fjjp0phP7v1Bzmpj0Bz8voKiYjHToMYoAYgKgFSAPc/SpPMby18wHAGPUUxcoo64J9jTpdpLFQAMgjNAEfygkqRjqcCmSKDGwHOF44pynbz0JPT3pZTl2DdMcj8aAKzkBTjAOD0J/wqJcBD8pyMjmnqMIcHJ246dSQf1pjuMngAd8dc0AVo1OWA6k+v4VISBjHp61JtBThRuHI4ppAVSAOAPT1//XQAxQCVA4A60SYAUDIx1560qr84+nenZ3sxzlQdvUdep/pQAiRhiNvf+HHQ0xF2SjaMhj1ParMf7rknIFO2bZTtU8/d9x0xQA2VWZsxDK9M9KKs2Kkh0kQsVPB68UUAZ0i/vGHQZpqggEE4Kk1auEy74IHJ61XkBDox/iyp+o6H8s/lQBLEw+ZT0YYprKI48AgOT1PpQo4HOOlSgBxgj5h0NAG/oKxiFZJW3svPsR1xVjVr6GKTzlUDYu7PvWPo3nP5pJxGnO3PWsq4S5ub5tzOsanG3GRQAkt8dR1GB87d8gI785r0XS4vslovyESgdT1rmfDejwT3SSSIGSNgR8orvL8xpZsMID2YD2NAHCav+8v5WyMqT3z3zWLaxs007M5O48A84FbtwPNV3wOW61nyIiHoM9zjmgCpIBBvuEQFl/1nuPX8qo37jy4Z4ywJweM+nepb93ENwoO4MMYzk1Ts7kXFqCQPkyuDz0/+saAKT3YN0I94UXACCTAAO4kH8sH86uvdJE4Vfu9B24x096zL/SrSafzWkmib7+Ipiik9OcH65P8AOq7W4hwzuCAfvtycZ7mgC5d3CzBwuWBBXIH9T/jWDd3C4+f5JFwrkjB/3s9x71oyFfK/dM20Mc84PvxXMapP9u1WHTopPLdk/eu+R5Sf3s9s44/GgCGe+dI7u5DMQ7CBR6gck4/MfiKS8v5ZI4SSoyARs57DsKy9ZuBFJGYYStivyxKOMDPUjsT/AIdauWEiXLKPLJVkJGeOfpQBo6PLPM7h3ZU7gt/LtXTIXkWPy1IGcAEcH3559PWqmnaUjW+9ZAZc5yvOPb3rQgUQv5b7twxh8ZyfX8aANOGMlV81i4ByeB+lWQZI3/d4xjGQoBNMQnZwTk9OcnH4VKg4DNxg8Z+v/wBegAaVgSCMEnOc4H8sd6FkIDpy27g//r/KoJmLAkK5Qc5wcf56U+A5A4JxksAKAJIW38O+3spxnP49f5UtyWXakQJJ+UdByf6CnBGdwBnaDztPHGOv61II1WVSQSRwOfu0AT2ySLEqEqARkcZ/WrCIpID5J3c7myPb2qNGbHAGeuD2qVCQoIzkj04PtQBPFGiDJQBiTkYwO3+FSKpxhlGDyT6VWEyL8qrknBIFTLLkAsCD7ngUAPXIAUjAHQZpi5WQc89xnv0qUEnknGT2puCBwBx+Of8AOaAHHG5GxkZx1phI3EY5z1NNX72D16euPanYO4Beg/WgBjlgAJCADgjPHrQM47DHfrmnYBY5BA54J7+tRSA7WGDke9ACp0AYYHBx6UjKcnaB0PWlQjqfu9M/WlUFWBB+Xrg+1AESkkbXA5PYY/rUThsOepUcDP8AKpiFL9hkDofWqz4PzDIx7mgBhHBAyTyDwcdOKQoSSeQD+HFBxk98kn8KOpGOB06UAJjIzkfL1pkjbgDzxgcD3p4LPEyqcDrj1pV+dAFOeD2HpQAmQqsSTtUdPSiJeFHGVGSWGPmPJ/n+lOjHnTYJBjiwzqR95jwoPqO59ce9PJLFmHJY56ZxQA0jgLkdDnA4NTxKCRux6+4qJSqHLOSO2eR9a0YrdorSOS4HlKw3KrD53HqB2Huce1ADrWVrKMBFyzjJB7en8zRUCuWZmf5yT1Y5x7UUAU5h+9bpyxH0pjwCZXi3bN33X/ukHIP+e2aszp+8c8YLGoT1xxkdDigCpE2R83yuDtdT1Vh1H51KAB6+uaddxnCXKffGElXH3umG+vb8qFOVBB9x70AWIpGydr7ZB0PY1ctCLk+WGXzM4Y4FZmCrZB6Vc0y7S2ug0qAxNwTnGDxzQB12mW6wRbCAoIzwaj1e6IjOz7o6DrTrm+Q2qvCcrt2g5zWJPcllOT16etACKwaL5vkJ7Csu8+84BOQMipZptoPFV3ZZS+CCcHgdaAMcTCcsNnK/eFU9O8ob0QHaTxz09qu3CvZq0i555yTz1qhYRskkiqPlY7i3r3oAg1BWZnQNtK4yT6c5A/A1A6vkbmDpwQCen0wauSRlbiRiQQWxz0alhtFn+4cHJ6N39KAMwylF+fBQcAN359eaoX1lZW+jT7dtzqF8/nSuq5MaAkRxg/z+nvW3d2SJE52kbctgegH09qwhC6wwxkkhI1U5PTgCgDlJJDLC24HA+9nvj/JqbSZUtVjMjDHpjp/nmn38QgklGB8x3A9cZ7fzrFSR/KypYgt+PvmgDvLTW2D5f7ncdMDt+NaUGsW8jglXUdMAZwOOa89tmaOQMxOM1tLPDLgAAEjj5u/GaAO9t76Jjyyg8ZLDHp0/M1eSVfKQKRhhx71y9pcKkKJIXCgZO4EfSry3SuoER9xyeP8AP/1qANxnOBu5OM9P5VG86wqAxYkjoOp/zisyW+MES87pSeMdvxp9qw2ma42rhvl5J4/qaANSLe24uR9CORzUqTKX8uPcx6EqcDP+eaymnmucovyRj7wHU/jWnYxFFaPapUcgrJ/Pj60ASMZ5SCq4BXIZSM49cGrUSy85RmHXkjI6/wCFPjJJAHCnqPT3/lVmIEKAR8uc+x9aACIbNo2kbeakGCp7HAxnuKjjBxlhzjseP/1VLIoYZb7h/KgBAxWXZvXcOQM4JH0z71NGpP3cCs1NPjk1B7vyyGCGMZ+uavxfKoR9wI6bhj/P6UALk5Y5CnPIxwKbkA8446ilyQnI5B6HuKD0BGfqD/T8qAG9OvTqDSHrjBB6fp/+qlHzFOARnqaQg5GOMjJGP8/5FADFwVKkYJ5B9TTF4UOWGB1PTFDsVDYXJ9PTFAGeMjaR+lABNgyDG3nHGeSATUByqlWOQD/X/wCtUsjZuVII5XnJ6c1CcBic5AJGc+/f3xmgCMAs+cep54/ChgM884bGew605idzA9zkDmkC84wOB39fWgBI/UjHGTx196ZI3lgf3gcAZPPpUoIUHBIHfPWmRI0t5GdwRVXzCfYHgD6nA/OgCZYlt7dIgcsDmQg8s56/4UgUANwcDrj60+YlmJ9BuYnk1c0uBPKN9cjFtG+2JcczSjqB7LwSfUigCW3t10+JLq5RHu2GYYmGQnfew9fQevJ9KqTSySeZK7NJIwLEsep9afLJJNKZJB8zckk/54pqldhGCoAJJ9aAI5FeQkB9mCew5oqN9kjkyqxbHQdqKALV1bYaZ4JBLCrE4cYdee+OMVVwMgjbjvirhkeG5d42+YMe1TtBFqAPk7be+H8J/wBXL/gfzoAzkJ3YbJQ/KdvGR7Ht9arGJ7WRFyHVzkH7ocZ5+h9qmcPFIyOhjfhWGDwef84qUKsqNFIQEJ4IP3G6Z98frmgCuu1kz93jGOmDSFMtgHk84poBjldGBEqjJAGN47fp0qYc8rll6DJ6e1AElvcvb7o2P7th09KlZkaPMbDPcZ6e9VCDnIBOOnpRnIbjOOcGgBskin7y9OjA9a5/UbyZZU8ghVA5JOCa3mgikJyMZ9CaZ/ZlmGEgiBI/v80AZ9iZJIjvBZhk5J6cVpXltttMjO8LknBA9etSp2wMH0I/Pp9KmXlOcZxwQO9AHPhPuuoO4MxI68Z/+tSITBIS3CE8kZP6Cp5cRBtzBA7nDdjyfzqrcsVVFZSccnAIoAratdI1tOFKn92wzwecH3/zmuf1S6IGI8BTnBx04rT1ORVtLpnwCYmVcDB5GAPpWNqURhgLAZHQ9yPagDndSlEoMrA/K3JAx/nvWUEEZf5SQSSOec5rV1FS1i7R7d33sehrFaUqiqG3yYySfXOc/r+lAFyO5JzwF+X73oansrto5NwyCCT17en8qwWkleTLuTuG7aPlB9Kkt0Hmlm+UDjjvQB3kF15m3AUKMHb1OPX+VX7SXbIsko+ZuAO/+f8APvXI2d4YztZ8xqckHtW/by+c9uVfGAMnPp/+qgDoLWNp2V5eQxOSOpFaRR3ClRhAOnoP85qpZruUBT+6UZAyM/5yK04nAXIXBXtgZNAElps8tfkUEjJyMZ9z61ehETlVSRRuHHAI5rNh2u+5PkLH7wGDkHOOPTNaMS4Kls4A449McUAXLXYHwEY+pVeB9cVcwARncoI5yearR4VRu+c4yMnkj8alEi5wAN3fnrQBMF4XLMB296Ux4U5AYHgEHoe1JGwI6jPXA65/zinrxuUkEHqPWgBrHDPjnBxinB1BwQMjv0z+lIwGSU4Ukd/u9aaS2QcdAMYoAdj5yQAQSSCP8+9ClQrhSVOMY/WkJG4YzjHPOSaY+VC7Rknjn+VAC44wATgevf1pQOBuUYAB5FKvqudp98CmkdTjAPX2oAjxtP3eM9u/tTFJGOcgdvSlf73Hc5GTj0pNpBJ2jGCOPXtQA1tyyKpxwMnP4VEx5wBnPAyfxqY7tz+2KgOcAjjjuT6UANLYYAH64PX0p5CkcfxHn1/CkLAc9CemW7e9PDFTjOQflA559qAIJ32kk/KicnI5P+FTwKYISWJ86QeY4znHYL/X8TUEcfnXMSH5Y9xLY6ACp7qXKu+Sep+pwTQAtnam/mdWcR20O15pD2BOMAf3jzj6e1Xb+5WeSNIYwkESCOGMjhVBJ/Mkk/U1JLD/AGbYQ2LHN0w8+7I7zMMhf+ArgfXNUjkcKMdvU0AKeoz+VIiDo2Cz4zR6knJ+lP2n72OKAGBSWY8AE5FFQ3EoZ8HovAooAtTf658f3jTBkHr0OfpUk/8ArX6j5jUa985oAuShdRhYy8XMS8sP+Wijn8xWWN8biN2GT9yRejD29/b2q1FJ5ciuBnadwH9Kk1CBGCvHkQTcqcf6tv8A9dAFW4jSW381cLLACykcfL/EP6jp0qFCGQSZPPXJ4qa3kAlG7kqRkH+LFVpEFpcGFeYXXzIsY6f3ePT/AAoAlbscD3HrTGXntgHrnrUikEEHJOeufrQRyR07gc8UARA845APPUVJnjJ6+tNwVGSxHQeuaUZOcAGgAUEyAAYU+w/linDjLLxt6kd/x/p0pHA4xx1wc5qQKAMc47HPegChcwrPE6lVJfOffk/n2rLECqxRMrgjKoOh9/14ragX9wDnjLA+vU1VvysfzIA87clemRk8nHQD1oAwb6JlBjXb5rfvD3yqngnjuen0rJ1FVK7QGAbrzwfb/wCvXRyWEm2RmZvMkbLuBjJ9B6AYrn9UhaJWEshOBtGOvtQByWtypFE0YJLFcMPQE1zdtymyPAfoM9MfX866bUNtwkpOVB6HHTPqKwNPgYs0TBcg5wO+Dgke3+NAFZ4NjpGo+b7m5sD6c06JvLJVnzx26ZrSFp5jcBiBwQRkc+n4Vm31p9nyIgQjZOeuM9v50AWVY784IzgEZx3Gf610mlSNLHGUDM2cAYIHp/LmuTtF3ToZQTGvJHfr6V2Wk43lc7UYHG4Ekc8cUAdhp0q+TiP7oOO3f/Jq3BdBlfplSQDnOTjNc9Yq9sC7gMucHB4OfatGKVA5A2kucHjPbp7UAaolU/MNpOdwBOPy49q0IHMpVlyo6AY/+t15/lWPZxtLIyOTjb93nKDr/Xr7Vt26skeSDjpjg9uT/n0/MAsKzLg7lcdFUHp19OtFncfaUy0bRvk/I68jmooLbe2ZV3KeAwyeMfX3q7HBGePmBHof8/r6UASKflx1A7dP/rVYUjYAxxg+n1qEAjDLkjrgjr+lPWReuXX/AHhxj9aAJASCTjBHX6035sEg9f8AHvSMSB83QfjzSZ3q/T3oAb92Qkd+5NOIJJ546g9+lMIOSM9Mfl6VJLwFI54HQ9uf8/jQAxW+Y+54GelObLbecDPPOP8AJpGAyME9dp/P/Cjj/ZJPHtQBFKMAM2e5z/8ArpVyVBbjv9KLgBUI2jp260qcqpHOfY0ARnIU5yuT0zkmoSBu28HHVvcdqlbOcD05xUZC85GeMdCc/X8+9ACBioOM7jnI9Pr1oDHaTkuc8/nx/KhVyxJIZj8vY/j7fWn7WY4Y5Xg4Pp780ANtl2GQnhgCM/3ef/10+Bn/ALQslWMyEOJJEI+8ifO3/joIpqYGQRtAA4Ge3+RVrR94j1K9zjan2ZCTnJY5fH4ZFACTyvLK8jnMjEkn3PJqMZZjjgfzpvpkHPpT+3GQRQAnyIMHls8UMGl+9nHYelDLtPf8O9KWyDjpnoKAImZYz91XJ6lqKJAc5wCx65ooAsTA+a+eu4/zpgPzcmnzf658/wB45pmecigAIqxaOD/o8uRDIcc/wt2NV+3PNA5Ax9OKAG3kbxSddrqdrfTt19P60siNc2jR/wDLWMGSE5PBHUfiKtXIFxbpI7HDDy5MdfTNUbKQxyIJAAyHDEA9B1/SgCC3k3oDyNwBBJ45FTLyV+X6nGc0hXyZXWMYRmPGOjZpOCeBwevGCKAFAPOCc+nX9KjOep69MjinsA4IyeDweKYWGcEDGTQA888cg9KQhgR1GB1GP50q7QWA7DPehh1AxzyeAf6GgCKElWzgAMW4OD3NJDGkckpAyXZmJPJI54/KnQ/6sqzHLM2M9jk/5/GkjcEfMBnc2OOvzEUANmiDFcFdwG0nHWub1myV8rt2knHsf85rqmQfNgkFueKpaoiSwsHBJyRjvzQB5hqdsIWAUeYOcJkgDP5E1gXyS2s32pN4xwQP884rt9Vs1Rn8vK8Bccj6/wBa57VTH5Nw+0NhTlFzn3oAy7eRdwmXG2RQSMkHrwMH2+lQXSgyMip8nfJ9zVGx1O3W6eGYqJDkBnxwecD2xjoPWrzCTzWnk+4Tj7wAI/H6CgBtnsLKhI5GOAfXiup02JvLRmIyD1H1P9BXKw4jmT5kJOcY5x39feuksZzhFDBAw4OffFAG9boWYLuLKc/1rTs7ZIoTiPGDu6YHWsWxIyfvEKuSxGP5Vs2twsiiORjlTyM+v+TQBsWi+XH8gG7JxgducVJJdOJwsY3dyApOf/rU2F1YgBiD03A4qwzmPK4EitnbgfMMd6ALNtKCrZzG3QgDI9scYq7GF3MzEc8n2zmqYQ4QkZXoyg/59aliD5Y4Cg9u9AFsOM88HP8AnilLfIe5IwcVAhIBeUnkj+Hp14p24ggKevOTx/KgBqSs0zxhsBAPyI/+vVleD069hzVZWX7RLwp+UHoP51KCNh6g9jk4/LpQA9lxIuR1z7UOMKQpGcHq2M4Oe9HDSRgsRk8cAk1IrLt5BYZ5zweh/rigCFT8uQcc8k+4FKxUckE4HT36UttFBJxG7xvuxgfX3+tMljmgb5/3sTDOUH3h2P6GgBrkshyMt1H50icICAefX6UxXEh3DfycElT1oVl5yCvTjBxigBCcHp8o4GKjGWVWbGQOnfnB/Dp2p5Qs3KrtGRjGSfoO9NYhzycgcBlNAADkFlZiNpOefyPpQihY/mwFYgYXnj3pXGZAMFmGWID9B2z70epIOD/CP1/GgCKWUpEzDDSH7qg457frWrdRpaWNpYxg/KnmTHP3nY96z4U867ijAGS4yRz3z/OrF5J515NJnjf69AOAP0oAjHTPGTx+FOGOAARjmmg55H5U4cAg596AEx8wGM5PPPWjqFXAz1pV5OQf/wBVC5XdzzgYoAhlJ3fKQO5470VKUHX1ooAknGJH7/Mf50z14p05/fuP9o/zpnselAB/P2o6cnoaD06mjnIoAsWjZWWIt/rEOPYgf4ZqjjdKGXALDBHTJGOee9WIpPJnjfG7awbH05pL+Lyb1lVgYX+dCRkYNAEMmWDZGOMkEAFTj8+o703jJKnn1PB5qRTu27uxzuHIJz1H1qIqONoDEjI4HOPpQA7GevB7nPamDn5vXptGB/n/ABpd/P7t+RnOTj8O9NxtYgAlS3ft/PvQAvG3HPTHt+f5U53wu7PHTr/+umuTjPln06dPftQExy5V3HcDgcUAJZwyywMRmKEOfnzk4z2H50kCqrzxqAHjkK7mPzEFQ38yelPt3JR884kYc8elVrl57fVLN7aO2lW4YQ3Mc6txHhj5iFSMOo6ZyDnFAFhmKqA3BHPHIqirCVXHBIyCcd6nmcGN+eQPXkj0+vvWeXH2TdxliTkHmgDM1QIwOW3c4K9M1xd7E8FyWQJ84BOeM49frjvXYTLLcTKAC0WfmI44x6/jWTe2Cp95myv3sfxcdv1oA4PWNHt01pLt1Hlz4LR5GVPqP0rSnt3kaRA52R7ShB7EdcZ+lWXt7a7uBbtIwOAMjqqjkGs6Rm0y6aKWTCFfkmH8XTAzyMe3tQBl/Z3S/B3lip+8fX/PFakuoNCYmA6nAJ/H/A1lXsjvcEpKTwSxJHTIqG6ZpCE7rgA9aAO30vUPMkXYcg8fe457V1uk7nUiXYiqx3EHJ6enpgjn3rznT4xFtMSMyMw3YOGx3x/hiuq0K5eORyP9UwO7zM8enXqaAOuWEMCUdwhb5SBycd6vWikAFiMhssSue3AH86y7W6gcrK2NoPBVsge9atrOrxr5QBXPAAzz27fT86ALihdwO/Ib5h8ufwFTAIxTDBv9pR/n/IqrFLtC7fu9AfT9fSp1bjAAD9M9sY9+aAHHdt5Ukk8nB5/zijeHkC54AO5s9KHbKblUlRk9c1HGhZU+bDHn5hnOaAFjYK4ON2RgkjoKtRhAMc7c4xVB8h84O08MCfun0qQXaBgjOp+XDHI69RQA6Vtt3b8kkMcdsnrWjNhTlSfm5HsO9YRuGnuEeLPykAHbxnOMD1rUgLeUyS4OzJQjjINABbqQhyRndnPXPNTFm8jCucLlh654FQ22QvHJqXlSo7dDQBE0m4E5bPbPXPNMdTuD7TsB5IFPk43AH3/GmSkNGcYEiNk9+O3X8KAIm27gAMtjOcZ6fn04pVbeMbztHpznH8qftdycKxH4k1G7BVZXc7eOGXGMcn9aAEIATLnBYZxkgdvUU8L5ZIwSARnJINNiLMzyfMI1OcEEBj/+rHNOf5N+/G49vwFAEun5E7Ef8s1zkDuRTWB3YHc1JbqsVtIWwsjHOM55P/1qb/GOeMUAAC8/WkbGCMZ70A5JA4Hc5pWICqB69KAHZIGAq8KTzTWfpxnucUj5YAdFwSffmlIHRfur0FADcb+Q3FFBwOBkj6UUASzY85z/ALVR/nT5j+9YZxyf503PtmgBOaPqf0pT/kUmOT7UAAJ4PeprrL2EEqDLwttAPcDkD+lQYBB5Bqe3wYJkyR91xx0IoArKFDMqDIPKnjp1/wAKSUMjZC/KeDk9PQZ96MCKSMhdq4KkDnBB/wDr/rTkjWSLy24QgAZGMcZB/lQBGdwAMi9T8ofgDuRz/Sk2+q8AEdgfr/X8aagZiykbHDYbYOp9cVIrZZ0IcYHIAznJ7igCMjgkbtp56dOO4+tI23gAKoyOBx1qQg4yPu9hjjH+RUMhI2Z7MOnuaAFs+Um/66t/6CtNlBbUIieoR2wO2cAf1os+TdAnIEx/9BWkiJkurs/3Akf6Fj/OgCtqOGSRDwCf/wBdVLi33RpgkMVGTnGf8/1q1cRl1Kg4JGc4FB2iJSMnr+BoAoxRLHCYsjJ6YwPSqk0T3DoUAG8fOMY4Hp+dbLQbQc9T6nmobTYjygDr/Fjr6UAcdNpBhnRowGO0JJ83IHb9e1cx4ytfJs5WZQJCQqsQTg//AKq9PvlEchwpKscZJzg8VwvxGljTRoJJCU3SKS3Y4DcY60AeWW9zcwtcozbmiU989D69xmujtIYrmJZmeVGCZGBwef8A9dY+rRGz1qHzleMSwxrKHQLtJQK3HTjrW3pMyvZGENtdTwV4DDPHGevP6UAadnN9naMTlUCkNvbgnnBz1/zmt2yuIhG4j8uRGPCMRjp2NYs0cUyJE5IfbtQ89eB3p9m8yx4jlYomUMh7D3+pNAHT28YlhdGaaJ15OP5+/YVrabNLDN80sYhOBjb39f6VzFvNLFcrIZ/MCL0zggEdDW7piSGNt0rsSQfmYnsBx3I6UAdbbSrKVG/fx0xwKu4UooD5II5I6+/5isezRlfcZVK9AMEfXH6Vq2k6ugKsQeuB680ATkE9T8uOhPP+eaLfAUccgkbuoFIJDvOCVHTPTNMjO9jzxwc9unP60APcbtu3b6DJ6DNZtxCQyuSPKUsWKjnGf5CtNdqj5cbgc49O2Kz3k8yEAruLKxYH36A+2KAH6WoCRMn3UdnHvuHBP51rhCCijn92SM+1ZugWwtdLhTkgDg9enStWTAliAB+6QPagCCLAlbtx+v8AkU49x/L1oBJY446U4nDn060ARFsyMN2AoHJ6fWkALEgj7y+mCR+P4URY8sZHU9P6UKuD0AYnJIGBmgBMAZBQNs6ZXt6Y/rTC33SWBYAltr59M4FOkQEZVRgcen40jBniWNgGyMYzQA3YvkjO3AHzFhwCeT60E/viCThmAI9s8U9yPMJBAP8AeGAcflTUUsdrjjBbbjofQ+nWgCbzC0SBvUsaRjgL6kGmksFXKDgckgClHJ3E8c0ALgkYUc0Yw3bIHWhMnGePahV+8c9TQAowBuAPYfhSfeHI60p7L+fvSEZOPwFAEcuflAxwPSipcKSd2MdsiigAkIMj4H8XP50i8cUr43t9f500c4xQAc8+n0oweaAxI74NHpzyOKADGRyKktP9aAQfnBBpgxSoSsikYLBs0AREAxsu05DZB6YIyKRckKRnpjrk9O3+e9PZt0soA3LuOCc9O1NT3zgnJABANADZsecr5OJBgnOcsP8A61CgHZudWA+XJ6DvxSzNmPp0YN1BIPfj6UEnrnjGM+3t7UAJtAB5C7uuOMjH5d6iucmHdzuX0/nUw4GBgHJ9/wBaaVBjIJyCOc0ARWhBe756yAj/AL5qDTsMlzID1upAfwCj+QH50/TT815GfvoydvY/4VFCPsF66uf9Hu5N+TwI5NoGPo2B+OPWgCwI8PnsKiWMGZ1J4PIHXmrkuVB3DGOx4PFRzKOGz8wOOtADZkEsbD+LnnFZMKPFKNxHOVIH863Nq7C3GAP5VkzhfM2ZAfBYKDzgnrQBTv5c5DlVDEgluAP8ivFviBdjVNWlitpo5bG2YFJUfKKDgMe2TvyM45x6V7ZqNrFPBNPMQ9vbDmLBIZyM8+uARgdyfavIJvBmt3Hiq5sLddtjcyee84C7VX72CM9QTjHcgdqAE1LRf7S8MxTW5/fpJgp1L8EKxY9sY61iaPJLC8cuWB2+VIspHPzdcn04r1ODQ00GGCKKbdbsDD5snUHaCAwHGCBgH14rgbjT5bTV7os6rbO+0pjo20Dd145oA24QjJAQmwjBOQPlweoI/wA81Lpx8p5LVwpyDKSRjIzwfr/jVSwuQ7GCRArbDtfuwyM7h+H5GtC2iVoTKVyUQhyeuehxz0w36UAXLWLagdW3MQemSGAPH6GtfR4vOkJjlYxt8qqScNznOPx6+1RxRRiweQgsFTc44+YYAxntg1c090WEbWitiy7Ecnov98AZ54PHt70Ab8M7KuZGG0Nszv6Y7YH1+lAiZp2kypXYAfY+pIz7VmQgpJHtOQ4AGEywUdRjg85q5FK9zKXwiRvnA3EAjp9386ANCKMLl/nB4+83tzUqMQwViNhJGW9Rz+NJskEe5GVQBkDGcDHpUQjdcl5i54w+0Z+tAE8kjtE20MD3IAxk1QkwSijoPl6feJGB7/8A6qld98ce8nnlgR0IPtj3/Kl01Ptl55oOFTkDHHXFAGxGuIY0H8OAePxpDJvuiu08ITn0JIH8qRpQDgAbAcZzx7/5+tESH5pCxGevuf8AI/nQBKvKngc81HOdsTdNx4xTlXhgeuKYSGk24B2/Pk0ALGuEVe549OTSdAoA5HIHBJ/DrTxnnBHHTj/PpTCPlYbSe4GMCgBpBCs0jDKjt2HvTCXOcDBbpz+FKx2hFjGTwDsGWpyRzFtwjCDkgu/P5DNAERUEK2F8zOcqRz+ualAxGOMkjq316il8mQhf38De2T/hTmtLvIWNYnG3jZISRz2yKAGSDdG2DgtznP6UR8qDwD3psxmiYLJA8ZUjORzn/PNEUiscB8jgHPrQBKvGTnik5GBnmg8Icd6Acc44oAOSfejOCH9yAKXPHPUjNI/G3PUAnFAEUhwF5FFLsJ6fpRQA/PzEnpnNKevQelIflJwKO59M0ABPB9fT0pe3GKTg88YpABk8cdaAFH1pYyRIv8LZ7CkznjqO1IjYlJIJagA3fOOOM9KRwELFckA8jGf89KaxIDZjYkcjjqaj+0BlARWPH5e2KAJs4DDkg8fj1pisqNyMKRgHn+Q4oHnHJEErHuQpJP5Ux5lXIkyh7h1xj86AJCflOFG3p8wOP8KFyvAHfkZzx+VIoVskYOe4POfz/pSkqOp5JzyaAKqfury4kxkPsyR+IqaSNJoWSUKY2GCO3+e9Iio89wCeCi4/P/8AVT4SNhVvlKHB+vrQBWtpPKaK0vWwxIWKduA/oreje/ep5EIB4AJ5wR/n1pZUSeMxuitGfvBhnPfpVXyLyKP/AEO9ZYxj91PEsyj2HRh+dAGd4q8RWnhvQ5Lu8bJ+7FF0Mreg/r7VwXwm1ebV77xFqurXCCQ+VlycBB8+FA/A4Ayeuc8Vq/Fq5uIPDghnFhcXF04toUWzw2T1IJY7Tj0rT8FeDrLw2nmRNJJLKieZ5uGCOOpXAGM5/QUAXnvLVL2SHUpJLGCVvOtVmibE/wAoVs4BIYYBCdeal0pGa5kvIUZDOQGikjOcKDg56g/eOD6gdRXQueVKFsZLAjkA1CYxvnZXVeAysU3du47c0AZGqQRy2t1G+PJmQIwIwYzkEE9T07+1eba7G638rTFFfKnjjdhduQPw54r1HUQ8F9JcRh1MyLuiQZUkd1zntu4rkfF1gl62La5jkYrvi3KNwPdT3x0GfagDhra2d32SYDgYEinAzjPb1963LJmjtXkkJVipzgFiBnv2rFiuzaJPbagqxSkbcMMDr29uP19quNcW8qu6XM2+MbCkbrhumD05HOKAOg06/WdQ0IAEgOUkORySOM844P8A9bFbEZEAtMhSsbFSnI3ArwOmeDz6frWHZWSNaEDfbzA5xHktgEcmtaGRFktXmCMYVClAcbm5JPPrnH4UAarssfzSGPeufkQ9PTn/AD0q5bTNboPlUSsBhHIGwf5PvWZFcXUjY1C3+ziUCU85BUdu/bnrV0XNohaa62xxjAjLcAtnv/k0AXbUPHlrk5kkOFZsEcenbvSSyIg527QwCnON3vz+FUmuA6nbtkXaR8r8AnAHH0zUFzOIkiGDv6oMdMf/AK+9AEV3qTO0NvFGZGkPOO3BzW9pMTW9sBIxDNjK4+8w4/Ae1ZugacIFW4lV3kYfe3dAeQB9K2IVaVi2Ni5LE98nrQBMwLIkUW0tjP8An9atIjpbxCQhi3zcDHHamwJg5C/M54HoP/1c/jUzEEFgMDoufSgBhzGjMWIABJJoiXCFmA3NycjoPSo1HmygdVXlge59KkLevXsTQAOw6ZCnGQCf8KaY8YDkBB1AwM804EKWwecY9qhY+cuMZX+ZoAcsjMCtvGI4zwcnOfXHc0CAMR57PI2e5yF/AYH5805sAk7h+PTj+lITkYyecbRnBoAdtiTCohI+g/pSMQCdg2f7gx+dQhyz/MRzwQO3/wBapMEgljnuefU0APE0qDhiwx24/TpSuUmTcAoI5yKZt6Z56cdKcozJkY5646GgBhPzL64/pS9wv4t+v+FLwSSDnnIHt0ppAOfU80AO/iz1PamSYwPUg0E8k+9CjnNADgOOn5UU8UUAIwyKYfc8dqkprL6daAGc4z2pc4B70vQ96b1OeeaADGeKVUVc857UAEtx70bt2CR04J9fagBQyp0RN3bcu7H0qVruVgeTHnnav+NQYyfujBPIxSFQARztAxQBLMGYkmV1OcHIUj9aiMlzGCrbXTH8HX6bScH86QHnA6YOMDrQr7WOGXb1xnmgBAIpsgAqRwdnykH3FBDRttYH2JP+f5mnMFYZb7+MbgcECmI5T5XJV+xXofcUARRuDdTEHcpiU8fX/P5U6dTkTLlj1kA6ke1L0uwV4Pk4YDgcN14pxDA+bGSpoAA4dAVO5SN2R6etOVQMA/dY9agmQKfMj+6OGT+oFVtbv4dL0a71CQgRwQmT646Y/GgDhLwf8JL8Vo4lw1losXmMMYzIe3vzt/Ku6MoN0sS85HNcp8ItPkt/D82q3YzdarM1w7Y/hycD+Z/GuovYSLjzYs8en50AakZDsgJwckewOKam1FO8bQTjcG689P1qvDJvtw3KOCFJ96neSVYx5XzHAz9KAEeYTxBHw8WcFGHKsPQ5rntQtVM4hZMRYynQ7e+QR261vrIJVLEFCByOv+eagkthJEHOdrN1ODQBx2qaZFOmyePDD7p6lT7dP89q5GfR5rGchYg0Z5HOcnvxjj6+1epTQgL5dwm6MttLE5+UAAHA7D0/lWNqSRwoIXUMiMNuB6nt2J96AOYsbtLYNDIGQk7gx+fj0znnv+ddFbyxiFZMEqWIRkGQOMDIx7VkzFHjAjwD6YPy4z0A4/D/APXSRx+bIrwMPLiyuChBz6gjP+cUAdGZ3cboyilwMrJnAGO/H0qO3Cw2yBYULsoCkdlHVv5VliG9ZRJEIGRjklVJ9+gP+FXbS1MQMr73JPzRxnauex6c8UAS3WoTBjDY28YkUcO3bjqcCrui6ZIlx593IxcEbS64GcdAP/1VFbzxREO0SbmHzYHf69a0nv2iCeQiuT83T9aANBoGKqZMpHwCv8Tcd/arUagxj5doHYd/SqVpcyMga93KG+YZOfUflWkoAQtyAMD/AOt9aAAHCD6gZ7jg15Jq3j/VvBviOfStYi+32WfMglH7uURknGezY6Z9q9X83LY6c5AH0P8AjXL+MPBVp4pudOk1GRk+zPmTZ1dCD8mewzj9cYzmgDV8La9Z+INLS700TeUzYJkiZMsOuCRz9RxWtgnGRx75ry2wvb34c6mthqYa48MzSH7NcAEm3ychT7e9enW8sVzbrLbuksUi7kdSCCPUGgBXywcDcAfbFBCrwR0U8A9en/16VQDxgYHGelMbgsFbnB96AHjn5mOOxxx+n+c01gxUkYDHjBGBzTgRkjgFe/pn0zQFDEupGCMA8jFADGIVDyxGMK3T/Oacq5HzBh68UMTjI4Gc4PH4Y/l+NRqQxAycA9+vvxQBIuWQ+oOc/jSqRkYHTr/s0BCnBZwRjPykA59sj2oXd8wyr4z14478c0AAABOPu/1NI3Yf1pkhEajKgL657/T0pFIc5Ug460AOC84HI96kC4FCjFLQAoooFFAAaKD1pKAFI75qI5yeBUtBUHtQBC5wgyOaeVxx0H9abtYjKgnHTpSqwAB+YHBz8p7UAIpGcY46A8c/rQyc7sHOeuaRj1ypJHbOfoetKByw+8M8Hjn8/rQAzGWxg5PbPGe/Hb1/ClOckE9OOv8AWnOMZBUkdzu4/nTfQbSe2Rx+nX9KABXY5ZS3yj6fl1/WiT5SCCQOnB7/AONKSFwMH6gHp9KQggAMcYbsO/TFAEIA+3L8oO6NlOfbB+tSoMABRwB7UwZN5BjO1ty464JU/wBfpTxypORxng/U/wCNACjJycnHfnv+f0rzf4sSyXraV4dtG/ealOGkUD7qqev6Z/A16QSBk9CBwSRXnHg5f+Ei+Iuta64zbWI+x2+B/F3P/oX50Ad/ZQw28EUECYjhVY1U87QOBU7r94qAeMEg8UvntBN8knlOOchevt060631m3lby72FTKBgyBQuf1xn3oAz3XYj7dxJO4CpkwY/kzj61dlu7FPuwvlhn5mXp07VTFwI8tEgKdgAMigCVEzhdmSeBUm6EyOnkhExwMDGffPWmJeqQOGDE4PoDSqRJMTtG1eckZ547UAQSoYiy+WkcecKQ/HPv2qhf6QtxbyMB5cjcApjI98Y9z/jXQzRqsYbL+X67e+KffWxtgirwhTJ+p70AebzWTQMVli8wf3ljAB/rmpbTSHdxOskkYU4wpIzx34rsJYAxJ2qMD1wWqWNQAmRhgOe2eOBQBlWsGWAdspwyfJkA5/p1qae2YgSR5Vz8rK+TitEoUkDLnB+8oPQdP60llKhvruG5ZgHYbRjOOKAOWl03fe7HLHdyAvrWta6eYcl/mYdBnpV+W0VbxdoBwCc5qeRQgH8TDAzigCm8AG9WzySasyyEJEqklzgn64qKZmYlFGXbqfQZqaKPyyCB8x/SgBY0WNCSfmIPzH1xQD8vXjPrmnsckknOOPrSKPXH06UAV9RsLbU7GW0vokmhlXaysK8yjm1H4Z6ksF00154VuH+WQ5ZrYnAA69P89evq7AjjB59s1X1C0gvbSW2vI0lt5BtdGXIIoASzuYL60E1pKksUy5R42DBgenP41YyATuIzgDGc+/SvKnXUfhlqW+Lzb3wtO+SoyzWrHJyB0x/P69fSrC+t9Ss1ubKUT28oDhg2VPHcf8A1qALDdFXk8c88/lQN8nUKi9jjk/SgAnO3BOdu0jH4UMDkBj1PRsfzBoAFhUE5CtngkjOPagjIGOP8O4xnmlypz90Y49xTGZlzglucZUcfr9KAFUhWBChfQ56H26Usr/uwdzEDrg8daF5zsyp9/WkYANgryeQeaAIwd2XUg56nOf/ANVSRpgkkc+tOxuOSB7HrTqACiiigBRRQKKACkpT1pKAClyaSigAIyCO2KYRzkjt0ODxUgo60AQgMwOGUY6Z7dqUg56kqeepwOvPf1FKykNke4JzijJyeMdQQAT+v5UAMGS21csPSmtuLdBxz9KlY/Kp6H3HWmjPGMls9kJ/oaAG+pPXrnj09PWnZySoxtYbsHORzk/r3oB5UhkX2IP8v89KGGIx1yD/AEoAr3LeWYpcHbFIHznquf8ADirQX5nAwMNgd8UyWETQvGwPK5AH45pkLM8YYgFiATx1JH/6qAMD4hat/YfhG+u1bbMU8uPjgu3Apnw30b+xPCFjbyACdx50ucfebn+WB+FaOv6BYa+lvHqEMsgt5RNGqMQQwz25yK2PJnwMRBGA4G8Z/EUAVruJniAiwGQ5BPANZ5tJnj/fR4k74A5568f1rXaOdVyIy3tUe4FyrBklXhg3HNAGYyyxARyxH0zxxSW8g8zbuAYHvwavzR712tgtjjHQ1VeASoVPVeMnAI+lAFhgkzs2fLBO4sBwff8AWnW82jFi016Uf+8kTMM/lWDfpJJOLa2meILgsB0PtRBbTxIBlduMkE4x+mKAOji1DRIvmm1dvKz0eNhj6DHP4Voalq9neRRyaUZrqRE2EsGXcOcH5sY61ydjpMs8nmzrGXY55fhB6dK6KCOO1hVY44255JY8/SgCUu6hfPi2tjJwQce3H/16jlEbeVIhbAPJH8iDVqMq0xeQZdujDoOn9OKp38KRT208xLQo4MgXPXt+tAF+4iQPzH5Y6BSOcepHWs6CKI3M7RDPI5J9M1PdkzSNJkLub0/Wq+n2yRPM8zkl8EeZ/nFAEzeRFwG556AnP4VREks11+6yka5HJ6nNLqNwNqxW7YkfI3KB07n8hmp4IhFEixZxj06j3oAfGiRKMc9ifU4qRNzTFEUu2MYHoBQigj5uvUe1KHMalIwV3ZLYPJOe9ADfJkEn750TrjkHt7ZqRYogPnmJP+yn+NRIOQe/8qcASOTk0APeESKRFMpfqqupUk/UcVEAQhDjbxjHWnrw2NxAPf0oCbJNzfMwzgKOPbrQBBdWsN5avb3KJPFICskbj76+npXmF3aX/wAONQkvdMV7vwzOwM9vzugJ/iHHT/PvXq2SCGG4dwcjH6VHOkbmSOZI5IXTLo3zKR7/AJ4oAqaPqdnq2nRXljOsltKPlYE8H0IPTmrbt85IOMDGenTsa4fRPBl/ofil5/Dl5FFodwrSXNtLjKN28v8AzwB34FduYZolJDLleq46fy/T2oATcq8q5K5yMHP15/KnMMgnGMAYx6+nP/1qa28klfLzyDtGP/r02HduOcFV5H15oAfg7sEtn1zj+VABPXr3Ipxycdc9yf8APtSgcUAKBg0lFFABRRRQAoooFFAAetJSnrSUAFFFFABSikooAWmgc04UUAREDcOnPHPSm7xnCjBPbv04qVlzjp7UwgqDnp6k9Pz4oAVSVJyG/u8pge3b/OaYTlcuxGAOCPlPp149sA4oVfMI8v5ugPBOfwp4XCNgMOME4IyaAERQ3XB55wRiohyAyfdcY98g4p65Ccbce1R221HuI2GF3CVR35GCB+NAFiOQKzRxnbn5iRxkfWkZBjnnnNO2BWOTuznDf0/lS4zmgCIK6k7WKt/eFP8ANZx5dwofjIYjkfQ9abLkYKg/QUgOfpjpQABEHy9G7AmqV3thm3MdqnuTxmrwGACRkeh7UkibkO4BkPXIBoAyCIuJDIjq3THOOB6fhUlvKrjy124HHPX9a2LVFCssaKi/eGAB9aju9PRn3p8snUN/n8qAJbbclu7xLySAelMl3GPMgCJjkt90HqB+lWrctCGA75PtUU7HyXQ/LHnoTyaAKpYyYCrIZSNpG7aMf571YvbpFhjgaPzArAZUEkA+hFVyxjbywChbOQByf1qKaHbIXiWRlRc4Dfe69D680ARXWqwxwkwxyKemWOWz04H4d6itmvr1pCxe1iwAOMs3X8BS29sEdJJ45Jp/Vx0PtnjvWjArJyV2uxoAIbOONWdck45ZjuP5/jTs7mO04Hc1McLE2HbORlvXA6AVDGw2licjP50APQFcZpin5m45zn8+aUNkgk8elGOetACgYDEg9KVvvHHrRjihsZJx15oAQHvnv0pzcNn8RikwMcd6TcMeu35setAABgnAx249P8/yprOy+WzZZhnB54x2FOxwoB56f/X/AJ0hKsmB8o9M9DQAckY2hiDjjr+VOWeSNcrI6Z7ZIx2qJS4YjOCCc5qSMkcFjj0B4oAat88yhAEnKcZK7sfjTzHFtG0kSDtnNG5s7c54xnNJj0oABRRRQAUUUUAFFFFACiigUUAB60lOP8+lJigBKKXFBFACUUtGOaAEoopcUAFIVB5o5pcUANZSyn5tvsBTAgZ8YGBxwB09Klx6ZFIRyD39aAIQGVxjhOwABpiBhcw43YZSmc+2R+oqZlKqAOVGDg1DdM0UaTYGY3V/yPNAE6g4TJOeD0pc9acU2SsOCAaQjJJoADxUZwOTwCafjJ9qaVDfjQAwnPbPNOVtrZGQ3cYzmm8K2D3oZWDcHIoAmQ4YSIcdsD0qdiTEhwMDPGKqRnPGOtaGn3KpiKRN6570AVozk88KaWQl8xnL5zj06VcvbcQMTGco3OD2qmCDkY560ARyQLE2/aAM85Bz+Zpq+TsJkG1QOQMcn/OKWS3yhZZGUcEg/NUlrYrJKHlcuE7GgCP5sBiuz0UVNbwmSTGTux61ekjiQBVTdnkk9aWOMQrLNjgYA/GgClfMFlaJDlY89u9VsbflB5HA9qVyxLOx5yc/XNRhjuJOSD39KAHFiW45p4HXuaaoOAcZqQjA6c/WgAxnp3pu7NBGMZHApAMHpigBWOFBoxtJx36U1gTgd6kXv2oAjGD1z+PUVJy689D2HvUa527vzNOHXg570ARnkn2OKWNCvXGf508KAScdaXFAB2pKWjFACUUuKMUAFFFHNABSU6koASinYooA/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Right uterine angiogram before uterine fibroid embolization demonstrates dilated branches of the right uterine artery supplying multiple hypervascular uterine fibroids (arrows) on the right.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27250=[""].join("\n");
var outline_f26_39_27250=null;
var title_f26_39_27251="Plain film hip dysplasia";
var content_f26_39_27251=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79994&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Plain film hip dysplasia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 443px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This frontal view of the pelvis demonstrates complete superolateral dislocation of the left femoral head (arrow). The left acetabulum is shallow (asterisk). Note the smaller size of the femoral epiphysis on the dislocated left side. The right hip is normal. The heart shape is a lead shield&nbsp;protecting the ovaries.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Scott B Rosenfeld, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27251=[""].join("\n");
var outline_f26_39_27251=null;
var title_f26_39_27252="EB simplex Dowling-Meara 2";
var content_f26_39_27252=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86393&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Epidermolysis bullosa simplex (EBS) of Dowling-Meara",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Typical herpetiform distribution of cutaneous lesions, including&nbsp;blisters, erosions, crusts, and atrophic scars, in EBS Dowling Meara.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dedee F Murrell, MD, Johann Bauer, MD, and Martin Laimer, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27252=[""].join("\n");
var outline_f26_39_27252=null;
var title_f26_39_27253="Synovial plicae anatomy";
var content_f26_39_27253=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F83267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F83267&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Synovial plicae anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 458px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     Four synovial plicae have been described: medial, suprapatellar, infrapatellar, and lateral. The \"shelf\" type medial patellar plica is most commonly associated with plica syndrome.",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27253=[""].join("\n");
var outline_f26_39_27253=null;
var title_f26_39_27254="Sigmoid volvulus";
var content_f26_39_27254=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F67675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F67675&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 531px\">",
"   <div class=\"ttl\">",
"    Sigmoid volvulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 511px; height: 497px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Plain abdominal radiograph of a patient with a sigmoid volvulus demonstrates a large air-filled sigmoid colon (arrow) extending from the pelvis to the right upper quadrant and the absence of air in the rectum (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mukesh Harisinghani, MD, Department of Radiology, Massachusetts General Hospital, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27254=[""].join("\n");
var outline_f26_39_27254=null;
var title_f26_39_27255="Rosiglitazone and metformin: Drug information";
var content_f26_39_27255=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Rosiglitazone and metformin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?14/42/15014?source=see_link\">",
"    see \"Rosiglitazone and metformin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219452\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avandamet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219453\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avandamet&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F219472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antidiabetic Agent, Biguanide;",
"     </li>",
"     <li>",
"      Antidiabetic Agent, Thiazolidinedione",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F219456\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Type 2 diabetes mellitus:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     First-line therapy (drug-naive patients): Initial: Rosiglitazone 2 mg and metformin 500 mg once or twice daily; may increase by 2 mg/500 mg per day after 4 weeks to a maximum of 8 mg/2000 mg per day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Second-line therapy:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Patients inadequately controlled on metformin alone",
"     </b>",
"     : Initial dose: Rosiglitazone 4 mg/day plus current dose of metformin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Patients inadequately controlled on rosiglitazone alone",
"     </b>",
"     : Initial dose: Metformin 1000 mg/day plus current dose of rosiglitazone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     When switching from combination rosiglitazone and metformin as separate tablets: Use current dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Dose adjustment:",
"     </i>",
"     Doses may be increased as increments of rosiglitazone 4 mg and/or metformin 500 mg, up to the maximum dose; doses should be titrated gradually.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     After a change in the metformin dosage, titration can be done after 1-2 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     After a change in the rosiglitazone dosage, titration can be done after 8-12 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Maximum dose:",
"     </i>",
"     Rosiglitazone 8 mg/metformin 2000 mg daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F219457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The initial and maintenance dosing should be conservative, due to the potential for decreased renal function (monitor). Generally, elderly patients should not be titrated to the maximum. Do not use in patients &ge;80 years unless normal renal function has been established.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F219458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use with renal disease or renal dysfunction (serum creatinine &ge;1.5 mg/dL in males or &ge;1.4 mg/dL in females or abnormal clearance).",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F219459\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not initiate therapy with active liver disease or ALT &gt;2.5 times the upper limit of normal.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F219435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avandamet&reg;: 2/500: Rosiglitazone 2 mg and metformin hydrochloride 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avandamet&reg;: 4/500: Rosiglitazone 4 mg and metformin hydrochloride 500 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avandamet&reg;: 2/1000: Rosiglitazone 2 mg and metformin hydrochloride 1000 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Avandamet&reg;: 4/1000: Rosiglitazone 4 mg and metformin hydrochloride 1000 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F219422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block accres drugH1Div\" id=\"F11245588\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Prescribing and Access Restrictions",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;\">",
"     As a requirement of the REMS program, the prescribing and dispensing of any rosiglitazone-containing medication in the U.S. requires physician and patient enrollment in the Avandia-Rosiglitazone Medicines Access Program&trade;. Complete program details are available at www.avandia.com or by calling the program Coordinating Center at 800-282-6342.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Health Canada requires written informed consent for new and current patients receiving rosiglitazone.",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F7874986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and at",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM143419.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM143419.pdf",
"     </a>",
"     , must be dispensed with this medication.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F219438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals. Patients who are NPO may need to have their dose held to avoid hypoglycemia.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F219437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Management of type 2 diabetes mellitus (noninsulin dependent, NIDDM) as an adjunct to diet and exercise in patients where dual rosiglitazone and metformin therapy is appropriate",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6049683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Avandamet&reg; may be confused with Anzemet&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F219470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Also see individual agents. Percentages of adverse effects as reported with the combination product.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (7% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (16%), diarrhea (13% to 14%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Upper respiratory tract infection (9% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Edema (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Dizziness (8%), fatigue (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypoglycemia (3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (10%), abdominal pain (5%), loose stools (5%), constipation (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Anemia (4% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (5%), back pain (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Sinusitis (6%), nasopharyngitis (6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Injury (8%), viral infection (5%), flu-like syndrome (1%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F219441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     NYHA Class III/IV heart failure (initiation of therapy); renal disease or renal dysfunction (serum creatinine &ge;1.5 mg/dL in males or &ge;1.4 mg/dL in females, or abnormal creatinine clearance which may also result from conditions such as cardiovascular collapse, acute myocardial infarction, and septicemia); acute or chronic metabolic acidosis, including diabetic ketoacidosis (with or without coma); concurrent iodinated radiocontrast administration (manufacturer recommends temporary discontinuation of metformin)",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to rosiglitazone, metformin, or any component of the formulation; any stage of heart failure (eg, NYHA Class I, II, III, or IV); history of lactic acidosis, regardless of precipitating factors; serious hepatic impairment; pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F219425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fractures: Increased incidence of bone fractures in females treated with rosiglitazone observed during analysis of long-term trial; majority of fractures occurred in the upper arm, hand and foot (differing from the hip or spine fractures usually associated with postmenopausal osteoporosis). Consider risk of fracture prior to initiation and during use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure/cardiac effects:",
"     <b>",
"      [U.S. Boxed Warning]: Thiazolidinediones, including rosiglitazone, may cause or exacerbate congestive heart failure;",
"     </b>",
"     closely monitor for signs and symptoms of congestive heart failure (eg, rapid weight gain, dyspnea, edema), particularly after initiation or dose increases. Not recommended for use in any patient with symptomatic heart failure. In the U.S., initiation of therapy is contraindicated in patients with NYHA class III or IV heart failure; in Canada use is contraindicated in patients with any stage of heart failure (NYHA I, II, III, IV). Use with caution in patients with edema; may increase plasma volume and/or cause fluid retention. A higher frequency of cardiovascular events has been noted in patients with NYHA class I or II heart failure treated with rosiglitazone. In addition, metformin should be used with caution in patients with heart failure requiring pharmacologic management, particularly in unstable or acute heart failure due to risk of lactic acidosis secondary to hypoperfusion. Rosiglitazone may also be associated with an increased risk of angina and MI. Use with caution in patients at risk for cardiovascular events and monitor closely. Discontinue if any deterioration in cardiac status occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hematologic effects: Rosiglitazone may decrease hemoglobin, hematocrit, and/or WBC count (slight); effects may be related to increased plasma volume and/or dose-related. Use rosiglitazone with caution in patients with anemia or depressed leukocyte counts (may reduce hemoglobin, hematocrit, and/or WBC). Metformin may impair vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     absorption; monitor for anemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Lactic acidosis:",
"     <b>",
"      [U.S. Boxed Warning]: Lactic acidosis is a rare, but potentially severe consequence of therapy with metformin.",
"     </b>",
"     Lactic acidosis should be suspected in any patient with diabetes receiving metformin with evidence of acidosis but without evidence of ketoacidosis. Discontinue metformin in clinical situations predisposing to hypoxemia, including conditions such as cardiovascular collapse, respiratory failure, acute myocardial infarction, acute congestive heart failure, and septicemia. The risk of accumulation and lactic acidosis increases with the degree of impairment of renal function.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Weight gain: Dose-related weight gain observed with use; mechanism unknown but likely associated with fluid retention and fat accumulation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes, type 1: Mechanism of rosiglitazone requires the presence of insulin; therefore, use in type 1 diabetes (insulin dependent, IDDM) or diabetic ketoacidosis is not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Avoid rosiglitazone and metformin use in patients with impaired liver function due to potential for lactic acidosis with metformin. Use rosiglitazone with caution in patients with elevated transaminases (AST or ALT); do not initiate in patients with active liver disease of ALT &gt;2.5 times the upper limit of normal (ULN) at baseline; evaluate patients with ALT &le;2.5 times ULN at baseline or during therapy for cause of enzyme elevation. During therapy, if ALT &gt;3 times ULN, reevaluate levels promptly and discontinue rosiglitazone if elevation persists or if jaundice occurs at any time during use. Idiosyncratic hepatotoxicity has been reported with another thiazolidinedione agent (troglitazone); avoid use in patients who previously experienced jaundice during troglitazone therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Macular edema/diabetic retinopathy: Use rosiglitazone with caution in patients with pre-existing macular edema or diabetic retinopathy; postmarketing reports of new-onset or worsening diabetic macular edema with decreased visual acuity has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Metformin is substantially excreted by the kidney; patients with renal function below the limit of normal for their age should not receive therapy. Use of concomitant medications that may affect renal function (ie, affect tubular secretion) may also affect metformin disposition. Metformin should be withheld in patients with dehydration and/or prerenal azotemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Stress-related states: It may be necessary to discontinue metformin and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypoglycemic agents: Combination therapy with other hypoglycemic agents may increase risk for hypoglycemic events; dose reduction with the concomitant agent may be warranted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Insulin: Avoid use of rosiglitazone with insulin due to an increased risk of edema, congestive heart failure, and myocardial ischemic events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Nitrates: Concomitant use of rosiglitazone with nitrates is not recommended. An increased risk of myocardial ischemia has been observed in nitrate users versus non-nitrate users in clinical studies.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Metformin/sulfonylureas (Canadian labeling; not in U.S. labeling): Rosiglitazone may be added to metformin or a sulfonylurea (if metformin is contraindicated or not tolerated) if glycemic control is inadequate. The use of triple therapy (rosiglitazone in combination with metformin and a sulfonylurea) is not indicated due to increased risks of congestive heart failure and fluid retention.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Metformin should not be initiated in patients &ge;80 years of age unless normal renal function is confirmed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Premenopausal/anovulatory females: Use rosiglitazone with caution in premenopausal, anovulatory women; may result in a resumption of ovulation, increasing the risk of pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ethanol use: Instruct patients to avoid excessive acute or chronic ethanol use; ethanol may potentiate metformin's effect on lactate metabolism.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Iodinated contrast: Metformin therapy should  be temporarily discontinued prior to or at the time of  intravascular administration of iodinated contrast media (potential for acute alteration in renal function). Metformin should be withheld for 48 hours after the radiologic study and restarted only after renal function has been confirmed as normal.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; REMS program:",
"     <b>",
"      [U.S. Boxed Warning]: Due to cardiovascular risks, rosiglitazone-containing medications are only available through the Avandia-Rosiglitazone Medicines Access Program&trade;.",
"     </b>",
"     Patients and prescribers must be registered with and meet conditions of the program. Call 1-800-282-6342 or visit www.avandia.com for more information.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical procedures: Metformin therapy should be suspended 2 days prior to any surgical procedures (resume only after normal intake resumed and normal renal function is verified).",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F219467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual components.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F219429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Carbonic Anhydrase Inhibitors: May enhance the adverse/toxic effect of MetFORMIN. Specifically, the risk of developing lactic acidosis may be increased.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Brinzolamide; Dorzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cephalexin: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): May diminish the hypoglycemic effect of Antidiabetic Agents. In some instances, corticosteroid-mediated HPA axis suppression has led to episodes of acute adrenal crisis, which may manifest as enhanced hypoglycemia, particularly in the setting of insulin or other antidiabetic agent use.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inducers (Strong): May increase the metabolism of CYP2C8 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Moderate): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Inhibitors (Strong): May decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C8 Substrates: CYP2C8 Inhibitors (Moderate) may decrease the metabolism of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dalfampridine: May increase the serum concentration of MetFORMIN. MetFORMIN may increase the serum concentration of Dalfampridine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May increase the serum concentration of CYP2C8 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: MetFORMIN may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gemfibrozil: May decrease the metabolism of Antidiabetic Agents (Thiazolidinedione). Management: Limit pioglitazone maximum adult dose to 15 mg/day, and consider dose reduction of rosiglitazone, when used in combination with gemfibrozil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypoglycemic Properties): May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypoglycemic Agents: May enhance the adverse/toxic effect of other Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Insulin: May enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iodinated Contrast Agents: May enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis. Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     LamoTRIgine: May increase the serum concentration of MetFORMIN. Management: The lamotrigine Canadian product monograph states that coadministration of these drugs is not recommended.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: May diminish the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Luteinizing Hormone-Releasing Hormone Analogs: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP2C8 Substrates. Management: Use CYP2C8 substrates at the lowest recommended dose, and monitor closely for adverse effects (including myopathy), during and in the 2 weeks following mifepristone treatment.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pegvisomant: May enhance the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pregabalin: May enhance the fluid-retaining effect of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May increase the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the hypoglycemic effect of Hypoglycemic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Hypoglycemic Agents. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Hypoglycemic Agents. Management: Consider increased monitoring of glycemic control with concomitant use of a hypoglycemic agent and an SSRI. Dosage adjustments of the hypoglycemic agent may be necessary upon SSRI initiation or discontinuation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Somatropin: May diminish the hypoglycemic effect of Antidiabetic Agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May decrease the metabolism of Antidiabetic Agents (Thiazolidinedione).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trimethoprim: May increase the serum concentration of MetFORMIN.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trospium: MetFORMIN may decrease the serum concentration of Trospium.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vasodilators (Organic Nitrates): May enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of myocardial ischemia was reported for users of this combination in a meta-analysis. Management: Consider alternatives to this combination when possible.  Rosiglitazone prescribing information states that the combination of rosiglitazone and a nitrate is not recommended.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F219449\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F219431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F219443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies were not conducted with this combination; therefore, rosiglitazone/metformin is classified as pregnancy category C. Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F219463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosiglitazone: Excretion in breast milk unknown/not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metformin: Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F219444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F219445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with meals. Avoid ethanol. Dietary modification based on ADA recommendations is a part of therapy. Monitor for signs and symptoms of vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and/or folic acid deficiency; supplementation may be required.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F219442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Avandamet Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-500 mg (60): $165.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2-1000 mg (60): $165.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-500 mg (60): $280.07",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-1000 mg (60): $280.07",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F219433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hemoglobin A",
"     <sub>",
"      1c",
"     </sub>",
"     ; signs and symptoms of fluid retention or heart failure; renal function (baseline and every 6 months); blood pressure; liver enzymes (prior to initiation of therapy, then periodically thereafter). Evaluate patients with ALT &le;2.5 times ULN at baseline or during therapy for cause of enzyme elevation. Patients with an elevation in ALT &gt;3 times ULN should be rechecked as soon as possible. If the ALT levels remain &gt;3 times ULN, therapy with rosiglitazone should be discontinued. Serum glucose, CBC; vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     and folate if anemia is present. Regular ophthalmic examinations",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F219436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Recommendations for glycemic control in nonpregnant adults with diabetes (ADA, 2012):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     : &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] Hb A",
"     <sub>",
"      1c",
"     </sub>",
"     goal may be targeted based on patient-specific characteristics)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Preprandial capillary plasma glucose: 70-130 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Peak postprandial capillary blood glucose: &lt;180 mg/dL",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F219446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Avandamet (AR, AT, AU, BB, BE, BG, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CZ, DE, DK, DO, EC, FI, FR, GB, GR, GT, GY, HK, HN, ID, IE, IL, IT, JM, KP, MT, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, RU, SE, SG, SK, SR, SV, TH, TR, TT, TW, UY, VE);",
"     </li>",
"     <li>",
"      Enselin 2M (IN);",
"     </li>",
"     <li>",
"      Interac (PY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F219424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Rosiglitazone is a thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin, without increasing pancreatic insulin secretion. It has a mechanism of action that is dependent on the presence of insulin for activity. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity (increases peripheral glucose uptake and utilization).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F219440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Diabetes Association, &ldquo;Standards of Medical Care in Diabetes Mellitus -- 2012,&rdquo;",
"      <i>",
"       Diabetes Care",
"      </i>",
"      , 2012, 35(Suppl 1):11-63.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/39/27255/abstract-text/22187469/pubmed\" id=\"22187469\" target=\"_blank\">",
"        22187469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Barrett BJ and Parfrey PS, &ldquo;Clinical Practice. Preventing Nephropathy Induced by Contrast Medium,&rdquo;",
"      <i>",
"       New Engl J Med",
"      </i>",
"      , 2006, 354(4):379-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/39/27255/abstract-text/16436769/pubmed\" id=\"16436769\" target=\"_blank\">",
"        16436769",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gerstein HC, Yusuf S, Bosch J, et al, &ldquo;Effect Of Rosiglitazone On The Frequency Of Diabetes In Patients With Impaired Glucose Tolerance or Impaired Fasting Glucose: A Randomized Controlled Trial. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication)Trial Investigators,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006,368(9541):2096-105.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/39/27255/abstract-text/16997664/pubmed\" id=\"16997664\" target=\"_blank\">",
"        16997664",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kahn SE, Haffner SM, Heise MA, et al, &ldquo;Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006:355(23):2427-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/39/27255/abstract-text/17145742/pubmed\" id=\"17145742\" target=\"_blank\">",
"        17145742",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lago RM, Singh PP, and Nesto RW, &ldquo;Congestive Heart Failure and Cardiovascular Death in Patients With Prediabetes and Type 2 Diabetes Given Thiazolidinediones: A Meta-Analysis of Randomized Clinical Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2007, 370(9593):1129-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/39/27255/abstract-text/17905165/pubmed\" id=\"17905165\" target=\"_blank\">",
"        17905165",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Morcos SK and Thomsen HS, &ldquo;Adverse Reactions to Iodinated Contrast Media,&rdquo; Eur Radiol, 2001, 11(7):1267-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/39/27255/abstract-text/11471623/pubmed\" id=\"11471623\" target=\"_blank\">",
"        11471623",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nissen SE, Wolski K, &ldquo;Effects Of Rosiglitazone On The Risk of Myocardial Infarction and Death From Cardiovascular Causes,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2007. Available at file://content.nejm.org/cgi/content/full/NEJMoa072761",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/39/27255/abstract-text/17517853/pubmed\" id=\"17517853\" target=\"_blank\">",
"        17517853",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Qaseem A, Humphrey LL, Sweet DE, et al,&ldquo;Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2012, 156(3):218-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/39/27255/abstract-text/22312141/pubmed\" id=\"22312141\" target=\"_blank\">",
"        22312141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Singh S, Loke YK, and Furberg CD, &ldquo;Long-Term Risk of Cardiovascular Events With Rosiglitazone,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2007, 298(10):1189-95.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?26/39/27255/abstract-text/17848653/pubmed\" id=\"17848653\" target=\"_blank\">",
"        17848653",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10163 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-7DB0BEB7E6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27255=[""].join("\n");
var outline_f26_39_27255=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709407\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219452\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219453\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219472\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219456\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219457\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219458\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219459\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219435\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219422\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11245588\">",
"      Prescribing and Access Restrictions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7874986\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219438\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219437\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6049683\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219470\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219441\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219425\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219467\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219429\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219449\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219431\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219443\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219463\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219444\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219445\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219442\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219433\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219436\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219446\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219424\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219440\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10163\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10163|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?14/42/15014?source=related_link\">",
"      Rosiglitazone and metformin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_39_27256="Coronary artery after DES";
var content_f26_39_27256=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F58375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F58375&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    Coronary artery at long-term follow-up after drug eluting stent implantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 514px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The individual stent struts can be recognized as signal rich, bright yellow structures casting a dorsal shadow on the vessel wall. All stent struts are covered towards the lumen by a thin, homogenous bright yellow layer, corresponding to neointima. (IC) OCT imaging catheter in the center of the lumen; asterisk indicates the angioplasty guide wire artefact.",
"    <div class=\"footnotes\">",
"     OCT: St. Jude/Lightlab Imaging C7XR.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Evelyn Regar, Thoraxcenter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27256=[""].join("\n");
var outline_f26_39_27256=null;
var title_f26_39_27257="Laboratory issues related to maternal serum screening for Down syndrome";
var content_f26_39_27257=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Laboratory issues related to maternal serum screening for Down syndrome",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/39/27257/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/39/27257/contributors\">",
"     Jacob A Canick, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/39/27257/contributors\">",
"     Geralyn M Messerlian, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/39/27257/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/39/27257/contributors\">",
"     Louise Wilkins-Haug, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/39/27257/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/39/27257/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/39/27257/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Screening markers are used to calculate a pregnant woman's risk of having a child with Down syndrome, thereby allowing her to make an informed choice about invasive diagnostic testing, which is costly and associated with some risk of pregnancy loss. A variety of serum markers are used to screen for Down syndrome in the first",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    second trimesters. This topic will review laboratory issues related to use of these markers. Clinical issues related to Down syndrome are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=see_link\">",
"       \"Overview of prenatal screening and diagnosis of Down syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link\">",
"       \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1493?source=see_link\">",
"       \"Second trimester maternal serum screening for Down syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=see_link\">",
"       \"Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SCREENING TESTS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Quadruple marker test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The quad test is performed in the second trimester (optimally at 15 to 18 weeks of gestation) and consists of alpha fetoprotein (AFP), unconjugated estriol (uE3), human chorionic gonadotropin (beta-hCG), and inhibin A (inhA) measurements. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1493?source=see_link\">",
"     \"Second trimester maternal serum screening for Down syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Combined test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combined test is performed in the first trimester. It involves sonographic determination of fetal nuchal translucency (NT) combined with measurement of the serum markers pregnancy-associated plasma protein-A (PAPP-A) and beta-hCG at 11 to 13 weeks of gestation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Integrated tests",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Full integrated test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The full integrated test consists of NT and PAPP-A measured at 10 to 13 weeks followed by measurement of AFP, uE3, hCG, and inhA at 15 to 18 weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Serum integrated test",
"    </span>",
"    &nbsp;&mdash;&nbsp;The serum integrated test includes all of the laboratory tests of the full integrated test (PAPP-A, AFP, uE3, beta-hCG, inhA), but no ultrasound marker (ie, no NT).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Step-wise sequential testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The step-wise sequential screening process involves performing the first trimester portion of the integrated screen and then offering chorionic villous sampling (CVS) to women whose results place them at very high risk (eg, &ge;1 in 50) of having an affected fetus. Those whose screen does not place them at very high risk go on to complete the second trimester portion of the integrated test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=see_link&amp;anchor=H4#H4\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\", section on 'Integrated tests'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sequential testing that is not done in a step-wise fashion is not recommended. This is called \"independent sequential screening,\" in which the second trimester test is performed without taking the first trimester markers into account.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Contingent testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contingent screening is defined in terms of three risk cut-offs: (1) women at very high risk of having a fetus with Down syndrome after first trimester combined testing are offered immediate invasive prenatal diagnosis, (2) women at very low risk are provided with their risk estimate and require no additional testing, and (3) women at intermediate risk have second trimester markers tested (AFP, uE3, hCG, and inhA) to get an integrated result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MEASUREMENT OF ANALYTE LEVELS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Second trimester Down syndrome tests can be interpreted between 14.0 and 22.9 weeks; however, neural tube defect screening results should only be interpreted at 15.0 weeks or later. If Down syndrome screening is performed at 14 weeks, a second sample is required at a later date for neural tube defect screening with AFP.",
"   </p>",
"   <p>",
"    First trimester combined tests can be interpreted when the serum is drawn between 10 and 13.9 weeks using PAPP-A, nuchal translucency, and free beta-hCG, but is limited to 11 to 13.9 weeks when using PAPP-A, nuchal translucency, and total beta-hCG measurements.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Quantifying analyte levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each of the serum analytes used in prenatal screening is measured using immunoassay technology; most often by automated methods. The levels of first and second trimester Down syndrome screening markers can be measured reliably when the blood sample is centrifuged within an hour and the serum is kept refrigerated and received by the testing laboratory within a week of being drawn [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Analyte values are initially measured as standardized mass units. For the five maternal serum analytes used in Down syndrome screening, the units most commonly used in the United States are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      AFP &mdash; either",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"     </li>",
"     <li>",
"      uE3 &mdash;",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"     </li>",
"     <li>",
"      beta-hCG &mdash;",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       IU/mL",
"      </span>",
"     </li>",
"     <li>",
"      inhA &mdash;",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"     </li>",
"     <li>",
"      PAPP-A &mdash;",
"      <span class=\"nowrap\">",
"       ng/mL",
"      </span>",
"      or",
"      <span class=\"nowrap\">",
"       mIU/mL",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Each mass value is converted to the screened woman's gestation-specific multiple of the median (MoM), since the serum levels of each analyte are constantly changing during the periods of gestation in which screening is done [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/2\">",
"     2",
"    </a>",
"    ]. The process of normalization requires that each screening laboratory develop sufficient data to generate stable gestation-specific medians. Medians should be generated by assay of fresh serum samples from women with singleton pregnancies between 15 and 22 gestational weeks inclusive for second trimester markers and between 10 or 11 and 13 weeks for first trimester markers.",
"   </p>",
"   <p>",
"    Regressed data should show that, in the early second trimester, MSAFP increases during the screening period by 15 to 20 percent per week, estriol increases by 20 to 25 percent per week, beta-hCG decreases in nonlinear fashion from 15 to 17 weeks and then very gradually from 17 to 22 weeks, and inhibin A exhibits a shallow U-shaped curve with its nadir at 17 weeks of gestation (",
"    <a class=\"graphic graphic_figure graphicRef76646 graphicRef68253 graphicRef66827 graphicRef54546 \" href=\"UTD.htm?33/22/34159\">",
"     figure 1A-D",
"    </a>",
"    ). First trimester PAPP-A levels increase by 30 to 50 percent per week between 10 and 13 weeks of gestation. Free and total beta-hCG levels reach a peak at about 10 weeks of gestation and decline through the remainder of the first trimester. Free beta-hCG levels decline more quickly than total beta-hCG (by about 10 to 30 percent and 5 to 10 percent per week, respectively).",
"   </p>",
"   <p>",
"    Patient data can be expressed as MoM values after population-based medians are established, thereby eliminating the effect of gestational age on the data. As an example, a MSAFP mass value of 25",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    measured at 15 weeks of gestation might calculate to a normalized value of 1.0 MoM. Similarly, a MSAFP mass value of 50",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    measured at 20 weeks might also calculate to a normalized value of 1.0 MoM. Thus, the MSAFP levels measured at these two different gestational weeks are comparable once they have been normalized for gestational age.",
"   </p>",
"   <p>",
"    Multiples of the median also provide a relatively simple way to compare an individual to the entire population being screened. By definition, the central value in unaffected singleton pregnancy is 1.0 MoM; thus, 2.0 MoM indicates that the woman is at twice the central value, while 0.5 MoM indicates that the woman is at one-half the central value.",
"   </p>",
"   <p>",
"    Prior to clinical implementation of any analyte as a screening marker, the distribution of its levels in unaffected and affected pregnancies must be thoroughly described. Most laboratories cannot assess analyte levels in affected pregnancies because of limited access to sufficient numbers of such samples; as a result, they must use data reported in the scientific literature [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/3-5\">",
"     3-5",
"    </a>",
"    ] or from commercial providers of software used in prenatal screening. In contrast, each screening laboratory can and should examine the distribution of MoM data in its total population, almost all of it coming from unaffected pregnancies. The parameters of the population distribution (the center of the distribution or mean of log MoM values, and the breadth of the distribution or standard deviation of the log MoM values) should be very close to published parameters of such distributions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CHANGES IN ANALYTE LEVELS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Down syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distributions of MoM values of AFP, uE3, beta-hCG, and inhA in the second trimester (",
"    <a class=\"graphic graphic_figure graphicRef52502 \" href=\"UTD.htm?14/48/15119\">",
"     figure 2",
"    </a>",
"    ), and PAPP-A, free beta-hCG, and total beta-hCG in the first trimester (",
"    <a class=\"graphic graphic_figure graphicRef61531 \" href=\"UTD.htm?33/45/34526\">",
"     figure 3",
"    </a>",
"    ) in unaffected and Down syndrome pregnancies are Gaussian (normal) on a logarithmic scale.",
"   </p>",
"   <p>",
"    Compared to unaffected pregnancies, levels of second trimester MSAFP and uE3 are, on average, 0.70-0.75 MoM in Down syndrome, and the levels of first trimester PAPP-A are, on average, 0.4 MoM. Therefore, for these markers, the distribution of affected population values is shifted to the left of the unaffected population. Second trimester levels of beta-hCG and inhibin A are about 2.0 MoM, the first trimester level of free beta-hCG is about 1.8 MoM, and the first trimester level of total beta-hCG is 1.4 MoM, thus shifting the distribution of affected population values for these markers to the right of the unaffected population. In examining overlapping distributions, the extent of the overlap is a function of both the average distance between the medians and the widths of the two distributions; the less overlap in the distributions, the better the marker's performance.",
"   </p>",
"   <p>",
"    The median MoM values of the second trimester markers in Down syndrome pregnancy are relatively constant when measured between 15 and 20 weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the median MoM values of the first trimester markers in Down syndrome pregnancies change systematically when measured between 10 and 13 weeks of gestation, and this change in marker performance should be accounted for in the calculation of patient-specific risk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/3\">",
"     3",
"    </a>",
"    ]. Median PAPP-A rises from about 0.4 MoM at 10 weeks to about 0.7 MoM at 13 weeks, so the performance of PAPP-A decreases as gestation progresses. Median free and total beta-hCG also rise during this period, and the rise results in increasing performance of these markers since they are both elevated in Down syndrome pregnancies (",
"    <a class=\"graphic graphic_figure graphicRef79124 \" href=\"UTD.htm?2/61/3039\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The reasons for altered maternal serum analytes in Down syndrome pregnancy are poorly understood. Placental secretory products, such as the clinically important markers beta-hCG and inhibin A (as well as other products such as progesterone&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/7\">",
"     7",
"    </a>",
"    ], human placental lactogen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/8\">",
"     8",
"    </a>",
"    ], and pregnancy-specific glycoprotein 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/9\">",
"     9",
"    </a>",
"    ]), are generally increased in the second trimester of Down syndrome pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/6,10-12\">",
"     6,10-12",
"    </a>",
"    ]. However, PAPP-A is also a placental secretory product, and its levels are low in the first trimester and not different from unaffected fetuses in the second trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/3\">",
"     3",
"    </a>",
"    ]. None of the genes for these placental products resides on chromosome 21, thereby eliminating a simple dosage effect to explain the increased or decreased concentrations. Placental size and weight are comparable in Down syndrome and unaffected pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. There may be an increase in the synthesis of specific placental proteins in Down syndrome, as suggested by beta-hCG and inhibin mRNA and protein studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Deficient syncytiotrophoblast formation may also have a role in abnormal placental secretion in affected pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    By comparison, secretory products synthesized in the fetus or requiring the combined fetoplacental unit are, on average, low in second trimester maternal serum from Down syndrome pregnancies. As an example, levels of AFP derived from the fetal liver are reduced, as are maternal serum and amniotic fluid concentrations of the fetoplacental steroid, uE3 [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/19,20\">",
"     19,20",
"    </a>",
"    ], and its fetal androgen precursor molecules, dehydroepiandrosterone sulfate (DHEA-S) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/20\">",
"     20",
"    </a>",
"    ] and 16-alpha-hydroxyDHEA-S [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanisms leading to this phenomenon of increased placental and decreased fetal products in second trimester maternal serum of Down syndrome pregnancy are actively being investigated [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/15-18,22-24\">",
"     15-18,22-24",
"    </a>",
"    ]. One hypothesis is that the serum analyte pattern is related to poorly functioning fetal tissue with compensatory placental hyperfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Conditions other than Down syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other conditions also have characteristic changes in analytes (",
"    <a class=\"graphic graphic_table graphicRef71552 \" href=\"UTD.htm?37/52/38732\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=see_link\">",
"     \"Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     INTERPRETATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal serum screening results are evaluated using risk-based assessment. A woman's a priori risk is determined based on her chronological age and history of previous Down syndrome pregnancy. This risk is then modified by relative risk factors called likelihood ratios, determined directly from each of her serum marker MoM values, and the degree of independence of each pair of markers (measured as an R value after log transformation of the MoMs). The final reported risk is her calculated patient-specific risk of having a fetus affected by Down syndrome in that pregnancy. The chosen cut-off for a screen positive result and recommendation for further diagnostic testing has been, by convention, the risk of Down syndrome pregnancy in a 35- or 37-year-old woman, although higher risk cut-offs are beginning to be used to obtain lower false positive rates when screening with higher performance tests, like the integrated test.",
"   </p>",
"   <p>",
"    The goal of screening is to maximize the detection rate while minimizing the false positive rate. The number of affected and unaffected individuals who are called screen positive (ie, those identified by the test as high risk) is dependent upon the prevalence of the disorder in the population being screened. If, as an example, testing the oldest 5 percent of pregnant women identifies 30 percent of all Down syndrome pregnancies, the screen positive group will have a six-fold higher risk",
"    <span class=\"nowrap\">",
"     (30/5)",
"    </span>",
"    of disease than the population from which it was selected. If the population prevalence of Down syndrome pregnancy is 1 in 700, the screen positives will have a group risk of 1 in 117 (ie, six times 1 in 700).",
"   </p>",
"   <p>",
"    A better screening test, such as one that identifies 90 percent of Down syndrome pregnancies and only 2 percent of unaffected pregnancies as screen positive (eg, integrated screen), will yield a group with a 45-fold higher risk",
"    <span class=\"nowrap\">",
"     (90/2)",
"    </span>",
"    than the population from which it was selected. Thus, the screen positives will have a group risk of 1 in 16 (ie, 45 times 1 in 700).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     VARIABLES THAT AFFECT PERFORMANCE AND INTERPRETATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Selection of risk cut-off",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each patient should be given the specific numerical risk of Down syndrome (eg, 1 in 100) calculated for her based on her age and screening test results. The risk cut-off chosen for test interpretation (ie, identifying patients as screen negative or screen positive) determines the detection and false positive rates for Down syndrome (",
"    <a class=\"graphic graphic_table graphicRef56294 \" href=\"UTD.htm?10/24/10635\">",
"     table 2",
"    </a>",
"    ). For a given test, as the risk cut-off gets higher, fewer women are screen positive and fewer affected pregnancies will be identified. If less stringent risk cut-offs are chosen, a greater number of affected pregnancies will be identified, but there will be more false positive tests leading to a larger number of couples experiencing parental anxiety and having to consider costly and potentially risky diagnostic procedures. Thus, there is always a trade-off between an optimal detection rate and a tolerable screen positive rate.",
"   </p>",
"   <p>",
"    By convention, the risk of Down syndrome pregnancy for a 35 year-old woman has been used as the cut-off to identify pregnancies at increased risk (ie, screen positive women). The appropriateness of this convention is in question because of the marked improvement in performance of new screening tests [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The 2007 American College of Obstetricians and Gynecologists guidelines recommend offering screening to women of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/27\">",
"     27",
"    </a>",
"    ], and a 2006 study suggests that amniocentesis may be safer than previously thought [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Midpregnancy versus term risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of Down syndrome is stated as either the risk of giving birth to an affected baby (so-called term risk) or the risk of carrying an affected fetus in the second trimester (midpregnancy risk). The latter conveys the risk of finding trisomy 21 at the typical time of prenatal genetic testing. Term risk is significantly lower than midtrimester risk at all maternal ages due to loss of affected fetuses in the late second and the third trimester (",
"    <a class=\"graphic graphic_table graphicRef75423 \" href=\"UTD.htm?16/60/17357\">",
"     table 3",
"    </a>",
"    ). Put another way, intrauterine demise occurs in more than one-third of Down syndrome fetuses between 12 weeks and term and in 20 to 25 percent between 16 weeks and term [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Thus, a midtrimester risk of Down syndrome of 1 in 190 is equivalent to a term risk of 1 in 250.",
"   </p>",
"   <p>",
"    Most screening programs report term risk. There is no advantage of reporting one type of risk over another, although it is essential to know which is being used and to use it consistently.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Effect of maternal age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since each woman's initial risk at screening is based upon her age-related risk for having a child with Down syndrome (",
"    <a class=\"graphic graphic_table graphicRef75423 \" href=\"UTD.htm?16/60/17357\">",
"     table 3",
"    </a>",
"    ), older women start at higher risk and are more often screen positive after prenatal screening than their younger counterparts. The detection of Down syndrome pregnancy is also higher in older women than in younger women. However, the risk of Down syndrome birth does not increase further after the age of 45, likely because of higher miscarriage rates in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prior pregnancy history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Geneticists generally tell patients the recurrence risk of aneuploidy is at least 1 percent if a woman has had a prior Down syndrome pregnancy (non-inherited type); this figure is based upon data published in the 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/32\">",
"     32",
"    </a>",
"    ]. Subsequent analyses of North American data [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/33\">",
"     33",
"    </a>",
"    ] and of previously published studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/34,35\">",
"     34,35",
"    </a>",
"    ] have suggested that the overall incremental risk of recurrence is less than 1 percent and that the excess risk is higher for younger than for older women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/33,36\">",
"     33,36",
"    </a>",
"    ]. For example, data from the United Kingdom National Down Syndrome Cytogenetic Register clearly show that the recurrence risk for younger women (under 27 years old) is about 4 or 5 per 1000 births, and that risk drops to 2 or 3 per 1000 in women in their early 30s [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/36\">",
"     36",
"    </a>",
"    ]. By ages 36 to 42, the excess risk is only 1 per 1000 births, and by age 44, there is no excess risk of recurrence.",
"   </p>",
"   <p>",
"    The risk of recurrence of inherited (ie, translocation) Down syndrome is usually much higher, but depends upon the specific translocation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=see_link&amp;anchor=H9#H9\">",
"     \"Congenital cytogenetic abnormalities\", section on 'Trisomy 21 (Down syndrome)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Method of gestational age determination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Error in the estimation of gestational age is the most common reason for a false positive result. If the true gestational age is earlier than reported, MSAFP, uE3, and PAPP-A MoM values will be falsely interpreted as low and beta-hCG will be falsely interpreted as elevated, a pattern replicating that seen in Down syndrome pregnancy (",
"    <a class=\"graphic graphic_figure graphicRef50763 \" href=\"UTD.htm?17/9/17565\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    A screen positive result initially based upon last menstrual period (LMP) should be adjusted if subsequent ultrasound evaluation of gestational age is substantially different (gestational age",
"    <span class=\"nowrap\">",
"     +/-",
"    </span>",
"    10 percent, eg, 10 or more days in the second trimester) from menstrual dating. Adjustment of screen positive reports based on a small ultrasound - LMP discrepancy may provide false reassurance and should be avoided.",
"   </p>",
"   <p>",
"    Sonographic measurement of biparietal diameter or crown rump length, neither of which is affected in Down syndrome fetuses, are the most appropriate methods of gestational age assessment on a population basis. Ultrasound dating results in a narrower distribution of serum marker values and a higher detection rate than LMP dating. In one study, at a fixed 5 percent false positive rate, the Down syndrome detection rate using the quadruple test increased by 9 percentage points when ultrasound rather than LMP dating was used [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=see_link\">",
"     \"Prenatal assessment of gestational age\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Adjustments to the MoM",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of factors can affect serum marker concentrations. While the impact on overall screening performance is improved only slightly by adjusting for these factors, adjustment is recommended because it will improve the estimate of an individual's risk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/5,37\">",
"     5,37",
"    </a>",
"    ]. These variables include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Race",
"     </li>",
"     <li>",
"      Body weight",
"     </li>",
"     <li>",
"      Multiple gestation",
"     </li>",
"     <li>",
"      Diabetes mellitus",
"     </li>",
"     <li>",
"      In vitro fertilization",
"     </li>",
"     <li>",
"      Previous false positive result",
"     </li>",
"     <li>",
"      Smoking",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Race",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concentrations of maternal serum AFP, PAPP-A, total hCG, and free beta-hCG are increased and inhA levels are decreased in African-American versus Caucasian women. Adjustment of AFP for African-American race is commonly done because it is the sole marker used in screening for neural tube defects. Differences in analyte levels for other races have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/38-40\">",
"     38-40",
"    </a>",
"    ], but adjustments may be difficult to implement because of limitations in patient self-reporting of",
"    <span class=\"nowrap\">",
"     race/ethnicity",
"    </span>",
"    or insufficient data. Laboratories that provide services to many women of other races may be able to determine their median data for these women. If not, adjustment of screening&nbsp;values&nbsp;for race provides only relatively small changes in risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Body weight",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum marker concentrations decrease as maternal body weight increases because the additional blood volume dilutes the amount of analyte that is present. Each analyte should be corrected for maternal body weight, measured ideally on the day the sample was drawn. Even though the overall impact is small, weight adjustment can have a substantial effect for individual results, especially for very light or heavy weight women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Multiple gestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum concentrations of each analyte are approximately twice as high in twin versus singleton pregnancies. Since the individual contribution of each twin to the maternal serum marker levels cannot be determined, prenatal screening in twin pregnancies is not as efficient as in singleton pregnancies. With correction of MoM values in twin gestation, a screening result can be generated that assumes each fetus contributes equally to the marker levels. However, a precise risk estimate cannot be given because of this assumption and because the actual marker levels in twin pregnancies affected with Down syndrome are not known with certainty. Serum screening is not generally considered interpretable in higher order pregnancies (eg, triplets, quadruplets). In such cases, ultrasound evaluation may be a useful screening alternative. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=see_link\">",
"     \"Sonographic findings associated with fetal aneuploidy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/28/11718?source=see_link\">",
"     \"Triplet pregnancy: Early pregnancy management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early studies found that second trimester maternal serum levels of AFP are significantly decreased (by up to 20 percent) in women with pregestational diabetes requiring insulin treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/41\">",
"     41",
"    </a>",
"    ] and, as a consequence, adjustment of AFP in women with diabetes has been recommended and implemented in most screening laboratories. The prevalence of diabetes has been increasing secondary to a major rise in obesity rates and contemporary studies show that AFP values are similarly reduced (by about 10 percent) among women with type 1 and type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], regardless of management with insulin or oral anti-diabetic agents.",
"   </p>",
"   <p>",
"    Use of AFP correction for diabetes has been questioned on the basis that weight adjustment alone is sufficient to correct values or that the traditionally used 20 percent adjustment may be too much [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/43-47\">",
"     43-47",
"    </a>",
"    ]. It has also been suggested that the decrease in MSAFP in diabetes is a function of glycemic control. A statistically significant inverse correlation between MSAFP and A1c has been shown in several studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]. Further investigation of this relationship is warranted.",
"   </p>",
"   <p>",
"    Second trimester levels of uE3 are modestly reduced (5 to 10 percent lower), while beta-hCG and inhA levels are not significantly altered in women with pregestational diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The effect of diabetes on first trimester serum markers is unclear. One report found decreased first trimester PAPP-A and beta-hCG levels in women with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/54\">",
"     54",
"    </a>",
"    ], while another found that the marker levels were not significantly altered [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     In vitro fertilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies show that maternal serum beta-hCG and inhA levels tend to be increased and uE3 levels decreased (the Down syndrome pattern) as a consequence of the hormonal treatment to stimulate the ovaries for in vitro fertilization (IVF) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/56,57\">",
"     56,57",
"    </a>",
"    ]. Without adjustment of these MoM values, the screen positive rate for such pregnancies is approximately twice the expected rate. Therefore, we recommend adjustment.",
"   </p>",
"   <p>",
"    There are multiple forms of assisted reproductive technologies (ART) in addition to in vitro fertilization. A similar adjustment of beta-hCG and inhibin A levels may be required for pregnancies resulting from oocyte donation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], ovulation induction, or intrauterine insemination [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/57,59\">",
"     57,59",
"    </a>",
"    ]. Such adjustment is difficult to implement, mainly because of the complexities of accurate reporting of these ART options to the screening laboratory. There are few reports on this issue so most, if not all, screening software programs only make adjustments for women who underwent IVF. However, as with race, adjustment of screening&nbsp;values&nbsp;for assisted reproductive technologies other than IVF will provide relatively small changes in risk.",
"   </p>",
"   <p>",
"    Several groups have now examined the effects of ART on first trimester screening markers. The most pronounced effect seems to be a decrease in serum levels of PAPP-A, on the order of a 10 to 20 percent reduction, in comparison to spontaneously achieved pregnancies. Most studies also find slightly increased levels of free beta-hCG and no change in NT for ART pregnancies. The variability in results is due, in part, to the heterogeneity of the types of ART analyzed and small group sizes. In the most common method of ART, hormonal ovarian stimulation followed by in vitro fertilization, there is a trend toward an increased screen positive rate, on the order of about two times higher than that expected (after maternal age adjustment) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/57,60,61\">",
"     57,60,61",
"    </a>",
"    ]. Adjustment of first trimester serum marker levels may be considered to reduce the rate of invasive diagnostic procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Previous false positive result",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who have false-positive results in one pregnancy are at increased risk of a false-positive result in a subsequent pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. In a study of women who had a false-positive result in their initial pregnancy, their false-positive rate for these women in the subsequent pregnancy was 20 percent",
"    <span class=\"nowrap\">",
"     (46/229)",
"    </span>",
"    versus only 6.6 percent in the overall population of tested women [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/62\">",
"     62",
"    </a>",
"    ]. This is caused by the correlation of serum markers between pregnancies. An algorithm has been developed that will minimize the problem of recurrent false positive results by adjusting the serum markers in all women according to their values in the previous unaffected pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal smoking also appears to affect analyte concentrations: AFP and inhA levels are higher and uE3, beta-hCG and PAPP-A levels are lower in smokers than in nonsmokers [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/7,55,64-68\">",
"     7,55,64-68",
"    </a>",
"    ]. Adjusting serum analyte levels for smoking status is becoming more common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alterations in serum marker levels have also been noted in association with factors such as parity, fetal gender [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/69,70\">",
"     69,70",
"    </a>",
"    ], and maternal systemic lupus erythematosus [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/71\">",
"     71",
"    </a>",
"    ]. In these cases, the effect is small, the data collected are insufficient to warrant adjustment, or the correction cannot be implemented easily.",
"   </p>",
"   <p>",
"    Other factors, such as renal",
"    <span class=\"nowrap\">",
"     insufficiency/hemodialysis,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/62/2023?source=see_link\">",
"     adrenocorticotropic hormone",
"    </a>",
"    insufficiency, and the use of various medications (eg, antiretroviral therapy), have also been associated with effects on maternal analyte levels [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27257/abstract/72-79\">",
"     72-79",
"    </a>",
"    ]. Further study is needed to confirm or exclude significant associations.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     CELL-FREE FETAL DNA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Examination of cell-free fetal nucleic acids in maternal blood can also be used as primary or secondary screening for fetal aneuploidy. The detection rate is higher and the false positive rate lower than for other Down syndrome screening tests. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1448?source=see_link\">",
"     \"Prenatal diagnosis using cell-free fetal nucleic acids in maternal blood\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Screening markers are used to calculate a pregnant woman's risk of having a child with Down syndrome, thereby helping her to make an informed choice about whether to undergo invasive diagnostic testing. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Prenatal screening results are evaluated using risk-based assessment. A woman's a priori risk is determined based upon her chronological age and history of previous Down syndrome pregnancy. This risk is then modified by her serum marker values. The final risk estimate is her calculated patient-specific risk of having a fetus affected by Down syndrome in that pregnancy. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Interpretation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Second trimester levels of maternal serum alpha fetoprotein (AFP), unconjugated estriol (uE3), and first trimester levels of pregnancy associated plasma protein-A (PAPP-A) are lower, on average, in pregnancies affected by Down syndrome than in unaffected pregnancies; beta-hCG and inhibin A levels are higher, on average, in affected than unaffected pregnancies. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Changes in analyte levels'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of factors affect screening test performance and must be considered when calculating and interpreting results. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Variables that affect performance and interpretation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/1\">",
"      Lambert-Messerlian GM, Eklund EE, Malone FD, et al. Stability of first- and second-trimester serum markers after storage and shipment. Prenat Diagn 2006; 26:17.",
"     </a>",
"    </li>",
"    <li>",
"     Wald, NJ. The detection of neural-tube defects by screening maternal blood. In: Prenatal Diagnosis, Boue, A (Ed), INSERM 1976, p. 227.",
"    </li>",
"    <li>",
"     Palomaki, GE, Messerlian, G, Canick, JA. A summary analysis of Down syndrome markers in the late first trimester. In: Advances in Clinical Chemistry, Vol 43, Makowski, G (Ed), Academic Press 2007. p.177.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/4\">",
"      Haddow JE, Palomaki GE, Knight GJ, et al. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. J Med Screen 1998; 5:115.",
"     </a>",
"    </li>",
"    <li>",
"     Wald, N. Down's syndrome. In: Antenatal and Neonatal Screening, Wald, N, Leck, I (Eds), Oxford University Press, Oxford, 2000. p. 85.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/6\">",
"      Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen 1997; 4:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/7\">",
"      Cuckle HS, Wald NJ, Densem JW, et al. The effect of smoking in pregnancy on maternal serum alpha-fetoprotein, unconjugated oestriol, human chorionic gonadotrophin, progesterone and dehydroepiandrosterone sulphate levels. Br J Obstet Gynaecol 1990; 97:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/8\">",
"      Ryall RG, Staples AJ, Robertson EF, Pollard AC. Improved performance in a prenatal screening programme for Down's syndrome incorporating serum-free hCG subunit analyses. Prenat Diagn 1992; 12:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/9\">",
"      Bartels I, Lindemann A. Maternal levels of pregnancy-specific beta 1-glycoprotein (SP-1) are elevated in pregnancies affected by Down's syndrome. Hum Genet 1988; 80:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/10\">",
"      Chard T. Biochemistry and endocrinology of the Down's syndrome pregnancy. Ann N Y Acad Sci 1991; 626:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/11\">",
"      Lambert-Messerlian GM, Saller DN Jr, Tumber MB, et al. Second-trimester maternal serum progesterone levels in Turner syndrome with and without hydrops and in trisomy 18. Prenat Diagn 1999; 19:476.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/12\">",
"      Qin QP, Christiansen M, Nguyen TH, et al. Schwangerschaftsprotein 1 (SP1) as a maternal serum marker for Down syndrome in the first and second trimesters. Prenat Diagn 1997; 17:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/13\">",
"      Golbus MS. Development in the first half of gestation of genetically abnormal human fetuses. Teratology 1978; 18:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/14\">",
"      Shepard TH, FitzSimmons JM, Fantel AG, Pascoe-Mason J. Placental weights of normal and aneuploid early human fetuses. Pediatr Pathol 1989; 9:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/15\">",
"      Eldar-Geva T, Hochberg A, deGroot N, Weinstein D. High maternal serum chorionic gonadotropin level in Downs' syndrome pregnancies is caused by elevation of both subunits messenger ribonucleic acid level in trophoblasts. J Clin Endocrinol Metab 1995; 80:3528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/16\">",
"      Lambert-Messerlian GM, Luisi S, Florio P, et al. Second trimester levels of maternal serum total activin A and placental inhibin/activin alpha and betaA subunit messenger ribonucleic acids in Down syndrome pregnancy. Eur J Endocrinol 1998; 138:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/17\">",
"      Dalgliesh GL, Aitken DA, Lyall F, et al. Placental and maternal serum inhibin-A and activin-A levels in Down's syndrome pregnancies. Placenta 2001; 22:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/18\">",
"      Frendo JL, Vidaud M, Guibourdenche J, et al. Defect of villous cytotrophoblast differentiation into syncytiotrophoblast in Down's syndrome. J Clin Endocrinol Metab 2000; 85:3700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/19\">",
"      Canick JA, Knight GJ, Palomaki GE, et al. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down's syndrome. Br J Obstet Gynaecol 1988; 95:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/20\">",
"      Cuckle HS, Wald NJ, Densem JW, et al. Second trimester amniotic fluid oestriol, dehydroepiandrosterone sulphate, and human chorionic gonadotrophin levels in Down's syndrome. Br J Obstet Gynaecol 1991; 98:1160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/21\">",
"      Wald, NJ, Cheng, R, Cuckle, HS, et al. Maternal serum levels of the estriol precursor, 16 alphaOHDHEAS, are low in Down syndrome pregnancy. Am J Hum Genet 1992; 51:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/22\">",
"      Newby D, Aitken DA, Crossley JA, et al. Biochemical markers of trisomy 21 and the pathophysiology of Down's syndrome pregnancies. Prenat Diagn 1997; 17:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/23\">",
"      Newby D, Aitken DA, Howatson AG, Connor JM. Placental synthesis of oestriol in Down's syndrome pregnancies. Placenta 2000; 21:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/24\">",
"      Frendo JL, Guibourdenche J, Pidoux G, et al. Trophoblast production of a weakly bioactive human chorionic gonadotropin in trisomy 21-affected pregnancy. J Clin Endocrinol Metab 2004; 89:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/25\">",
"      Malone FD, Canick JA, Ball RH, et al. First-trimester or second-trimester screening, or both, for Down's syndrome. N Engl J Med 2005; 353:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/26\">",
"      Wald NJ, Rodeck C, Hackshaw AK, Rudnicka A. SURUSS in perspective. BJOG 2004; 111:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/27\">",
"      ACOG Committee on Practice Bulletins. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstet Gynecol 2007; 109:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/28\">",
"      Eddleman KA, Malone FD, Sullivan L, et al. Pregnancy loss rates after midtrimester amniocentesis. Obstet Gynecol 2006; 108:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/29\">",
"      Tabor A, Philip J, Madsen M, et al. Randomised controlled trial of genetic amniocentesis in 4606 low-risk women. Lancet 1986; 1:1287.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/30\">",
"      Savva GM, Morris JK, Mutton DE, Alberman E. Maternal age-specific fetal loss rates in Down syndrome pregnancies. Prenat Diagn 2006; 26:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/31\">",
"      Morris JK, De Vigan C, Mutton DE, Alberman E. Risk of a Down syndrome live birth in women 45 years of age and older. Prenat Diagn 2005; 25:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/32\">",
"      Stene J, Stene E, Mikkelsen M. Risk for chromosome abnormality at amniocentesis following a child with a non-inherited chromosome aberration. A European Collaborative Study on Prenatal Diagnoses 1981. Prenat Diagn 1984; 4 Spec No:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/33\">",
"      Warburton D, Dallaire L, Thangavelu M, et al. Trisomy recurrence: a reconsideration based on North American data. Am J Hum Genet 2004; 75:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/34\">",
"      Noble J. Natural history of Down's syndrome: a brief review for those involved in antenatal screening. J Med Screen 1998; 5:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/35\">",
"      Warburton D, Kline J, Stein Z, et al. Does the karyotype of a spontaneous abortion predict the karyotype of a subsequent abortion? Evidence from 273 women with two karyotyped spontaneous abortions. Am J Hum Genet 1987; 41:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/36\">",
"      Morris JK, Mutton DE, Alberman E. Recurrences of free trisomy 21: analysis of data from the National Down Syndrome Cytogenetic Register. Prenat Diagn 2005; 25:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/37\">",
"      Kagan KO, Wright D, Spencer K, et al. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics. Ultrasound Obstet Gynecol 2008; 31:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/38\">",
"      Hsu JJ, Hsieh TT, Hsieh FJ. Down syndrome screening in an Asian population using alpha-fetoprotein and free beta-hCG: a report of the Taiwan Down Syndrome Screening Group. Obstet Gynecol 1996; 87:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/39\">",
"      Watt HC, Wald NJ, Smith D, et al. Effect of allowing for ethnic group in prenatal screening for Down's syndrome. Prenat Diagn 1996; 16:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/40\">",
"      Benn PA, Clive JM, Collins R. Medians for second-trimester maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated estriol; differences between races or ethnic groups. Clin Chem 1997; 43:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/41\">",
"      Wald NJ, Cuckle H, Boreham J, et al. Maternal serum alpha-fetoprotein and diabetes mellitus. Br J Obstet Gynaecol 1979; 86:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/42\">",
"      Thornburg LL, Knight KM, Peterson CJ, et al. Maternal serum alpha-fetoprotein values in type 1 and type 2 diabetic patients. Am J Obstet Gynecol 2008; 199:135.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/43\">",
"      Sprawka N, Lambert-Messerlian G, Palomaki GE, et al. Adjustment of maternal serum alpha-fetoprotein levels in women with pregestational diabetes. Prenat Diagn 2011; 31:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/44\">",
"      Evans MI, Harrison HH, O'Brien JE, et al. Correction for insulin-dependent diabetes in maternal serum alpha-fetoprotein testing has outlived its usefulness. Am J Obstet Gynecol 2002; 187:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/45\">",
"      Martin AO, Dempsey LM, Minogue J, et al. Maternal serum alpha-fetoprotein levels in pregnancies complicated by diabetes: implications for screening programs. Am J Obstet Gynecol 1990; 163:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/46\">",
"      Milunsky A, Alpert E, Kitzmiller JL, et al. Prenatal diagnosis of neural tube defects. VIII. The importance of serum alpha-fetoprotein screening in diabetic pregnant women. Am J Obstet Gynecol 1982; 142:1030.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/47\">",
"      Sancken U, Bartels I. Biochemical screening for chromosomal disorders and neural tube defects (NTD): is adjustment of maternal alpha-fetoprotein (AFP) still appropriate in insulin-dependent diabetes mellitus (IDDM)? Prenat Diagn 2001; 21:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/48\">",
"      Reece EA, Davis N, Mahoney MJ, Baumgarten A. Maternal serum alpha-fetoprotein in diabetic pregnancy: correlation with blood glucose control. Lancet 1987; 2:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/49\">",
"      Baumgarten A, Robinson J. Prospective study of an inverse relationship between maternal glycosylated hemoglobin and serum alpha-fetoprotein concentrations in pregnant women with diabetes. Am J Obstet Gynecol 1988; 159:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/50\">",
"      Baumgarten A, Reece EA, Davis N, Mahoney MJ. A reassessment of maternal serum alpha-fetoprotein in diabetic pregnancy. Eur J Obstet Gynecol Reprod Biol 1988; 28:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/51\">",
"      Henriques CU, Damm P, Tabor A, et al. Decreased alpha-fetoprotein in amniotic fluid and maternal serum in diabetic pregnancy. Obstet Gynecol 1993; 82:960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/52\">",
"      Huttly W, Rudnicka A, Wald NJ. Second-trimester prenatal screening markers for Down syndrome in women with insulin-dependent diabetes mellitus. Prenat Diagn 2004; 24:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/53\">",
"      Evans MI, O'Brien JE, Dvorin E, et al. Similarity of insulin-dependent diabetics' and non-insulin-dependent diabetics' levels of beta-hCG and unconjugated estriol with controls: no need to adjust as with alpha-fetoprotein. J Soc Gynecol Investig 1996; 3:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/54\">",
"      Spencer K, Cicero S, Atzei A, et al. The influence of maternal insulin-dependent diabetes on fetal nuchal translucency thickness and first-trimester maternal serum biochemical markers of aneuploidy. Prenat Diagn 2005; 25:927.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/55\">",
"      Lambert-Messerlian G, Palomaki GE, Canick JA. Adjustment of serum markers in first trimester screening. J Med Screen 2009; 16:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/56\">",
"      Wald NJ, White N, Morris JK, et al. Serum markers for Down's syndrome in women who have had in vitro fertilisation: implications for antenatal screening. Br J Obstet Gynaecol 1999; 106:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/57\">",
"      Lambert-Messerlian G, Dugoff L, Vidaver J, et al. First- and second-trimester Down syndrome screening markers in pregnancies achieved through assisted reproductive technologies (ART): a FASTER trial study. Prenat Diagn 2006; 26:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/58\">",
"      Maymon R, Shulman A. Comparison of triple serum screening and pregnancy outcome in oocyte donation versus IVF pregnancies. Hum Reprod 2001; 16:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/59\">",
"      R&auml;ty R, Virtanen A, Koskinen P, et al. Maternal serum beta-hCG levels in screening for Down syndrome are higher in singleton pregnancies achieved with ovulation induction and intrauterine insemination than in spontaneous singleton pregnancies. Fertil Steril 2001; 76:1075.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/60\">",
"      Amor DJ, Xu JX, Halliday JL, et al. Pregnancies conceived using assisted reproductive technologies (ART) have low levels of pregnancy-associated plasma protein-A (PAPP-A) leading to a high rate of false-positive results in first trimester screening for Down syndrome. Hum Reprod 2009; 24:1330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/61\">",
"      Gjerris AC, Loft A, Pinborg A, et al. First-trimester screening markers are altered in pregnancies conceived after IVF/ICSI. Ultrasound Obstet Gynecol 2009; 33:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/62\">",
"      Wald NJ, Huttly WJ, Rudnicka AR. Prenatal screening for Down syndrome: the problem of recurrent false-positives. Prenat Diagn 2004; 24:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/63\">",
"      Wald NJ, Barnes IM, Birger R, Huttly W. Effect on Down syndrome screening performance of adjusting for marker levels in a previous pregnancy. Prenat Diagn 2006; 26:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/64\">",
"      Bartels I, Hoppe-Sievert B, Bockel B, et al. Adjustment formulae for maternal serum alpha-fetoprotein, human chorionic gonadotropin, and unconjugated oestriol to maternal weight and smoking. Prenat Diagn 1993; 13:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/65\">",
"      Spencer K. The influence of smoking on maternal serum AFP and free beta hCG levels and the impact on screening for Down syndrome. Prenat Diagn 1998; 18:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/66\">",
"      Ferriman EL, Sehmi IK, Jones R, Cuckle HS. The effect of smoking in pregnancy on maternal serum inhibin A levels. Prenat Diagn 1999; 19:372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/67\">",
"      Spencer K, Bindra R, Cacho AM, Nicolaides KH. The impact of correcting for smoking status when screening for chromosomal anomalies using maternal serum biochemistry and fetal nuchal translucency thickness in the first trimester of pregnancy. Prenat Diagn 2004; 24:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/68\">",
"      Urato AC, Quinn R, Pulkkinen A, et al. Maternal smoking during pregnancy and false positive maternal serum alpha-fetoprotein (MSAFP) screening for open neural tube defects. Prenat Diagn 2008; 28:778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/69\">",
"      Aitken DA, Wallace EM, Crossley JA, et al. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. N Engl J Med 1996; 334:1231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/70\">",
"      Wald NJ, Densem JW, Smith D, Klee GG. Four-marker serum screening for Down's syndrome. Prenat Diagn 1994; 14:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/71\">",
"      Hackshaw AK, Wald NJ. Repeat testing in antenatal screening for Down syndrome using dimeric inhibin-A in combination with other maternal serum markers. Prenat Diagn 2001; 21:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/72\">",
"      Einstein FH, Wright RL, Trentacoste S, et al. The impact of protease inhibitors on maternal serum screening analyte levels in pregnant women who are HIV positive. Am J Obstet Gynecol 2004; 191:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/73\">",
"      Yudin MH, Prosen TL, Landers DV. Multiple-marker screening in human immunodeficiency virus-positive pregnant women: Screen positivity rates with the triple and quad screens. Am J Obstet Gynecol 2003; 189:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/74\">",
"      Weintrob N, Drouin J, Vallette-Kasic S, et al. Low estriol levels in the maternal triple-marker screen as a predictor of isolated adrenocorticotropic hormone deficiency caused by a new mutation in the TPIT gene. Pediatrics 2006; 117:e322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/75\">",
"      Cheng PJ, Liu CM, Chang SD, et al. Elevated second-trimester maternal serum hCG in patients undergoing haemodialysis. Prenat Diagn 1999; 19:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/76\">",
"      Le Meaux JP, Tsatsaris V, Schmitz T, et al. Maternal biochemical serum screening for Down syndrome in pregnancy with human immunodeficiency virus infection. Obstet Gynecol 2008; 112:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/77\">",
"      Pekarek DM, Chapman VR, Neely CL, et al. Medication effects on midtrimester maternal serum screening. Am J Obstet Gynecol 2009; 201:622.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/78\">",
"      Benachi A, Dreux S, Kaddioui-Maalej S, et al. Down syndrome maternal serum screening in patients with renal disease. Am J Obstet Gynecol 2010; 203:60.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27257/abstract/79\">",
"      Savvidou MD, Samuel I, Syngelaki A, et al. First-trimester markers of aneuploidy in women positive for HIV. BJOG 2011; 118:844.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 414 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-3AAB480B33-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27257=[""].join("\n");
var outline_f26_39_27257=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H33\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SCREENING TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Quadruple marker test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Combined test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Integrated tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Full integrated test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Serum integrated test",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Step-wise sequential testing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Contingent testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MEASUREMENT OF ANALYTE LEVELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Quantifying analyte levels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CHANGES IN ANALYTE LEVELS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Conditions other than Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      VARIABLES THAT AFFECT PERFORMANCE AND INTERPRETATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Selection of risk cut-off",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Midpregnancy versus term risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Effect of maternal age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prior pregnancy history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Method of gestational age determination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Adjustments to the MoM",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Race",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Body weight",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Multiple gestation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Previous false positive result",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Smoking",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      CELL-FREE FETAL DNA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/414\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/414|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/21/8541\" title=\"figure 1A\">",
"      MSAFP level by gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/59/3005\" title=\"figure 1B\">",
"      Estriol by gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/14/237\" title=\"figure 1C\">",
"      hCG by gestational age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/54/2925\" title=\"figure 1D\">",
"      Inhibin level by gestation age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/48/15119\" title=\"figure 2\">",
"      Analyte MoMs in the second trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/45/34526\" title=\"figure 3\">",
"      Analyte MoMs in the first trimester",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/61/3039\" title=\"figure 4\">",
"      Analyte medians",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/9/17565\" title=\"figure 5\">",
"      Variation of MoM values by GA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/414|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/52/38732\" title=\"table 1\">",
"      Maternal serum marker pattern in selected fetal syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/24/10635\" title=\"table 2\">",
"      Risk cut off for Downs testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/60/17357\" title=\"table 3\">",
"      Maternal age-related Down syndrome risk at 3 gestational ages",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/0/23562?source=related_link\">",
"      Congenital cytogenetic abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/22/7529?source=related_link\">",
"      First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/27/22969?source=related_link\">",
"      Overview of prenatal screening and diagnosis of Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/57/18329?source=related_link\">",
"      Pregnancy outcomes predicted by serum markers assayed in Down syndrome screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34553?source=related_link\">",
"      Prenatal assessment of gestational age",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/26/1448?source=related_link\">",
"      Prenatal diagnosis using cell-free fetal nucleic acids in maternal blood",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/29/1493?source=related_link\">",
"      Second trimester maternal serum screening for Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22170?source=related_link\">",
"      Sonographic findings associated with fetal aneuploidy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/28/11718?source=related_link\">",
"      Triplet pregnancy: Early pregnancy management",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_39_27258="Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults";
var content_f26_39_27258=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bowel preparation for colonoscopy and flexible sigmoidoscopy in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/39/27258/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/39/27258/contributors\">",
"     Yousif I A-Rahim, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/39/27258/contributors\">",
"     Myron Falchuk, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/39/27258/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/39/27258/contributors\">",
"     John R Saltzman, MD, FACP, FACG, FASGE",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?26/39/27258/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?26/39/27258/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?26/39/27258/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A successful colonoscopy or flexible sigmoidoscopy requires clear visualization of the mucosal surface of the colon, and the degree of bowel cleansing is a critical factor in determining the quality, difficulty, speed, and completeness of the examination [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the most frequently used methods for bowel preparation for colonoscopy and flexible sigmoidoscopy and will provide recommendations for addressing commonly encountered problems. An overview of colonoscopy in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31178?source=see_link\">",
"     \"Overview of colonoscopy in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148488578\">",
"    <span class=\"h1\">",
"     COLONOSCOPY PREPARATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148492007\">",
"    <span class=\"h2\">",
"     Patient instructions, medications, and diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should be provided with written instructions that are simple, easy to follow, and in a language the patient understands. Patients should also be instructed to read the instructions at least a week prior to the colonoscopy since medication and dietary changes are often required several days prior to the examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H330966487\">",
"    <span class=\"h3\">",
"     Medications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most medications may be continued up to the time of colonoscopy and are taken with a small sip of water the day of the colonoscopy. Some medications may need to be adjusted prior to colonoscopy, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    and insulin. Oral iron should also be stopped at least five days before the colonoscopy, since it makes the residual feces black, viscous, and difficult to clear.",
"   </p>",
"   <p>",
"    Decisions regarding the management of antiplatelet agents or anticoagulants must weigh the risks of bleeding from the procedure with the probability of a thromboembolic event occurring while the antithrombotic medication is interrupted (",
"    <a class=\"graphic graphic_table graphicRef50700 \" href=\"UTD.htm?43/43/44731\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef77634 \" href=\"UTD.htm?40/0/40971\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/2\">",
"     2",
"    </a>",
"    ]. Furthermore, the urgency of the procedure and the availability of alternative tests must be evaluated (eg, a bleeding scan in a patient with acute lower gastrointestinal bleeding). Whenever possible, management decisions about antithrombotic agents should be made following discussion with the patient and the clinician prescribing the medication.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    &nbsp;and nonsteroidal anti-inflammatory drugs in standard doses may be continued safely in patients undergoing colonoscopy, including in those who require polypectomy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=see_link\">",
"     \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=see_link\">",
"     \"Management of antiplatelet agents in patients undergoing endoscopic procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link\">",
"     \"Endoscopic procedures in patients with disorders of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the risk of infection related to routine diagnostic or therapeutic colonoscopy is low, antibiotic prophylaxis is not recommended for colonoscopy (",
"    <a class=\"graphic graphic_table graphicRef51133 \" href=\"UTD.htm?30/19/31037\">",
"     table 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=see_link\">",
"     \"Antibiotic prophylaxis for gastrointestinal endoscopic procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H160742642\">",
"    <span class=\"h3\">",
"     Diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients need to consume clear liquids or a low residue diet for at least one day prior to elective colonoscopy. Our approach is to recommend a low residue diet for five days prior to colonoscopy, with only clear liquids allowed the day prior to the examination. Patients should not consume any liquids for two hours prior to the procedure.",
"   </p>",
"   <p>",
"    A low residue diet is low in fiber, and patients should be instructed to avoid foods that are high in fiber, such as fruits, vegetables, and whole grains (",
"    <a class=\"graphic graphic_table graphicRef51448 \" href=\"UTD.htm?17/2/17453\">",
"     table 4",
"    </a>",
"    ). Clear liquids include water, clear broth, coffee or tea (without milk), ices, gelatin, and fruit juices, such as apple, grapefruit, and lemonade. Liquids that are red can be mistaken for blood in the colon and can obscure mucosal details, so they should be avoided.",
"   </p>",
"   <p>",
"    Randomized trials suggest that patients who are allowed to consume a low residue diet the day prior to the procedure may have preparation quality similar to that seen in patients instructed to consume clear liquid diets, with greater patient satisfaction [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Whether similar results would be seen outside of a randomized trial is not yet known.",
"   </p>",
"   <p>",
"    Patients typically take no food by mouth for six to eight hours prior to the procedure (sometimes longer if there is known or suspected delayed gastric emptying) and no liquids (other than sips with medications) for two hours [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/5\">",
"     5",
"    </a>",
"    ]. Recommendations differ with regard to preprocedure fasting for elective procedures. The American Society for Anesthesiology (ASA) guidelines state that prior to a procedure, patients should fast a minimum of two hours following clear liquid ingestion or six hours for a light meal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/6\">",
"     6",
"    </a>",
"    ]. By contrast, the American College of Emergency Physicians states \"recent food intake is not a contraindication for administering procedural sedation and analgesia, but should be considered in choosing the timing and target level of sedation\" [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/7\">",
"     7",
"    </a>",
"    ]. Our practice is to follow the ASA approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148488585\">",
"    <span class=\"h2\">",
"     Choosing a preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;All of the available preparations can produce adequate cleansing results with acceptable tolerance, though results for individual patients are variable. As a result, none of the regimens has been universally adopted. Our approach is to use a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    preparation for most patients with no comorbid illnesses and to use a full-volume polyethylene glycol (PEG) preparation for patients who are unable to take magnesium citrate. We avoid preparations that contain",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    because of the small risk of ischemic colitis associated with bisacodyl. (See",
"    <a class=\"local\" href=\"#H148495700\">",
"     'Magnesium citrate'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H148494535\">",
"     'Polyethylene glycol solutions'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Overall, regimens that use hyperosmotic laxatives, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    , appear to be better tolerated than the polyethylene glycol (PEG)-containing regimens, although not all have been directly compared. However, the hyperosmotic laxative regimens may lead to volume and electrolyte shifts and should be avoided in patients with heart failure, renal impairment, decompensated cirrhosis, or pre-existing electrolyte imbalances (including patients on diuretics that may affect electrolyte levels or cause dehydration). In addition, older adults (&gt;65 years of age) may be at increased risk of fluid and electrolyte abnormalities, so hyperosmotic preparations should be used with caution.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H149537130\">",
"    <span class=\"h3\">",
"     Contraindications to oral lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;While most patients are able to undergo an oral lavage for colonoscopy, there are some situations in which it is contraindicated. In addition, some patients have contraindications to the use of specific colonoscopy preparations. (See",
"    <a class=\"local\" href=\"#H330965656\">",
"     'Patient characteristics'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H330965790\">",
"     'Indication for colonoscopy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Oral lavages should not be used in patient with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An ileus",
"     </li>",
"     <li>",
"      Significant gastric retention",
"     </li>",
"     <li>",
"      Suspected or established mechanical bowel obstruction",
"     </li>",
"     <li>",
"      Severe colitis",
"     </li>",
"     <li>",
"      Neurologic impairment that prevents safe swallowing (though it may be possible in such patients to administer the preparation using a nasogastric tube)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H330965656\">",
"    <span class=\"h3\">",
"     Patient characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the largest factors when choosing a preparation is the patient&rsquo;s medical history. For most patients with no significant past medical history, both PEG-based preparations and hyperosmotic preparations may be used, whereas in patients at risk for fluid and electrolyte shifts, such as those with heart failure, PEG-based preparations are preferred.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H149537222\">",
"    <span class=\"h4\">",
"     Patients without significant comorbid illnesses",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients without significant comorbid illnesses, the choice of preparation depends upon what preparation the patient is most likely to tolerate. In many cases, the lower-volume preparations will be better tolerated than large-volume PEG preparations. For patients without significant comorbid illnesses, our preferred preparation is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    which can be taken as two 450 mL (15 oz) doses. (See",
"    <a class=\"local\" href=\"#H148495700\">",
"     'Magnesium citrate'",
"    </a>",
"    below.)",
"    <br/>",
"    <br/>",
"    Other lower-volume preparations include PEG combined with an additional agent to promote bowel cleansing (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    or ascorbic acid),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    -based preparations, sodium sulfate preparations, and sodium picosulfate preparations. We avoid preparations that use bisacodyl because it has rarely been associated with ischemic colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, we avoid sodium phosphate-based preparations because a growing number of reports have demonstrated serious electrolyte abnormalities and renal complications, including in patients who did not have pre-existing risk factors. (See",
"    <a class=\"local\" href=\"#H352180686\">",
"     'Safety of sodium phosphate preparations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H149537229\">",
"    <span class=\"h4\">",
"     Older adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older adults (&gt;65 years of age) may be at increased risk of fluid and electrolyte abnormalities, so hyperosmotic preparations should be used with caution [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/9\">",
"     9",
"    </a>",
"    ]. Our preference is to use a PEG-based preparation in such patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H149537236\">",
"    <span class=\"h4\">",
"     Patients with heart failure, renal insufficiency, end-stage liver disease, or electrolyte imbalances",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperosmolar preparations should be avoided in patients with heart failure, renal insufficiency (glomerular filtration rate &gt;60",
"    <span class=\"nowrap\">",
"     mL/min/1.73",
"    </span>",
"    m",
"    <sup>",
"     2",
"    </sup>",
"    ), end-stage liver disease, or electrolyte imbalances. These preparations may cause fluid and electrolyte shifts and many are renally excreted. Patients with these comorbid illnesses should instead receive one of the PEG-based preparations. (See",
"    <a class=\"local\" href=\"#H148494535\">",
"     'Polyethylene glycol solutions'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H148493872\">",
"     'Hyperosmotic preparations'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H149537243\">",
"    <span class=\"h4\">",
"     Patients who are pregnant",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of colonoscopy preparations are lacking in patients who are pregnant. Colonoscopy should only be performed in such patients if there is a strong indication. We prefer PEG-based preparations as they are used for the treatment of constipation in women who are pregnant, are thought to be low-risk, and have been recommended for colonoscopy preparation in consensus guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Because hyperosmolar solutions can cause fluid and electrolyte abnormalities, they should be used with caution in women who are pregnant [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H330965790\">",
"    <span class=\"h3\">",
"     Indication for colonoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In most cases, the preparation chosen does not depend upon the indication for the examination. However, for patients with suspected lower gastrointestinal bleeding, inflammatory bowel disease, or unexplained chronic diarrhea, certain preparations are preferred.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Suspected lower",
"      </strong>",
"      <strong>",
"       gastrointestinal",
"      </strong>",
"      <strong>",
"       bleeding",
"      </strong>",
"      &mdash; Patients with suspected lower gastrointestinal bleeding typically receive a high-volume PEG-based preparation given rapidly (four to eight liters given over two to three hours) to ensure adequate lavage [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/13-15\">",
"       13-15",
"      </a>",
"      ]. The preparation is continued until the effluent is clear. In many cases, placement of a nasogastric tube is required to administer the high volumes of PEG solution that are required. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=see_link&amp;anchor=H5#H5\">",
"       \"Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient\", section on 'Colonoscopy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Suspected inflammatory bowel",
"      </strong>",
"      <strong>",
"       disease or unexplained chronic diarrhea",
"      </strong>",
"      &mdash; Hyperosmolar preparations may cause mucosal damage that resembles inflammatory bowel disease, leading to diagnostic confusion [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/16\">",
"       16",
"      </a>",
"      ]. PEG-based preparations do not damage the colonic mucosa, and should be used in patients being evaluated for possible inflammatory bowel disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H330965760\">",
"    <span class=\"h3\">",
"     Prior poor preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in whom an adequate examination of the colon cannot be achieved due to an inadequate preparation usually require a repeat examination after a more thorough attempt at bowel cleansing. Factors that have been associated with inadequate bowel preparations include administration of the entire preparation the night before the colonoscopy rather than split-dosing, later colonoscopy starting time, failure to follow the preparation instructions, inpatient status, constipation as the indication for the procedure, use of tricyclic antidepressants, male gender, obesity, and a history of diabetes, cirrhosis, stroke, or dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Enemas can be used in patients who present to endoscopy with a poor distal colon preparation and in patients with a defunctionalized distal colon [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/10\">",
"     10",
"    </a>",
"    ]. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    enemas may increase complications in older adults (&gt;65 years of age) and should be avoided in such patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H148488437\">",
"     'Flexible sigmoidoscopy preparation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients who were noncompliant due to a misunderstanding of instructions can be counseled and directed to repeat the same bowel regimen. On the other hand, for patients who did not tolerate or failed to respond adequately to the original preparation an alternative preparation should be tried. In addition, for patients who received the entire preparation the evening prior to the examination, split-dosing of the preparation should be considered, as it is associated with better preparation quality. (See",
"    <a class=\"local\" href=\"#H148491583\">",
"     'Split-dose lavage'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Some patients continue to have an inadequate preparation despite compliance with the regimen, switching regimens, and using a split-dose lavage. In such patients, we suggest one or more of the following:",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Two days of clear liquids (instead of one)",
"     </li>",
"     <li>",
"      Scheduling a morning procedure time",
"     </li>",
"     <li>",
"      Adding another cathartic if there are no contraindications (eg, using a full-volume PEG solution followed by a bottle of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"       magnesium citrate",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Double administration of the preparation over a two-day period (with the exception of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Typically in this situation, we will give two days of clear liquids, double administration of the preparation over a two-day period, and schedule a morning procedure. If the patient&rsquo;s preparation was extremely poor (eg, there was retained solid stool), we will also consider adding a second cathartic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H330965697\">",
"    <span class=\"h3\">",
"     Cost",
"    </span>",
"    &nbsp;&mdash;&nbsp;The costs of the preparations vary widely and may be an issue for patients who lack insurance coverage for the preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. In the United States,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    is available over-the-counter and is often the least expensive option (less than $10). Full-volume (4L) PEG solutions cost approximately $20 to $35, whereas low-volume PEG solutions, sodium sulfate, and the sodium picosulfate cost approximately $60 to $70.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     Sodium phosphate",
"    </a>",
"    tablet preparations cost $100 or more.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148491576\">",
"    <span class=\"h2\">",
"     Timing of administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The method of administration can influence both cleansing quality and patient compliance. We recommend split-dosing, especially for patients who will be having their procedures in the afternoon, rather than giving the entire preparation the evening before the procedure. The dose of the preparation given the morning of the colonoscopy should be given five hours prior to the examination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148491583\">",
"    <span class=\"h3\">",
"     Split-dose lavage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Split-dose lavage refers to administration of half of the preparation the evening prior to the colonoscopy and the second half the morning of the colonoscopy. The timing of the morning dose should take into account how long the patient needs to fast prior to the procedure. The American Society for Anesthesiology (ASA) guidelines state that prior to a procedure, patients should fast a minimum of two hours following clear liquid ingestion or six hours for a light meal [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/6\">",
"     6",
"    </a>",
"    ]. If split-dose lavage is being used, we recommend that patients consume their morning dose five hours prior to the procedure. For patients with early morning procedures, this may require that the patient take the morning dose as early as 2:00 am (See",
"    <a class=\"local\" href=\"#H160742642\">",
"     'Diet'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An advantage to split-dose preparation over administering the entire preparation the evening prior to the examination (full-dose lavage) has been demonstrated in multiple randomized trials, meta-analyses, and observational studies [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/25-34\">",
"     25-34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis that included five of the trials with a total of 1232 patients found satisfactory bowel preparations were more likely with split-dose lavage compared with full-dose lavage (odds ratio [OR] 3.7) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/32\">",
"       32",
"      </a>",
"      ]. In addition, patients receiving split-dose lavage were more likely to report willingness to repeat the same preparation (OR 1.8), were less likely to discontinue the preparation (OR 0.53), and reported less nausea (OR 0.55).",
"     </li>",
"     <li>",
"      A second meta-analysis with nine trials (four of which were included in the first meta-analysis) also found that satisfactory bowel preparations were more likely with a split-dose polyethylene glycol preparation compared with other preparations (OR 3.5) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, an observational study has suggested higher adenoma detection rates following system-wide implementation of split-dose lavage. Prior to implementation, 9 percent of patients received a split-dose lavage, whereas after implementation, 74 percent did. The adenoma detection rate increased from 27 percent prior to implementation to 32 percent after implementation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148491620\">",
"    <span class=\"h3\">",
"     Same-day preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients undergoing afternoon procedures, same-day preparations have also been studied and appear to be effective and better tolerated than full-dose or split-dose preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/17,35-37\">",
"     17,35-37",
"    </a>",
"    ]. As an example, in an endoscopist-blinded trial, 227 patients were assigned to receive sodium picosulfate either the morning of the colonoscopy (at 7 am and 10 am), or starting the day prior to the colonoscopy (at noon, 5 pm, and 8 am the morning of the colonoscopy) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/36\">",
"     36",
"    </a>",
"    ]. Patients who received the same-day preparation had better overall bowel cleansing compared with those who received split-dosing. In the same-day preparation group, bowel cleansing was graded as excellent, average, or poor in 47, 52, and 1.5 percent of patients, respectively. In the patients who received the split-dose preparation, the rates were 50, 40, and 11 percent, respectively. Adverse events such as sleep interruption, fecal incontinence, and vomiting occurred less often in the same-day preparation group.",
"   </p>",
"   <p>",
"    While same-day preparation may be an option for patients undergoing afternoon procedures, a large-volume purgative is impractical in patients undergoing early morning procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148493757\">",
"    <span class=\"h2\">",
"     Improving tolerability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients find the preparations for colonoscopy unpalatable and difficult to drink. Measures that may make preparations easier to consume include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Using split-dosing",
"     </li>",
"     <li>",
"      Chilling the solution",
"     </li>",
"     <li>",
"      Drinking the solution through a straw",
"     </li>",
"     <li>",
"      Using the flavor packets included with many polyethylene glycol (PEG) solutions, or if the PEG solution is unflavored, adding clear, sugar-free, powdered flavor enhancers (eg, Crystal Light) or lemon juice to it",
"     </li>",
"     <li>",
"      Sucking on lemon slices",
"     </li>",
"     <li>",
"      Giving",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       metoclopramide",
"      </a>",
"      5 to 10 mg orally prior to starting the preparation to prevent nausea",
"     </li>",
"     <li>",
"      Using lower-volume preparations when possible",
"     </li>",
"     <li>",
"      Discontinuing the preparation once the stool produced is clear (not just liquid), particularly if the colonoscopy is scheduled for the morning",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While sports drinks, sugar-free, powdered flavor enhancers, and carbohydrate-electrolyte solutions have been used to improve the palatability of PEG and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    solutions, improved flavor does not necessarily mean improved tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition, care must be taken to avoid altering the osmolarity of the preparation or adding substrates that can be metabolized into explosive gases or alter the amount of water and salts absorbed. Our practice is to recommend that patients either use the flavor packets that are provided with many of the preparations, or to use a sugar-free, powdered flavor enhancer.",
"   </p>",
"   <p>",
"    The above measures can also be used for patients who develop nausea, vomiting, or excessive bloating after starting the preparation. In addition, patients who are having difficulty with the preparation can be instructed to temporarily interrupt the regimen (for one to two hours) or slow the rate of consumption.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148493791\">",
"    <span class=\"h2\">",
"     Specific preparations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148494535\">",
"    <span class=\"h3\">",
"     Polyethylene glycol solutions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Balanced electrolyte solutions that contain polyethylene glycol (PEG) are isosmotic, minimizing fluid exchange across the colonic membrane (",
"    <a class=\"graphic graphic_table graphicRef71253 \" href=\"UTD.htm?35/42/36523\">",
"     table 5",
"    </a>",
"    ). PEG is a high-molecular weight, nonabsorbable polymer that exerts an osmotic effect on the electrolyte solution, keeping the solution within the colon. This then minimizes the potential for systemic electrolyte disturbances. Some of the commercially available PEG solutions come with flavoring to increase palatability [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/38\">",
"     38",
"    </a>",
"    ]. Likewise, sulfate-free solutions have been developed that are less salty and more palatable compared with the standard solutions [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/39\">",
"     39",
"    </a>",
"    ]. PEG solutions may also be combined with other laxatives in order to decrease the amount of PEG solution that needs to be consumed.",
"   </p>",
"   <p>",
"    Advantages of PEG-based preparations include the fact that they do not damage the colonic mucosa, they cause minimal osmotic fluid shifts into the intestine, and they are safer than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    -based preparations in patients with impaired renal function, congestive heart failure, decompensated cirrhosis, or baseline electrolyte abnormalities.",
"   </p>",
"   <p>",
"    The major disadvantages of PEG-based preparations are the large volume of fluid (4 L) that patients must drink and the unpalatable taste, which is only partially camouflaged by flavoring.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     Metoclopramide",
"    </a>",
"    may be helpful in selected patients by decreasing nausea or vomiting and promoting bowel motility. However, the routine addition of metoclopramide conferred no significant benefit in terms of bowel preparation or discomfort in a small randomized trial [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/40\">",
"     40",
"    </a>",
"    ]. Some patients may achieve adequate bowel preparation without consuming the entire 4 L of fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/41\">",
"     41",
"    </a>",
"    ]. We generally recommend that patients discontinue drinking the solution once their efflux becomes watery and clear, provided they are able to clearly understand the instructions.",
"   </p>",
"   <p>",
"    Full-volume PEG preparations include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      GoLYTELY",
"     </li>",
"     <li>",
"      Colyte",
"     </li>",
"     <li>",
"      NuLytely (sulfate-free)",
"     </li>",
"     <li>",
"      TriLyte (sulfate-free)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Full-volume PEG solutions are typically taken as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Starting at approximately 6 pm the evening prior to the colonoscopy, the patient takes 240 mL (8 oz) every 10 minutes. If split-dosing is being used, half of the solution is consumed the evening before the colonoscopy and the other half is consumed the morning of the colonoscopy, five hours prior to the examination. If split-dosing is not being used, the entire preparation is taken the evening prior to the examination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Low-volume PEG preparations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HalfLytely (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/27/2484?source=see_link\">",
"       polyethylene glycol electrolyte solution-bisacodyl",
"      </a>",
"      ): At noon the day before the colonoscopy the patient takes two 5 mg",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=see_link\">",
"       bisacodyl",
"      </a>",
"      delayed-release tablets. Starting at approximately 6 pm the evening prior to the colonoscopy, the patient takes 240 mL (8 oz) of the PEG solution every 10 minutes for a total of two liters. Currently, there is no split-dosing regimen for HalfLytely.",
"     </li>",
"     <li>",
"      MoviPrep (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"       polyethylene glycol electrolyte solution",
"      </a>",
"      -ascorbic acid): Starting at approximately 6 pm the evening prior to the colonoscopy, the patient consumes one liter of the",
"      <span class=\"nowrap\">",
"       PEG/ascorbic",
"      </span>",
"      acid solution over one hour (240 mL [8 oz] every 15 minutes x 4 doses). Approximately 1.5 hours later, the second liter is consumed over one hour. Patients should also take in an additional liter (32 oz) of clear liquids the evening before the colonoscopy. For split-dosing, the patient consumes the second liter of",
"      <span class=\"nowrap\">",
"       PEG/ascorbic",
"      </span>",
"      acid five hours prior to the colonoscopy. Patients receiving split-dosing should consume an addition half liter (16 oz) of clear liquids both the evening prior to and the morning of the procedure.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       MiraLax/GlycoLax",
"      </span>",
"      with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=see_link\">",
"       bisacodyl",
"      </a>",
"      : An alternative to balanced electrolyte solutions containing PEG is over-the-counter",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/19/23860?source=see_link\">",
"       polyethylene glycol 3350",
"      </a>",
"      <span class=\"nowrap\">",
"       (MirLax/GlycoLax)",
"      </span>",
"      combined with bisacodyl. PEG 3350 is mixed in 2 liters (64 oz) of a clear liquid (often a sports drink or sugar-free powdered drink), yielding a PEG solution that is not electrolyte balanced. Patients are instructed to take bisacodyl 10 mg (two 5 mg tablets) at noon. Once the patient has a bowel movement, or after a maximum of six hours, the patient takes 240 mL (8 oz) the PEG 3350 solution every 10 to 15 minutes until 2 liters (64 oz) are consumed.",
"      <br/>",
"      <br/>",
"      Some authorities have raised concerns with regard to this preparation due to its lack of a built-in electrolyte replacement solution [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/42\">",
"       42",
"      </a>",
"      ]. In addition, some data suggest it is not as effective as high-volume gut lavage [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/43\">",
"       43",
"      </a>",
"      ]. Finally, this preparation does not have approval from the U.S. Food and Drug Administration (FDA) for use as a bowel preparation prior to colonoscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148496844\">",
"    <span class=\"h4\">",
"     Efficacy of PEG-based preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have demonstrated that balanced electrolyte solutions containing PEG are associated with good cleansing efficacy and reasonable patient tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/44-49\">",
"     44-49",
"    </a>",
"    ]. A meta-analysis that included eight randomized trials comparing PEG solutions to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    -containing preparations found that PEG preparations were associated with an \"adequate\" preparation quality in 33 to 91 percent of patients (median 69 percent) and an \"excellent\" preparation quality in 6 to 49 percent of patients (median 36 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/50\">",
"     50",
"    </a>",
"    ]. However, approximately 19 percent of patients were unable to complete the preparation.",
"   </p>",
"   <p>",
"    <br/>",
"    A low-volume PEG preparation combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    (HalfLytely) was compared with a standard full-volume PEG preparation in 200 patients who were randomly assigned to a 2-liter PEG lavage with bisacodyl or a 4-liter PEG lavage [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/51\">",
"     51",
"    </a>",
"    ]. There were no significant differences in the quality of lavage. By contrast, there were significant differences in the preparation side-effects, with significantly less nausea, fullness, vomiting, and overall discomfort with the low-volume preparation.",
"    <br/>",
"   </p>",
"   <p>",
"    A second low-volume PEG preparation that contains ascorbic acid (MoviPrep) appears to be comparable to preparation with a 4-liter PEG lavage or a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    -based preparation, though there were no substantial improvements in tolerability [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Of note, preparations that contain ascorbic acid should be used cautiously in patients with glucose-6-phosphate dehydrogenase deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link&amp;anchor=H8#H8\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\", section on 'Lists of safe and unsafe drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148496955\">",
"    <span class=\"h4\">",
"     Safety of PEG-based preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Overall, PEG-based preparations are safe. They typically do not cause fluid and electrolyte shifts as are seen with hyperosmotic preparations. However, there have been reports of asymptomatic increases in plasma volume and exacerbations of heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. Other reported adverse events include pulmonary aspiration, Mallory-Weiss tear, esophageal perforation, pancreatitis, colitis, cardiac dysrhythmia, hyponatremia in patients with renal failure, and a syndrome of inappropriate antidiuretic hormone secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While rare,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    use has been associated with ischemic colitis [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/8,56\">",
"     8,56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148493872\">",
"    <span class=\"h3\">",
"     Hyperosmotic preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperosmotic preparations work by exerting an osmotic effect, drawing water into the intestine, which leads to bowel distention and stimulation of evacuation. Hyperosmotic laxatives containing magnesium cations or phosphate anions are commonly termed saline laxatives. Advantages of hyperosmotic preparations are that the volume of medication consumed is typically small (though additional fluids must be consumed as well) and patients often find them more palatable.",
"    <br/>",
"    <br/>",
"    In the past, non-absorbable carbohydrates, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/42/3752?source=see_link\">",
"     mannitol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/0/29699?source=see_link\">",
"     sorbitol",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33316?source=see_link\">",
"     lactulose",
"    </a>",
"    , were used. However, the routine use of non-absorbable carbohydrate preparations is now avoided due to the risk of explosion during electrosurgical procedures (such as some polypectomies) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/57\">",
"     57",
"    </a>",
"    ]. Explosion occurs because of the production of hydrogen gas by bacterial fermentation of the non-absorbed carbohydrates in the colon.",
"   </p>",
"   <p>",
"    Disadvantages of hyperosmotic preparations include the potential for causing fluid and electrolyte shifts by drawing water into the intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/10\">",
"     10",
"    </a>",
"    ]. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    -based preparations have been associated with renal damage. As a result, these preparations should only be used in patients with good renal function who do not have congestive heart failure, decompensated cirrhosis, or baseline electrolyte abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148495700\">",
"    <span class=\"h4\">",
"     Magnesium citrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no standardized method for giving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. Our protocol is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients are instructed to start a low residue diet five days prior to the examination (see",
"      <a class=\"local\" href=\"#H160742642\">",
"       'Diet'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      The day before the colonoscopy, patients start a clear liquid diet",
"     </li>",
"     <li>",
"      The first dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"       magnesium citrate",
"      </a>",
"      is 1.5 bottles (450 mL or 15 oz) and is taken at 7 pm, followed by at least three 240 mL (8 oz) glasses of clear liquids over two hours",
"     </li>",
"     <li>",
"      A second 1.5 bottle dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"       magnesium citrate",
"      </a>",
"      is taken five hours prior to the colonoscopy, followed by three 240 mL (8 oz) glasses of clear liquids over one hour",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     Magnesium citrate",
"    </a>",
"    is generally well-tolerated, and one study comparing magnesium citrate with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    suggested improved cleansing with magnesium citrate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/58\">",
"     58",
"    </a>",
"    ]. Magnesium citrate is renally excreted and should be avoided in patients with renal insufficiency. Hypermagnesemia (in some cases fatal) has been reported in patients with suspected or known renal insufficiency and in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. As with all hyperosmotic preparations, magnesium citrate should also be avoided in patients with heart failure, renal insufficiency, decompensated cirrhosis, or baseline electrolyte abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148495759\">",
"    <span class=\"h4\">",
"     Sodium phosphate preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     Sodium phosphate",
"    </a>",
"    preparations are as effective as PEG-based and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    -based preparations and are generally well tolerated in healthy adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/46-50,58,63-66\">",
"     46-50,58,63-66",
"    </a>",
"    ]. However, the use of sodium phospate preparations is limited because of the potential for renal damage, including acute phosphate nephropathy, even in patients with normal renal function. (See",
"    <a class=\"local\" href=\"#H352180686\">",
"     'Safety of sodium phosphate preparations'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The",
"    <a class=\"external\" href=\"file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103354.htm\">",
"     FDA",
"    </a>",
"    has required manufacturers of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    products to include a black box warning regarding potential complications as well as institute programs to reduce the risk [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/67\">",
"     67",
"    </a>",
"    ]. Furthermore, the FDA advises that consumers should only use oral phosphate preparations for bowel cleansing pursuant to a prescription of a healthcare provider and that over-the-counter oral sodium phosphate products not be used for bowel cleansing. Currently, only sodium phosphate tablets (Visicol, OsmoPrep) are available in the United States for colonoscopy preparation.",
"   </p>",
"   <p>",
"    Because of adverse events associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    preparations, patients with any of the following disorders should",
"    <strong>",
"     not",
"    </strong>",
"    receive sodium phosphate preparations (see",
"    <a class=\"local\" href=\"#H352180686\">",
"     'Safety of sodium phosphate preparations'",
"    </a>",
"    below):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with heart failure, renal insufficiency, end-stage liver disease, or pre-existing electrolyte abnormalities",
"     </li>",
"     <li>",
"      Patients at increased risk for electrolyte abnormalities, including patients on diuretics that may affect electrolyte levels or cause dehydration and older adults (&gt;65 years of age) [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/9\">",
"       9",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients taking angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, nonsteroidal antiinflammatory drugs, or other drugs that affect renal perfusion or function, since these patients may be at increased risk of acute phosphate nephropathy [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/68,69\">",
"       68,69",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients with suspected inflammatory bowel disease or diarrhea of unknown etiology, as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      may cause mucosal damage, leading to diagnostic confusion [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/70\">",
"       70",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59493388\">",
"    <span class=\"h5\">",
"     Formulations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       Sodium phosphate",
"      </a>",
"      <strong>",
"       tablets",
"      </strong>",
"      &mdash; Sodium phosphate tablets (Visicol, OsmoPrep) can be used for colonoscopy preparation in patients with normal renal function, though these laxatives have received a black box warning from the FDA due to their potential to cause renal damage. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13527?source=see_link&amp;anchor=H7#H7\">",
"       \"Overview of the causes and treatment of hyperphosphatemia\", section on 'Acute phosphate nephropathy'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Visicol tablets are taken in a split-dose. The usual adult dose consists of 40 tablets. On the day before the colonoscopy, three tablets are ingested with 240 mL (8 oz) of clear liquids every 15 minutes for a total of 20 tablets (the final dose consists of two tablets). On the day of the procedure, this is repeated three to five hours before the colonoscopy. A simpler regimen of 20 tablets the evening prior to colonoscopy (four tablets every 15 minutes with 240 mL [8 oz] of clear liquid) and 8 to 12 tablets three to five hours before colonoscopy appears to be equally effective [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/71\">",
"       71",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      A problem with Visicol tablets is that they contain microcrystalline cellulose (an insoluble binder) that can deposit in the right colon and require additional irrigation. A newer, residue-free formulation of sodium phosphate tablets (OsmoPrep) appears to have overcome this limitation [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/72\">",
"       72",
"      </a>",
"      ]. On the day before colonoscopy, four OsmoPrep tablets are ingested with 240 mL (8 oz) of clear liquids every 15 minutes for a total of 20 tablets. On the day of the procedure, three to five hours before the colonoscopy, four tablets are given with 240 mL (8 oz) of clear liquids every 15 minutes for a total of 12 tablets.",
"     </li>",
"     <li>",
"      <strong>",
"       Aqueous",
"      </strong>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      &mdash; Over-the-counter aqueous sodium phosphate (Fleet Phospho-Soda) was one of the most commonly used saline laxatives for colonoscopy preparation. However, aqueous sodium phosphate is no longer available because of the risk of renal toxicity and renal failure. (See",
"      <a class=\"local\" href=\"#H352180686\">",
"       'Safety of sodium phosphate preparations'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H352180686\">",
"    <span class=\"h5\">",
"     Safety of sodium phosphate preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;While",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    preparations are safe in most healthy individuals, a growing number of reports have demonstrated their potential to cause serious electrolyte and renal complications.",
"   </p>",
"   <p>",
"    Adverse effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    preparations include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute phosphate nephropathy: Acute phosphate nephropathy is more likely to occur in patients with underlying renal insufficiency, but it has been described in patients with normal renal function. It can result in chronic and end-stage renal disease [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/73\">",
"       73",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=see_link\">",
"       \"Acute phosphate nephropathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Fluid shifts: Fluid shifts may precipitate intravascular volume depletion.",
"     </li>",
"     <li>",
"      Hyperphosphatemia: Although serum phosphate concentrations increase in patients taking",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      preparations, the rise is clinically insignificant in most patients who adhere to the recommended regimen [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/46-48,63,74,75\">",
"       46-48,63,74,75",
"      </a>",
"      ]. Exceptions are patients with renal insufficiency (a glomerular filtration rate of &lt;50 percent of normal) who can develop severe hyperphosphatemia [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/38\">",
"       38",
"      </a>",
"      ]. A review of the literature found that all of the patients in whom severe hyperphosphatemia developed following use of a phosphate-containing laxative had some degree of renal insufficiency at the time of laxative administration [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/76\">",
"       76",
"      </a>",
"      ]. Impaired bowel motility may also be a risk factor [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/77\">",
"       77",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13527?source=see_link&amp;anchor=H6#H6\">",
"       \"Overview of the causes and treatment of hyperphosphatemia\", section on 'Exogenous phosphate'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Electrolyte abnormalities: Electrolyte abnormalities, including a fall in the serum calcium and potassium and a rise in the serum sodium, have been seen, are typically clinically insignificant, and reverse within hours [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/47,48,63,74,75\">",
"       47,48,63,74,75",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Tonic-clonic seizures: Seizures have been reported in patients who had no history of a seizure disorder or pre-existing electrolyte abnormalities who received Visicol tablets. A report of four such patients demonstrated that all had developed marked electrolyte abnormalities [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/78\">",
"       78",
"      </a>",
"      ]. Three of the four patients had followed the label instructions.",
"     </li>",
"     <li>",
"      Mucosal damage: Sodium-phosphate can cause colonic mucosal abnormalities that mimic other conditions, such as injury from nonsteroidal antiinflammatory drugs, drug-induced injury, or inflammatory bowel disease. In a prospective study of 730 patients receiving a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      preparation, mucosal lesions were seen in 24 (3.3 percent) including erosions, aphthoid lesions, and ulcers [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/16\">",
"       16",
"      </a>",
"      ]. Histologic findings included focal active inflammation, mucosal disruption and erosions, edema of the lamina propria, mucosal hyperemia, focal hemorrhage, lymphoid nodules, and ulceration. Whether these findings were due to the sodium phosphate is unclear since the study did not include a control group. Nevertheless, similar findings have been described by others [",
"      <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/70,79\">",
"       70,79",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148495840\">",
"    <span class=\"h4\">",
"     Sodium sulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    -based preparations are preparations containing sodium sulfate (SuPrep [sodium, potassium, and magnesium sulfates bowel preparation kit], Suclear [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"     polyethylene glycol electrolyte solution",
"    </a>",
"    and sulfate solution kit]). Sulfate is a poorly absorbed anion and when tested in patients who did not have heart failure, renal insufficiency, end-stage liver disease, or electrolyte abnormalities it did not produce significant fluid and electrolyte shifts [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. Since it has not been tested in patients at risk for fluid shifts and electrolyte abnormalities, our practice is to avoid sodium sulfate-based preparations in such patients.",
"   </p>",
"   <p>",
"    Sodium sulfate is given in one of two ways. SuPrep is given as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The evening prior to the colonoscopy, the patient consumes one 180 mL (6 oz) bottle of sodium sulfate that has been diluted with 300 mL (10 oz) of water",
"     </li>",
"     <li>",
"      The patient should drink an additional liter (32 oz) of fluid over the following hour",
"     </li>",
"     <li>",
"      A second dose is taken the same way the morning of the colonoscopy (we suggest doing so five hours prior to the examination)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Suclear is also taken in two doses, but the composition of the two doses is different. The first dose is a sodium sulfate, potassium sulfate, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27031?source=see_link\">",
"     magnesium sulfate",
"    </a>",
"    solution, whereas the second dose is a PEG-3350, sodium chloride,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/52/840?source=see_link\">",
"     sodium bicarbonate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    solution. It is recommended that it be taken as a split dose. For split dosing:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The evening prior to the colonoscopy, the patient consumes one 180 mL (6 oz) bottle of sodium sulfate solution that has been diluted with 300 mL (10 oz) of water. The patient should try to consume the entire dose within 20 minutes.",
"     </li>",
"     <li>",
"      The patient should drink an additional 480 mL (16 oz) of water over the following two hours and another 480 mL (16 oz) prior to going to bed.",
"     </li>",
"     <li>",
"      The following morning, at least 3.5 hours prior to the examination, the patient mixes the second PEG-3350-based dose in 2 liters (64 oz) of water. A flavor pack may be added to the solution to improve palatability. The patient then drinks 16 oz of fluid every 20 minutes (1 hour 20 minutes total). Consumption of the solution must be completed by two hours prior to the colonoscopy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the entire Suclear preparation is given the evening prior to the colonoscopy, the first dose should be consumed at least 3.5 hours prior to going to bed, followed by an additional 480 mL (16 oz) of water over two hours. Approximately two hours after starting the first dose, the second dose is consumed, followed by an additional 480 mL (16 oz) of water. With this regimen, the patient consumes approximately 3.5 liters (3.5 quarts) of fluid over as little as 3.5 hours.",
"   </p>",
"   <p>",
"    Randomized trials have shown that sodium sulfate preparations are at least as effective as PEG preparations [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. A noninferiority trial comparing a sodium sulfate-based preparation with a preparation containing PEG with ascorbic acid showed that the sodium sulfate regimen was not inferior to the PEG-containing regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/81\">",
"     81",
"    </a>",
"    ]. For those receiving the sodium sulfate preparation, successful preparations were seen in 82 percent of those who took the entire preparation the evening prior to the colonoscopy and in 97 percent who received a split-dose preparation. For those receiving the PEG preparation, the rates were 80 and 96 percent, respectively. The study also showed that there were no clinically significant differences in the preparations with regard to patient tolerance or changes in laboratory parameters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148495847\">",
"    <span class=\"h4\">",
"     Sodium picosulfate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preparations containing sodium picosulfate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    (CitraFleet, Picolax, Picoprep-3) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/0/44037?source=see_link\">",
"     sodium picosulfate-magnesium oxide-citric acid",
"    </a>",
"    (Prepopik, Pico-Salix) are also available. Sodium picosulfate acts as a stimulant laxative, whereas magnesium citrate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/32/28165?source=see_link\">",
"     magnesium oxide",
"    </a>",
"    , and citric acid act as osmotic laxatives. As with other hyperosmotic preparations, sodium picosulfate-based preparations should not be used in patients with heart failure, renal insufficiency, end-stage liver disease, or electrolyte abnormalities.",
"   </p>",
"   <p>",
"    The formulation available in the United States (Prepopik) is given as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The first packet of the preparation is mixed with 150 mL (5 oz) of water and consumed between 5 pm and 9 pm, followed by five 240 mL (8 oz) drinks of a clear liquid consumed within five hours",
"     </li>",
"     <li>",
"      The next day, the second dose is taken five hours prior to colonoscopy, followed by at least three 240 mL (8 oz) drinks of a clear liquid",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Alternatively, both doses may be given the day prior to the colonoscopy (the first between 4 pm and 6 pm, with the second dose being given approximately six hours later). However, the split-dose method is preferred because it has been shown to result in superior colon cleansing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several randomized trials comparing sodium picosulfate-based preparations with an aqueous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    preparation found that the sodium picosulfate-based preparations were better tolerated and produced a similar degree of cleansing [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/84-86\">",
"     84-86",
"    </a>",
"    ]. However, one trial found that colon cleansing was better with oral sodium phosphate [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/87\">",
"     87",
"    </a>",
"    ]. In addition, a trial that compared a sodium picosulfate-based preparation with a PEG-3350 preparation found the two preparations were similar with regard to bowel cleansing, but the sodium picosulfate-based preparation was better tolerated by patients [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With regard to safety, studies in normal volunteers have noted transient, minor changes in serum sodium, potassium, and calcium. In general, the preparations have been well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H330966170\">",
"    <span class=\"h3\">",
"     Stimulant laxatives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before the early 1980s, stimulant laxatives, such as castor oil,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/21/40276?source=see_link\">",
"     senna",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=see_link\">",
"     bisacodyl",
"    </a>",
"    were the most commonly used form of bowel preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. These laxatives increase peristalsis and promote fluid secretion into the intestinal lumen. These regimens were harsh and not very effective and have been abandoned by most endoscopists as primary preparations. However, stimulant laxatives have been combined with PEG solutions and hyperosmotic solutions to decrease the volume of fluid that needs to be consumed. (See",
"    <a class=\"local\" href=\"#H148494535\">",
"     'Polyethylene glycol solutions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H148493872\">",
"     'Hyperosmotic preparations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H148488437\">",
"    <span class=\"h1\">",
"     FLEXIBLE SIGMOIDOSCOPY PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preparation for flexible sigmoidoscopy typically involves two",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    enemas given the morning of the examination [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/91\">",
"     91",
"    </a>",
"    ]. Oral preparations have also been used with equal or superior efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. While it is generally believed that enema preparations are more tolerable to patients, at least two studies suggested that an oral preparation was more tolerable than preparation with an enema [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. An oral preparation should be used for patients undergoing flexible sigmoidoscopy with argon plasma coagulation. In such patients, there is a small risk of a gas explosion if the entire colon is not cleansed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8410?source=see_link&amp;anchor=H27#H27\">",
"     \"Angiodysplasia of the gastrointestinal tract\", section on 'Argon plasma coagulation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"     sodium phosphate",
"    </a>",
"    enemas have been associated with complications, particularly in older adults [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. In one retrospective series (mean age 80 years, range 61 to 89 years), complications included hypotension and volume depletion, hyperphosphatemia, hypo- or hyperkalemia, metabolic acidosis, severe hypocalcemia, renal failure, and EKG changes (prolonged QT interval) [",
"    <a class=\"abstract\" href=\"UTD.htm?26/39/27258/abstract/22\">",
"     22",
"    </a>",
"    ]. As a result, in patients over the age of 65 years, the risks of oral preparations (eg, polyethylene glycol lavage or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"     magnesium citrate",
"    </a>",
"    ) and sodium phosphate enemas need to be weighed for each individual patient before deciding upon an appropriate preparation. As examples, oral polyethylene glycol may be preferred in a patient with renal insufficiency, whereas enemas may be preferred in a patient at risk for aspiration. (See",
"    <a class=\"local\" href=\"#H148494535\">",
"     'Polyethylene glycol solutions'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H148495700\">",
"     'Magnesium citrate'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=see_link\">",
"       \"Patient information: Colonoscopy (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=see_link\">",
"       \"Patient information: Colonoscopy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All of the available colonoscopy preparations can produce adequate cleansing results with acceptable tolerance. Colonoscopy preparations that use hyperosmotic laxatives, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"       magnesium citrate",
"      </a>",
"      , appear to be better tolerated than the polyethylene glycol (PEG)-containing regimens. However, the hyperosmotic laxative regimens may lead to volume and electrolyte shifts and should be avoided in patients with heart failure, renal insufficiency, decompensated cirrhosis, or pre-existing electrolyte imbalances (including patients on diuretics that may affect electrolyte levels or cause dehydration). (See",
"      <a class=\"local\" href=\"#H148488585\">",
"       'Choosing a preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that colonoscopy preparations be administered in a split-dose rather than being given entirely the evening prior to the colonoscopy (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Spit-dose lavage produces improved colon cleansing and patient tolerance compared with giving the entire preparation the evening prior to the colonoscopy. (See",
"      <a class=\"local\" href=\"#H148491583\">",
"       'Split-dose lavage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most patients without significant comorbid illnesses, we suggest using a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"       magnesium citrate",
"      </a>",
"      preparation rather than a preparation using a balanced electrolyte solution with PEG (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). PEG-based preparations are a reasonable alternative in patients who have not tolerated or have had a poor preparation with magnesium citrate in the past, who are being evaluated for possible inflammatory bowel disease, or who have unexplained chronic diarrhea. (See",
"      <a class=\"local\" href=\"#H149537222\">",
"       'Patients without significant comorbid illnesses'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H330965790\">",
"       'Indication for colonoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with a history of heart failure, renal insufficiency, end-stage liver disease, or electrolyte abnormalities, we suggest using a preparation containing a balanced electrolyte solution with PEG rather than a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"       magnesium citrate",
"      </a>",
"      preparation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest",
"      <strong>",
"       not",
"      </strong>",
"      using preparations that use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6213?source=see_link\">",
"       bisacodyl",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Bisacodyl has been associated with a small risk of ischemic colitis. (See",
"      <a class=\"local\" href=\"#H149537236\">",
"       'Patients with heart failure, renal insufficiency, end-stage liver disease, or electrolyte imbalances'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For older adults (&gt;65 years of age), we suggest using a preparation containing a balanced electrolyte solution with PEG rather than a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/14/39140?source=see_link\">",
"       magnesium citrate",
"      </a>",
"      preparation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Older adults may be at increased risk for fluid and electrolyte shifts induced by hyperosmotic preparations. (See",
"      <a class=\"local\" href=\"#H149537229\">",
"       'Older adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      using oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      bowel preparations (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). While rare, these preparations have been associated with serious adverse events, including acute phosphate nephropathy and carry a black box warning. (See",
"      <a class=\"local\" href=\"#H352180686\">",
"       'Safety of sodium phosphate preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For flexible sigmoidoscopy preparation, we suggest that most patients under the age of 65 years receive two phosphate enemas rather than an oral preparation (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, patients undergoing argon plasma coagulation should receive a full oral preparation to minimize the risk of gas explosion. (See",
"      <a class=\"local\" href=\"#H148488437\">",
"       'Flexible sigmoidoscopy preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients undergoing flexible sigmoidoscopy who are &ge;65 years old receive an oral preparation with an electrolyte balanced solution containing PEG rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/22/5480?source=see_link\">",
"       sodium phosphate",
"      </a>",
"      enemas, provided they are not at risk for aspiration (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Significant complications have been associated with sodium phosphate enema use in older adults. In patients who are at risk for aspiration, the aspiration risk must be weighed against the risk of receiving a sodium phosphate enema. (See",
"      <a class=\"local\" href=\"#H148488437\">",
"       'Flexible sigmoidoscopy preparation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/1\">",
"      Froehlich F, Wietlisbach V, Gonvers JJ, et al. Impact of colonic cleansing on quality and diagnostic yield of colonoscopy: the European Panel of Appropriateness of Gastrointestinal Endoscopy European multicenter study. Gastrointest Endosc 2005; 61:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/2\">",
"      ASGE Standards of Practice Committee, Anderson MA, Ben-Menachem T, et al. Management of antithrombotic agents for endoscopic procedures. Gastrointest Endosc 2009; 70:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/3\">",
"      Park DI, Park SH, Lee SK, et al. Efficacy of prepackaged, low residual test meals with 4L polyethylene glycol versus a clear liquid diet with 4L polyethylene glycol bowel preparation: a randomized trial. J Gastroenterol Hepatol 2009; 24:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/4\">",
"      Sipe BW, Fischer M, Baluyut AR, et al. Effect of low residual diet on colonoscopy bowel preparation. Gastrointest Endosc 2012; 75:AB163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/5\">",
"      Faigel DO, Eisen GM, Baron TH, et al. Preparation of patients for GI endoscopy. Gastrointest Endosc 2003; 57:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/6\">",
"      Committee on Obstetric Practice, American College of Obstetricians and Gynecologists. ACOG Committee Opinion No. 441: Oral intake during labor. Obstet Gynecol 2009; 114:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/7\">",
"      Godwin SA, Caro DA, Wolf SJ, et al. Clinical policy: procedural sedation and analgesia in the emergency department. Ann Emerg Med 2005; 45:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/8\">",
"      Baudet JS, Castro V, Redondo I. Recurrent ischemic colitis induced by colonoscopy bowel lavage. Am J Gastroenterol 2010; 105:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/9\">",
"      Beloosesky Y, Grinblat J, Weiss A, et al. Electrolyte disorders following oral sodium phosphate administration for bowel cleansing in elderly patients. Arch Intern Med 2003; 163:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/10\">",
"      Wexner SD, Beck DE, Baron TH, et al. A consensus document on bowel preparation before colonoscopy: prepared by a task force from the American Society of Colon and Rectal Surgeons (ASCRS), the American Society for Gastrointestinal Endoscopy (ASGE), and the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES). Gastrointest Endosc 2006; 63:894.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/11\">",
"      Mahadevan U, Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology 2006; 131:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/12\">",
"      Ell C, Fischbach W, Keller R, et al. A randomized, blinded, prospective trial to compare the safety and efficacy of three bowel-cleansing solutions for colonoscopy (HSG-01*). Endoscopy 2003; 35:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/13\">",
"      Atreja A, Nepal S, Lashner BA. Making the most of currently available bowel preparations for colonoscopy. Cleve Clin J Med 2010; 77:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/14\">",
"      Jensen DM, Machicado GA. Diagnosis and treatment of severe hematochezia. The role of urgent colonoscopy after purge. Gastroenterology 1988; 95:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/15\">",
"      Machicado GA, Jensen DM. Acute and chronic management of lower gastrointestinal bleeding: cost-effective approaches. Gastroenterologist 1997; 5:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/16\">",
"      Rejchrt S, Bures J, Sirok&yacute; M, et al. A prospective, observational study of colonic mucosal abnormalities associated with orally administered sodium phosphate for colon cleansing before colonoscopy. Gastrointest Endosc 2004; 59:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/17\">",
"      Church JM. Effectiveness of polyethylene glycol antegrade gut lavage bowel preparation for colonoscopy--timing is the key! Dis Colon Rectum 1998; 41:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/18\">",
"      Ness RM, Manam R, Hoen H, Chalasani N. Predictors of inadequate bowel preparation for colonoscopy. Am J Gastroenterol 2001; 96:1797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/19\">",
"      Taylor C, Schubert ML. Decreased efficacy of polyethylene glycol lavage solution (golytely) in the preparation of diabetic patients for outpatient colonoscopy: a prospective and blinded study. Am J Gastroenterol 2001; 96:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/20\">",
"      Borg BB, Gupta NK, Zuckerman GR, et al. Impact of obesity on bowel preparation for colonoscopy. Clin Gastroenterol Hepatol 2009; 7:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/21\">",
"      Mendoza J, Legido J, Rubio S, Gisbert JP. Systematic review: the adverse effects of sodium phosphate enema. Aliment Pharmacol Ther 2007; 26:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/22\">",
"      Ori Y, Rozen-Zvi B, Chagnac A, et al. Fatalities and severe metabolic disorders associated with the use of sodium phosphate enemas: a single center's experience. Arch Intern Med 2012; 172:263.",
"     </a>",
"    </li>",
"    <li>",
"     file://secure.medicalletter.org/TML-article-1408b (Accessed on January 18, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/24\">",
"      ASGE Technology Committee, Mamula P, Adler DG, et al. Colonoscopy preparation. Gastrointest Endosc 2009; 69:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/25\">",
"      El Sayed AM, Kanafani ZA, Mourad FH, et al. A randomized single-blind trial of whole versus split-dose polyethylene glycol-electrolyte solution for colonoscopy preparation. Gastrointest Endosc 2003; 58:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/26\">",
"      Aoun E, Abdul-Baki H, Azar C, et al. A randomized single-blind trial of split-dose PEG-electrolyte solution without dietary restriction compared with whole dose PEG-electrolyte solution with dietary restriction for colonoscopy preparation. Gastrointest Endosc 2005; 62:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/27\">",
"      Park SS, Sinn DH, Kim YH, et al. Efficacy and tolerability of split-dose magnesium citrate: low-volume (2 liters) polyethylene glycol vs. single- or split-dose polyethylene glycol bowel preparation for morning colonoscopy. Am J Gastroenterol 2010; 105:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/28\">",
"      Marmo R, Rotondano G, Riccio G, et al. Effective bowel cleansing before colonoscopy: a randomized study of split-dosage versus non-split dosage regimens of high-volume versus low-volume polyethylene glycol solutions. Gastrointest Endosc 2010; 72:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/29\">",
"      Matro R, Shnitser A, Spodik M, et al. Efficacy of morning-only compared with split-dose polyethylene glycol electrolyte solution for afternoon colonoscopy: a randomized controlled single-blind study. Am J Gastroenterol 2010; 105:1954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/30\">",
"      Abdul-Baki H, Hashash JG, Elhajj II, et al. A randomized, controlled, double-blind trial of the adjunct use of tegaserod in whole-dose or split-dose polyethylene glycol electrolyte solution for colonoscopy preparation. Gastrointest Endosc 2008; 68:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/31\">",
"      Park JS, Sohn CI, Hwang SJ, et al. Quality and effect of single dose versus split dose of polyethylene glycol bowel preparation for early-morning colonoscopy. Endoscopy 2007; 39:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/32\">",
"      Kilgore TW, Abdinoor AA, Szary NM, et al. Bowel preparation with split-dose polyethylene glycol before colonoscopy: a meta-analysis of randomized controlled trials. Gastrointest Endosc 2011; 73:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/33\">",
"      Gurudu SR, Ramirez FC, Harrison ME, et al. Increased adenoma detection rate with system-wide implementation of a split-dose preparation for colonoscopy. Gastrointest Endosc 2012; 76:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/34\">",
"      Enestvedt BK, Tofani C, Laine LA, et al. 4-Liter split-dose polyethylene glycol is superior to other bowel preparations, based on systematic review and meta-analysis. Clin Gastroenterol Hepatol 2012; 10:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/35\">",
"      Varughese S, Kumar AR, George A, Castro FJ. Morning-only one-gallon polyethylene glycol improves bowel cleansing for afternoon colonoscopies: a randomized endoscopist-blinded prospective study. Am J Gastroenterol 2010; 105:2368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/36\">",
"      Longcroft-Wheaton G, Bhandari P. Same-day bowel cleansing regimen is superior to a split-dose regimen over 2 days for afternoon colonoscopy: results from a large prospective series. J Clin Gastroenterol 2012; 46:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/37\">",
"      Parra-Blanco A, Nicolas-Perez D, Gimeno-Garcia A, et al. The timing of bowel preparation before colonoscopy determines the quality of cleansing, and is a significant factor contributing to the detection of flat lesions: a randomized study. World J Gastroenterol 2006; 12:6161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/38\">",
"      Diab FH, Marshall JB. The palatability of five colonic lavage solutions. Aliment Pharmacol Ther 1996; 10:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/39\">",
"      DiPalma JA, Marshall JB. Comparison of a new sulfate-free polyethylene glycol electrolyte lavage solution versus a standard solution for colonoscopy cleansing. Gastrointest Endosc 1990; 36:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/40\">",
"      Brady CE 3rd, DiPalma JA, Pierson WP. Golytely lavage--is metoclopramide necessary? Am J Gastroenterol 1985; 80:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/41\">",
"      Vilien M, Rytk&oslash;nen M. Golytely preparation for colonoscopy: 1.5 liters is enough for outpatients. Endoscopy 1990; 22:168.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.ncbi.nlm.nih.gov/pmc/articles/PMC2886377/pdf/GH-05-S19-3.pdf (Accessed on November 10, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/43\">",
"      Hjelkrem M, Stengel J, Liu M, et al. MiraLAX is not as effective as GoLytely in bowel cleansing before screening colonoscopies. Clin Gastroenterol Hepatol 2011; 9:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/44\">",
"      DiPalma JA, Brady CE 3rd, Stewart DL, et al. Comparison of colon cleansing methods in preparation for colonoscopy. Gastroenterology 1984; 86:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/45\">",
"      Froehlich F, Fried M, Schnegg JF, Gonvers JJ. Palatability of a new solution compared with standard polyethylene glycol solution for gastrointestinal lavage. Gastrointest Endosc 1991; 37:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/46\">",
"      Vanner SJ, MacDonald PH, Paterson WG, et al. A randomized prospective trial comparing oral sodium phosphate with standard polyethylene glycol-based lavage solution (Golytely) in the preparation of patients for colonoscopy. Am J Gastroenterol 1990; 85:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/47\">",
"      Kolts BE, Lyles WE, Achem SR, et al. A comparison of the effectiveness and patient tolerance of oral sodium phosphate, castor oil, and standard electrolyte lavage for colonoscopy or sigmoidoscopy preparation. Am J Gastroenterol 1993; 88:1218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/48\">",
"      Cohen SM, Wexner SD, Binderow SR, et al. Prospective, randomized, endoscopic-blinded trial comparing precolonoscopy bowel cleansing methods. Dis Colon Rectum 1994; 37:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/49\">",
"      Frommer D. Cleansing ability and tolerance of three bowel preparations for colonoscopy. Dis Colon Rectum 1997; 40:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/50\">",
"      Hsu CW, Imperiale TF. Meta-analysis and cost comparison of polyethylene glycol lavage versus sodium phosphate for colonoscopy preparation. Gastrointest Endosc 1998; 48:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/51\">",
"      DiPalma JA, Wolff BG, Meagher A, Cleveland Mv. Comparison of reduced volume versus four liters sulfate-free electrolyte lavage solutions for colonoscopy colon cleansing. Am J Gastroenterol 2003; 98:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/52\">",
"      Ell C, Fischbach W, Bronisch HJ, et al. Randomized trial of low-volume PEG solution versus standard PEG + electrolytes for bowel cleansing before colonoscopy. Am J Gastroenterol 2008; 103:883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/53\">",
"      Bitoun A, Ponchon T, Barthet M, et al. Results of a prospective randomised multicentre controlled trial comparing a new 2-L ascorbic acid plus polyethylene glycol and electrolyte solution vs. sodium phosphate solution in patients undergoing elective colonoscopy. Aliment Pharmacol Ther 2006; 24:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/54\">",
"      Granberry MC, White LM, Gardner SF. Exacerbation of congestive heart failure after administration of polyethylene glycol-electrolyte lavage solution. Ann Pharmacother 1995; 29:1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/55\">",
"      Turnage RH, Guice KS, Gannon P, Gross M. The effect of polyethylene glycol gavage on plasma volume. J Surg Res 1994; 57:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/56\">",
"      Lopez Morra HA, Fine SN, Dickstein G. Colonic ischemia with laxative use in young adults. Am J Gastroenterol 2005; 100:2134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/57\">",
"      Bigard MA, Gaucher P, Lassalle C. Fatal colonic explosion during colonoscopic polypectomy. Gastroenterology 1979; 77:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/58\">",
"      Berkelhammer C, Ekambaram A, Silva RG, Silva RG. Low-volume oral colonoscopy bowel preparation: sodium phosphate and magnesium citrate. Gastrointest Endosc 2002; 56:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/59\">",
"      Chen CC, Ng WW, Chang FY, Lee SD. Magnesium citrate-bisacodyl regimen proves better than castor oil for colonoscopic preparation. J Gastroenterol Hepatol 1999; 14:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/60\">",
"      Kontani M, Hara A, Ohta S, Ikeda T. Hypermagnesemia induced by massive cathartic ingestion in an elderly woman without pre-existing renal dysfunction. Intern Med 2005; 44:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/61\">",
"      Schelling JR. Fatal hypermagnesemia. Clin Nephrol 2000; 53:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/62\">",
"      Golzarian J, Scott HW Jr, Richards WO. Hypermagnesemia-induced paralytic ileus. Dig Dis Sci 1994; 39:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/63\">",
"      Henderson JM, Barnett JL, Turgeon DK, et al. Single-day, divided-dose oral sodium phosphate laxative versus intestinal lavage as preparation for colonoscopy: efficacy and patient tolerance. Gastrointest Endosc 1995; 42:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/64\">",
"      Golub RW, Kerner BA, Wise WE Jr, et al. Colonoscopic bowel preparations--which one? A blinded, prospective, randomized trial. Dis Colon Rectum 1995; 38:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/65\">",
"      Aronchick CA, Lipshutz WH, Wright SH, et al. A novel tableted purgative for colonoscopic preparation: efficacy and safety comparisons with Colyte and Fleet Phospho-Soda. Gastrointest Endosc 2000; 52:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/66\">",
"      Kastenberg D, Chasen R, Choudhary C, et al. Efficacy and safety of sodium phosphate tablets compared with PEG solution in colon cleansing: two identically designed, randomized, controlled, parallel group, multicenter phase III trials. Gastrointest Endosc 2001; 54:705.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103354.htm (Accessed on January 23, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/68\">",
"      Desmeules S, Bergeron MJ, Isenring P. Acute phosphate nephropathy and renal failure. N Engl J Med 2003; 349:1006.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm103354.htm (Accessed on May 31, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/70\">",
"      Zwas FR, Cirillo NW, el-Serag HB, Eisen RN. Colonic mucosal abnormalities associated with oral sodium phosphate solution. Gastrointest Endosc 1996; 43:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/71\">",
"      Rex DK, Chasen RM, Pochapin MB. Lower doses of Visicol are safe and effective for colon cleansing (abstract). Am J Gastroenterol 2001; 96(Suppl):S163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/72\">",
"      Wruble L, Demicco M, Medoff J, et al. Residue-free sodium phosphate tablets (OsmoPrep) versus Visicol for colon cleansing: a randomized, investigator-blinded trial. Gastrointest Endosc 2007; 65:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/73\">",
"      Heher EC, Thier SO, Rennke H, Humphreys BD. Adverse renal and metabolic effects associated with oral sodium phosphate bowel preparation. Clin J Am Soc Nephrol 2008; 3:1494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/74\">",
"      Lieberman DA, Ghormley J, Flora K. Effect of oral sodium phosphate colon preparation on serum electrolytes in patients with normal serum creatinine. Gastrointest Endosc 1996; 43:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/75\">",
"      Huynh T, Vanner S, Paterson W. Safety profile of 5-h oral sodium phosphate regimen for colonoscopy cleansing: lack of clinically significant hypocalcemia or hypovolemia. Am J Gastroenterol 1995; 90:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/76\">",
"      Fine A, Patterson J. Severe hyperphosphatemia following phosphate administration for bowel preparation in patients with renal failure: two cases and a review of the literature. Am J Kidney Dis 1997; 29:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/77\">",
"      Fass R, Do S, Hixson LJ. Fatal hyperphosphatemia following Fleet Phospo-Soda in a patient with colonic ileus. Am J Gastroenterol 1993; 88:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/78\">",
"      Mackey AC, Shaffer D, Prizont R, Prizant R. Seizure associated with the use of visicol for colonoscopy. N Engl J Med 2002; 346:2095; author reply 2095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/79\">",
"      Pockros PJ, Foroozan P. Golytely lavage versus a standard colonoscopy preparation. Effect on normal colonic mucosal histology. Gastroenterology 1985; 88:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/80\">",
"      Patel V, Nicar M, Emmett M, et al. Intestinal and renal effects of low-volume phosphate and sulfate cathartic solutions designed for cleansing the colon: pathophysiological studies in five normal subjects. Am J Gastroenterol 2009; 104:953.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/81\">",
"      Di Palma JA, Rodriguez R, McGowan J, Cleveland Mv. A randomized clinical study evaluating the safety and efficacy of a new, reduced-volume, oral sulfate colon-cleansing preparation for colonoscopy. Am J Gastroenterol 2009; 104:2275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/82\">",
"      Rex DK, Di Palma JA, Rodriguez R, et al. A randomized clinical study comparing reduced-volume oral sulfate solution with standard 4-liter sulfate-free electrolyte lavage solution as preparation for colonoscopy. Gastrointest Endosc 2010; 72:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/83\">",
"      Flemming JA, Vanner SJ, Hookey LC. Split-dose picosulfate, magnesium oxide, and citric acid solution markedly enhances colon cleansing before colonoscopy: a randomized, controlled trial. Gastrointest Endosc 2012; 75:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/84\">",
"      Schmidt LM, Williams P, King D, Perera D. Picoprep-3 is a superior colonoscopy preparation to Fleet: a randomized, controlled trial comparing the two bowel preparations. Dis Colon Rectum 2004; 47:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/85\">",
"      Renaut AJ, Raniga S, Frizelle FA, et al. A randomized controlled trial comparing the efficacy and acceptability of phospo-soda buffered saline (Fleet) with sodium picosulphate/magnesium citrate (Picoprep) in the preparation of patients for colonoscopy. Colorectal Dis 2008; 10:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/86\">",
"      Hookey LC, Vanner SJ. Pico-salax plus two-day bisacodyl is superior to pico-salax alone or oral sodium phosphate for colon cleansing before colonoscopy. Am J Gastroenterol 2009; 104:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/87\">",
"      Tjandra JJ, Chan M, Tagkalidis PP. Oral sodium phosphate (Fleet) is a superior colonoscopy preparation to Picopre (sodium picosulfate-based preparation). Dis Colon Rectum 2006; 49:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/88\">",
"      Katz PO, Rex DK, Epstein M, et al. A dual-action, low-volume bowel cleanser administered the day before colonoscopy: results from the SEE CLEAR II study. Am J Gastroenterol 2013; 108:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/89\">",
"      Keeffe EB. Colonoscopy preps: what's best? Gastrointest Endosc 1996; 43:524.",
"     </a>",
"    </li>",
"    <li>",
"     Cotton PB, Williams CB. Practical gastrointestinal endoscopy, 3rd edition, Blackwell Scientific Publications, Oxford, London 1990. p.160.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/91\">",
"      Brown AR, DiPalma JA. Bowel preparation for gastrointestinal procedures. Curr Gastroenterol Rep 2004; 6:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/92\">",
"      Bini EJ, Unger JS, Rieber JM, et al. Prospective, randomized, single-blind comparison of two preparations for screening flexible sigmoidoscopy. Gastrointest Endosc 2000; 52:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?26/39/27258/abstract/93\">",
"      Sharma VK, Chockalingham S, Clark V, et al. Randomized, controlled comparison of two forms of preparation for screening flexible sigmoidoscopy. Am J Gastroenterol 1997; 92:809.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2665 Version 20.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-A18C3F2596-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27258=[""].join("\n");
var outline_f26_39_27258=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148488578\">",
"      COLONOSCOPY PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148492007\">",
"      Patient instructions, medications, and diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H330966487\">",
"      - Medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H160742642\">",
"      - Diet",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148488585\">",
"      Choosing a preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H149537130\">",
"      - Contraindications to oral lavage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H330965656\">",
"      - Patient characteristics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H149537222\">",
"      Patients without significant comorbid illnesses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H149537229\">",
"      Older adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H149537236\">",
"      Patients with heart failure, renal insufficiency, end-stage liver disease, or electrolyte imbalances",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H149537243\">",
"      Patients who are pregnant",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H330965790\">",
"      - Indication for colonoscopy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H330965760\">",
"      - Prior poor preparation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H330965697\">",
"      - Cost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148491576\">",
"      Timing of administration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148491583\">",
"      - Split-dose lavage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148491620\">",
"      - Same-day preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148493757\">",
"      Improving tolerability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H148493791\">",
"      Specific preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148494535\">",
"      - Polyethylene glycol solutions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H148496844\">",
"      Efficacy of PEG-based preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H148496955\">",
"      Safety of PEG-based preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H148493872\">",
"      - Hyperosmotic preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H148495700\">",
"      Magnesium citrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H148495759\">",
"      Sodium phosphate preparations",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H59493388\">",
"      - Formulations",
"     </a>",
"    </li>",
"    <li class=\"dashItem2\">",
"     <a class=\"outlineLink\" href=\"#H352180686\">",
"      - Safety of sodium phosphate preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H148495840\">",
"      Sodium sulfate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H148495847\">",
"      Sodium picosulfate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H330966170\">",
"      - Stimulant laxatives",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H148488437\">",
"      FLEXIBLE SIGMOIDOSCOPY PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2665\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2665|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/43/44731\" title=\"table 1\">",
"      Bleeding risk GI procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?40/0/40971\" title=\"table 2\">",
"      Risk GI procedure conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/19/31037\" title=\"table 3\">",
"      ASGE guidelines Abx prophylxs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?17/2/17453\" title=\"table 4\">",
"      Dietary fiber in foods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?35/42/36523\" title=\"table 5\">",
"      Comp oral lavage solutions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/55/7032?source=related_link\">",
"      Acute phosphate nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/13/8410?source=related_link\">",
"      Angiodysplasia of the gastrointestinal tract",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/25/41367?source=related_link\">",
"      Antibiotic prophylaxis for gastrointestinal endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/7/30841?source=related_link\">",
"      Approach to resuscitation and diagnosis of acute lower gastrointestinal bleeding in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/36/5702?source=related_link\">",
"      Management of antiplatelet agents in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/28/31178?source=related_link\">",
"      Overview of colonoscopy in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/13/13527?source=related_link\">",
"      Overview of the causes and treatment of hyperphosphatemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?9/30/9698?source=related_link\">",
"      Patient information: Colonoscopy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/11/18611?source=related_link\">",
"      Patient information: Colonoscopy (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f26_39_27259="MAOI drugs and foods";
var content_f26_39_27259=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80345&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Foods contraindicated during therapeutic use of monoamine oxidase inhibitors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Foods",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Absolutely restricted:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Aged cheeses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Aged and cured meats",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Improperly stored or spoiled meats, fish, or poultry",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Banana peel; broad bean pods",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Marmite",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Sauerkraut",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Soy sauce and other soy condiments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Draft beer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Consume in moderation:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Red or white wine (no more than two 4-ounce glasses per day)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       Bottled or canned beer, including nonalcoholic (no more than two 12-ounce servings per day)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Hirsch, M, Birnbaum, RJ. An Approach to psychopharmacological treatment. In: The Ten-Minute guide to psychiatric diagnosis and treatment, Stern, TA (Ed). New York: Professional Publishing Group, Ltd, 2005. p. 355. Copyright &copy;2005 Castle Connolly Graduate Medical Publishing, Ltd.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27259=[""].join("\n");
var outline_f26_39_27259=null;
var title_f26_39_27260="Language delay red flags";
var content_f26_39_27260=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Red flags* for language delay",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Red flag",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type of skill",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Birth or any age",
"       </td>",
"       <td>",
"        Does not respond to sounds, particularly parent's voice",
"       </td>",
"       <td>",
"        Receptive language",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        6 to 9 months",
"       </td>",
"       <td>",
"        Does not babble",
"       </td>",
"       <td>",
"        Expressive language",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        Does not use \"mama\" or \"dada\" to call parent",
"       </td>",
"       <td>",
"        Expressive language",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        15 months",
"       </td>",
"       <td>",
"        Does not use specific single word or word approximation other than \"mama\" or \"dada\" to request or comment",
"       </td>",
"       <td>",
"        Expressive language",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does not use a point to request something out of reach",
"       </td>",
"       <td>",
"        Gestural communication",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        18 months",
"       </td>",
"       <td>",
"        Does not have at least five words used spontaneously to make requests or to comment on or label objects (assessed by asking: \"How does she let you know what she wants?\" or \"What words does she use to ask for things?\")",
"       </td>",
"       <td>",
"        Expressive language",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does not follow familiar one-step direction without gesture",
"       </td>",
"       <td>",
"        Receptive language",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does not point to something in order to share enjoyment or excitement with another person (joint attention)",
"       </td>",
"       <td>",
"        Gestural communication",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        24 months",
"       </td>",
"       <td>",
"        Uses fewer than 50 words",
"       </td>",
"       <td>",
"        Expressive language",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Does not combine two words together to create new meaning. (See caution below.)&bull;",
"       </td>",
"       <td>",
"        Expressive language",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Typically the age at which 90 percent of typically developing children have attained the skill.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      Parents may report",
"      <strong>",
"       stock phrases",
"      </strong>",
"      (eg, \"let's go,\" \"all done,\" \"good job\") or",
"      <strong>",
"       compound nouns",
"      </strong>",
"      (\"dump truck,\" \"Tyrannosaurus rex,\" \"baby doll\") as examples of this skill.",
"      <strong>",
"       These do not count as novel two-word combinations",
"      </strong>",
"      . Ask parents for specific examples, and probe further if these types of examples are the only ones provided.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27260=[""].join("\n");
var outline_f26_39_27260=null;
var title_f26_39_27261="Hypokalemia and DI";
var content_f26_39_27261=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F65801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F65801&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Decrease in ability to maximally concentrate the urine in patients with progressive potassium depletion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 209px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The average total K+ deficit was 350 meq or about 10 percent of the total body K+. (From Rubini, M, J Clin Invest, 40:2215, 1961, by copyright permission of the American Society for Clinical Investigation.)",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27261=[""].join("\n");
var outline_f26_39_27261=null;
var title_f26_39_27262="FEC plus paclitaxel for MBC";
var content_f26_39_27262=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F86825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F86825&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sequential fluorouracil, epirubicin, and cyclophosphamide (FEC) followed by weekly paclitaxel for metastatic breast cancer",
"    <sup>",
"     [1]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle/course length: 21 days (FEC), 7 days (paclitaxel).",
"        <br/>",
"        Duration of therapy: 4 cycles (FEC), 8 weeks (paclitaxel).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cycles 1 through 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fluorouracil",
"       </td>",
"       <td>",
"        600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Drug is available in 50 mg/mL solution that needs no further dilution prior to administration as slow IV push over five minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Epirubicin",
"       </td>",
"       <td>",
"        90 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Administer as an IV push into a free flowing IV solution with normal saline (NS) or 5 percent dextrose (D5W), generally over 3 to 20 minutes. May dilute in NS or D5W and infuse over 30 to 60 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cyclophosphamide",
"       </td>",
"       <td>",
"        600 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute with 250 mL NS or D5W and administer over 30 to 60 minutes.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cycles 5 through 12",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Paclitaxel",
"       </td>",
"       <td>",
"        100 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL NS* and administer over one hour; special tubing needed",
"        <sup>",
"         &Delta;",
"        </sup>",
"        .",
"       </td>",
"       <td>",
"        Weekly for 8 weeks",
"       </td>",
"      </tr>",
"      <tr>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Hydration:",
"        </strong>",
"        Patients should maintain adequate oral hydration (2 to 3 L/day during administration and for one to two days after) and void frequently to reduce the risk of hemorrhagic cystitis",
"        <sup>",
"         [2]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        The emesis risk with FEC is HIGH (&gt;90 percent frequency of emesis). The emesis risk with paclitaxel monotherapy is LOW (10 to 30 percent frequency of emesis). Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        Premedicate with dexamethasone plus both an H1 and an H2 receptor antagonist prior to paclitaxel administration",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Epirubicin is a vesicant; avoid extravasation",
"        <sup>",
"         [4]",
"        </sup>",
"        . Paclitaxel can cause significant tissue damage; avoid extravasation",
"        <sup>",
"         [3]",
"        </sup>",
"        . Fluorouracil and cyclophosphamide are irritants. Refer to UpToDate topic on \"Chemotherapy extravasation injury\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with G-CSF is not indicated",
"        <sup>",
"         [1]",
"        </sup>",
"        . Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        A lower starting dose of paclitaxel may be needed in patients with liver impairment. A lower starting dose of fluorouracil may be needed for patients with liver impairment, dihydropyrimidine dehydrogenase (DPD) deficiency, or renal impairment. A lower starting dose of cyclophosphamide may be needed in patients with renal impairment. A lower starting dose of epirubicin may be needed in patients with renal or hepatic impairment. Refer UpToDate topics on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\" and \"Chemotherapy hepatotoxicity and dose modification in patients with liver disease\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiac issues:",
"        </strong>",
"        Epirubicin is associated with dose-dependent cardiomyopathy, the incidence of which is related to cumulative dose. Assess baseline left ventricular ejection fraction (LVEF) prior to initiating therapy. Epirubicin is contraindicated for patients with recent myocardial infarction, severe myocardial dysfunction, severe arrhythmias, or prior treatment with maximum cumulative doses of anthracyclines. Refer to UpToDate topic on \"Cardiotoxicity of anthracycline-like chemotherapy agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess liver and renal function tests prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess CBC with differential prior to and during each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor for diarrhea and cutaneous toxicity (palmar-plantar erythrodysesthesias).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in neurologic function prior to each treatment with paclitaxel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Monitor cumulative epirubicin dose. Reassess LVEF periodically during therapy as clinically indicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity",
"        <sup>",
"         &loz;",
"        </sup>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        If the ANC &le;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        or platelets &le;75,000/mm",
"        <sup>",
"         3",
"        </sup>",
"        on day 1 of each cycle, therapy should be delayed until counts recover. For grade 3 clinically relevant toxicity during treatment, reduce doses of all drugs by 25 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Gastrointestinal toxicity:",
"        </strong>",
"        Hold fluorouracil for grade 3 diarrhea or mucositis until recovery to &le;grade 1. Upon recovery, reduce fluorouracil dose by 25 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        . Discontinue therapy for grade 4 gastrointestinal (or other non-hematologic) toxicity",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Severe diarrhea and mucositis after fluorouracil should prompt evaluation for dihydropyrimidine dehydrogenase deficiency. Refer to UpToDate topic on \"Enterotoxicity of chemotherapeutic agents\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurotoxicity:",
"        </strong>",
"        For grade 2 or higher peripheral neuropathy reduce paclitaxel doses by 20 percent",
"        <sup>",
"         [3]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Cardiac toxicity:",
"        </strong>",
"        Discontinue therapy for any clinically significant adverse cardiac events",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     ANC: absolute neutrophil count; CBC: complete blood count; G-CSF: granulocyte-colony stimulating factor; IV: intravenous; ULN: upper limit of normal.",
"     <br>",
"      * Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"      <br>",
"       &Delta; Paclitaxel can be administered in NS, D5W, or NS/D5W at varying concentrations between 0.3 to 1.2 mg/mL. Use glass or polypropylene bottles or polypropylene or polyolefin plastic bags, and administer through polyethylene-lined administration sets with a microporous membrane 0.22 microns or less.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        For any clinically relevant grade 3 toxicity, consider reducing the dose of all drugs by 25 percent, and discontinue therapy for any nonhematologic grade 4 toxicity",
"        <sup>",
"         [1]",
"        </sup>",
"        .",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Martin M, et al. J Nat Cancer Inst 2008; 100:805.",
"      </li>",
"      <li>",
"       Cytoxan (cyclophosphamide) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at: dailymed.nlm.nih.gov, accessed on February 24, 2012).",
"      </li>",
"      <li>",
"       Taxol (paclitaxel) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine.  (Available online at: dailymed.nlm.nih.gov, accessed on February 24, 2012).",
"      </li>",
"      <li>",
"       Ellence (epirubicin hydrochloride) injection. US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on February 24, 2012).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27262=[""].join("\n");
var outline_f26_39_27262=null;
var title_f26_39_27263="TSC hypomelanotic macules";
var content_f26_39_27263=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F61601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F61601&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hypomelanotic macules on the torso of a child with tuberous sclerosis complex",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 353px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f26_39_27263=[""].join("\n");
var outline_f26_39_27263=null;
